



here's to life

ANNUAL REPORT 2020-21

First Time in
The **WORLD***



BEXIMCO PHARMACEUTICALS LIMITED



*During the pandemic, Beximco Pharma became the first company in the world to launch generic versions of the breakthrough antiviral drugs Remdesivir and Molnupiravir for COVID-19 which were originally developed by Gilead Sciences and Merck/Ridgeback Biotherapeutics respectively.

ANNUAL REPORT

2020-21



here's to life

BEXIMCO PHARMACEUTICALS LIMITED

Date of Release: November 30, 2021

“Beximco Pharma aspires to become a globally admired generic pharmaceutical company, committed to enhancing human health and life.”



Contents

Our Essence	05	Media Spotlights	64
About the Company	07	Chairman's Statement	66
Corporate Information	09	Management Discussion and Analysis	71
Our Journey	10	Report of the Directors to the Shareholders	74
Our Subsidiaries	13	Report of the Audit Committee	91
Our Products	17	Activities and other Details of Nomination and Remuneration Committee (NRC)	93
Our Market	23	Investor Relations	95
Our Manufacturing Capabilities	24	Dividend Policy Statement	99
Our Global Accreditations	30	Value Added Statement	101
Research and Development	31	Consolidated Financial Statements - Beximco Pharmaceuticals Ltd. and Its Subsidiaries	103
Board and Management	32	Financial Statements- Beximco Pharmaceuticals Limited	124
Financial Highlights	42	Financial Statements- Nuvista Pharma Limited	157
Operational Highlights	45	Financial Statements- Beximco Pharma API Limited	184
Accolades and Awards	46	Notice of Annual General Meeting	194
Our People	48	Proxy Form	195
Environment, Health and Safety	54		
Our CSR Initiatives	56		
Corporate Events	60		



We take it minute by minute, drop by drop, molecule by molecule. The miracle of a pyramid is in the perfection of every stone. The miracle of life is in the health of every cell. At Beximco Pharma, we are tireless at achieving such perfection in every molecule of our medicines. That's our little contribution to life.

Here's to perfection. Here's to life.



here's to life

Our Essence

Mission

We are committed to enhancing human health and wellbeing by providing contemporary and affordable medicines, manufactured in full compliance with global quality standards. We continually strive to improve our core capabilities to address the unmet medical needs of the patients and to deliver outstanding results for our shareholders.

Vision

We will be one of the most trusted, admired and successful pharmaceutical companies in the region with a focus on strengthening research and development capabilities, creating partnerships and building presence across the globe.

Core Values

Our core values define who we are; they guide us to take decisions and help realize our individual and corporate aspirations.

Commitment to Quality

We adopt industry best practices in all our operations to ensure highest quality standards of our products.

Customer Satisfaction

We are committed to satisfying the needs of our customers, both internal and external.

People Focus

We give high priority on building capabilities of our employees and empower them to realize their full potential.

Accountability

We encourage transparency in everything we do and strictly adhere to the highest ethical standards. We are accountable for our own actions and responsible for sustaining corporate reputation.

Corporate Social Responsibility

We actively take part in initiatives that benefit our society and contribute to the welfare of our people. We take great care in managing our operations with high concern for safety and environment.





About the Company

Beximco Pharmaceuticals Limited is a leading manufacturer and exporter of medicines in Bangladesh. Incorporated in 1976, the Company started its operation importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands. From that humble beginning, Beximco Pharma has grown from strength to strength. Today, it has become an emerging global generic pharma company in the region. The Company manufactures more than 300 products in different forms and strengths covering almost all therapeutic categories. The Company's manufacturing facilities have been accredited by the leading global regulatory authorities, and medicines manufactured by the Company are now being exported to more than 50 countries including the highly regulated markets of USA, Europe, Canada and Australia. The Company has won the National Export (Gold) trophy for 5 times. It currently has more than 5,000 permanent full time employees including professionals like pharmacists, doctors, engineers, chemists, microbiologists, accountants, lawyers, information technology specialists, and graduates from other disciplines.

Beximco Pharma has received recognitions from different national and global organizations for its excellence, innovation, and performance. It is the winner of the highly prestigious SCRIP Award 2017 ("Best Pharma Company in an Emerging Market"), Global Generics & Biosimilar Awards 2019 ("Company of the Year, Asia Pacific"), CPhI Pharma Awards 2020 ("Innovation in Response to COVID-19"). In 2021, Beximco Pharma was recognized as "The Company of the Year, Asia Pacific" at the Global Generics and Biosimilar Awards 2021.

The Company is listed with Dhaka and Chittagong stock exchanges of Bangladesh and the Alternative Investment Market (AIM) of London Stock Exchange.

Beximco Pharma holds 85.22% stake in Nuvista Pharma Limited (formerly Organon Bangladesh), a leading non-listed Bangladeshi pharmaceutical company specializing in hormone and steroid drugs. In 2021, the Company acquired a majority stake (54.6%) in Sanofi Bangladesh Limited, a subsidiary company of global pharmaceutical giant Sanofi Group.



At Beximco Pharma, it is not just about how many products we sell, but rather, it is about the lives we save

Corporate Information

Registered Office

17 Dhanmondi R/A, Road No. 2
Dhaka- 1205, Bangladesh
Phone: +880-2-58611891
Fax: +880-2-58613470
E-mail: beximchq@bol-online.com

Operational Headquarters

19 Dhanmondi R/A, Road No. 7, Dhaka- 1205, Bangladesh
Phone: +880-2-58611001
Fax: +880-2-58614601
E-mail: info@bpl.net
Website: www.beximcopharma.com

Factory

Tongi Plant

126 Kathaldia, Auchpara, Tongi
Gazipur-1711, Bangladesh

Kaliakoir Plant

Plot No. 1070/1083, Mouchak, Kaliakoir, Gazipur
Bangladesh

Stock Exchange Listing

Dhaka Stock Exchange
Chittagong Stock Exchange
AIM of London Stock Exchange

Public Relations

IMPACT PR

Apartment No. A-1, House No. 17
Road No. 4, Gulshan-1
Dhaka-1212, Bangladesh

FTI Consulting LLP

200 Aldersgate
Aldersgate Street, London EC1A 4HD
United Kingdom

Legal Advisor

Huq & Co. 47/1 Purana Paltan Dhaka-1000, Bangladesh	Hoque & Associates House No. 11, Suite No. 201 Road No. 108, Gulshan-2 Dhaka-1212, Bangladesh
---	--

Auditors

M. J. Abedin & Co.
Chartered Accountants
National Plaza (3rd Floor),
109, Bir Uttam C. R. Datta Road
Dhaka- 1205, Bangladesh

Bankers

Janata Bank Ltd.
AB Bank Ltd.
First Security Islami Bank Ltd.
Dhaka Bank Ltd.
Agrani Bank Limited

Subsidiaries

Novista Pharma Limited

Mascot Plaza, 8th Floor
107/A, Sonargaon Janapath; Sector- 7
Uttara C.A, Dhaka - 1230, Bangladesh
Phone: +880-2-58952811

Factory

48, Tongi Industrial Area, Block-C, Tongi
Gazipur.

Sanofi Bangladesh Limited

6/2/A Segun Bagicha, Dhaka-1000

Factory

Tongi Station Road, Gazipur

Beximco Pharma API Limited


17 Dhanmondi, Road No. 2
Dhaka-1205, Bangladesh


Associates

BioCare Manufacturing Sdn Bhd

Seri Iskandar Pharmaceutical Park
32600 Bota, Perak, Malaysia

Our Journey







Our Subsidiaries

Nuvista Pharma Limited

Nuvista Pharma Limited (NPL) was originally formed as Organon (Pakistan) Limited in 1963 as a subsidiary of Organon Holding BV, the Netherlands. The Company has been operating in Bangladesh since 1964. In the post-independent Bangladesh, it was incorporated as Organon (Bangladesh) Limited. Following the divestment of Organon's equity to the local management in 2006, the Company was renamed as Nuvista Pharma Limited. Through acquisition of 85.22% stake by Beximco Pharma in 2018, Nuvista Pharma became the subsidiary of the Company.

Nuvista Pharma currently produces a total of 84 products covering several therapeutic categories with leading position in hormones, steroids and women's health segment. The manufacturing facilities of Nuvista Pharma is situated at Tongi Industrial Area Gazipur. NPL's manufacturing plant has facilities for injection, tablet and capsule and specialty products like hormone and steroid. The facilities are accumulated in a multistoried building covering 126,408 sft floor area.

NPL employs over 1100 people of diverged skills, academic and professional backgrounds.

Sanofi Bangladesh Limited

Sanofi Bangladesh Limited (SBL) was part of global biopharmaceutical company Sanofi S.A. before being taken over by Beximco Pharma in 2021. SBL started its operation in Bangladesh as part of the British chemical company, May & Baker. Following a series of mergers, it became known as Sanofi-Aventis in 2004, before being renamed in 2013 as Sanofi Bangladesh Limited. Beximco Pharmaceuticals Limited acquired 54.6% stake of SBL held by Sanofi Group represented through May & Baker Limited and Fisons Limited. The remaining 45.4% is held by Bangladesh Government through Bangladesh Chemical Industries Corporation (20%) and Ministry of Industries (25.4%).

Sanofi Bangladesh's state-of-the-art manufacturing facilities, including a PIC/S certifiable manufacturing facility for the leading antibiotic, cephalosporin, are spread over c25 acres of land, located at Tongi, Gazipur. The plant operated by SBL has manufacturing capabilities across several drug technologies, including tablets, capsules, topical, liquids, powder for suspension as well as sterile liquids and powders. The Corporate Headquarters is located at Segun Bagicha, Dhaka in a six storied building over a 26 katha land.

Sanofi Bangladesh has over 800 employees and produces approximately 100 branded generic products. SBL has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. SBL also imports certain global brands of Sanofi including vaccines, insulins and chemotherapy drugs for sale in the Bangladesh market.

Beximco Pharma took over the control of the company effective from 01 October 2021.





First Bangladeshi pharma company to export medicine to U.S.A



Our growing presence in overseas markets, combined with our reputation as a world class manufacturer, drives us to aspire to even greater heights.

Our Products

Beximco Pharma currently produces more than 300 generics available in well over 500 presentations. Beximco Pharma's portfolio encompasses wide range of therapeutic categories namely antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, central nervous system, dermatology, gastrointestinal etc. The Company has sound expertise with specialized and advanced drug delivery systems such as metered dose inhalers, dry powder inhalers, nasal sprays, sterile ophthalmic, lyophilized injectable, oral thin films, suppositories etc. creating strong differentiation for the Company. Many of its brands remain consistent leaders in their respective therapeutic categories. Napa, Napa Extra, Neofloxin, Atova, Azmasol, Arlin, Bexitrol F, D-Rise, Bizoran, Amdocal, Tofen, Tyclav etc. are household names with strong brand equity. The Company is continually focused on expanding and diversifying its product portfolio in order to ensure that people have access to newer, better treatment options at affordable cost. The expanding portfolio, including high value, differentiated, and difficult to copy products, will continue to remain as a driver of its growth.

Beximco Pharma also produces a number of active pharmaceutical ingredients (APIs) for its captive consumption as well as sale to other pharmaceutical manufacturers. The Company is working on strengthening the API portfolio and its current pipeline includes a number of patented, high value products.

Our Leading Brands

Analgesics	NAPA	Tablet	Paracetamol 500 mg
		Syrup	Paracetamol 120 mg / 5 ml
		Suspension	Paracetamol 120 mg / 5 ml
		Drops	Paracetamol 80 mg / ml
		Suppository	Paracetamol 125 mg, 250 mg And 500 mg
		Injection	Paracetamol 10 mg / ml
	NAPA ONE	Tablet	Paracetamol 1000 mg
NAPA EXTRA	Tablet	Paracetamol 500 mg + Caffeine 65 mg	
NAPA EXTEND	Tablet	Paracetamol 665 mg Extended Release	
NAPADOL	Tablet	Paracetamol 325 mg + Tramadol 37.5 mg	
NAPA RAPID	Tablet	Paracetamol 500 mg (with Actizorb technology)	
Joint Supplement	JOINTEC MAX	Tablet	Glucosamine 750 mg + Diacerein 50 mg
Muscle Relaxant	RELENTUS	Tablet	Tizanidine 2 mg
NSAIDs	DINOVO	Tablet	Naproxen 375 mg + Esomeprazole 20 mg, Naproxen 500 mg + Esomeprazole 20 mg
	VOLIGEL	Cream	Diclofenac Sodium 50 mg
	XIDOLAC	Tablet	Ketorolac Tromethamine 10 mg
		Injection	Ketorolac Tromethamine 30 mg / ml
	ZOLFIN	Tablet	Aceclofenac 100 mg
Oral Anti-Diabetic	GLIPITA	Tablet	Sitagliptin 50 mg, Sitagliptin 100 mg
	GLIPITA M	Tablet	Sitagliptin 50 mg + Metformin Hydrochloride 500 mg, Sitagliptin 50 mg + Metformin Hydrochloride 1000 mg
	TRANETA	Tablet	Linagliptin 5 mg
	TRANETA M	Tablet	Linagliptin 2.5 mg + Metformin Hydrochloride 500 mg, Linagliptin 2.5 mg + Metformin Hydrochloride 850 mg, Linagliptin 2.5 mg + Metformin Hydrochloride 1000 mg
	JARDIAN	Tablet	Empagliflozin 10 mg, Empagliflozin 25 mg














Oral Anti-Diabetic	JARDIMET	Tablet	Empagliflozin 5 mg + Metformin Hydrochloride 500 mg
	VIBOSE	Tablet	Voglibose 0.2 mg, Voglibose 0.3 mg
	INFORMET	Tablet	Metformin Hydrochloride 500 mg, Metformin Hydrochloride 500 mg LA, Metformin Hydrochloride 850 mg, Metformin Hydrochloride 1000 mg
Insulin	GENSULIN	Injection	Human Insulin 100 IU / ml Injection
	SEMGLEE	Prefield Pen	Insulin Glargine 100IU/ML
	REGLUTIDE	Injection	Semaglutide inn 1.34 mg/ml
Anti-Histamines	ATRIZIN	Tablet	Cetirizine Hydrochloride 10 mg
		Syrup	Cetirizine Hydrochloride 5 mg / 5 ml
		Drops	Cetirizine Hydrochloride 2.5 mg / ml
	AXODIN	Tablet	Fexofenadine HCl 120 mg, Fexofenadine HCl 180 mg
		Suspension	Fexofenadine HCl 30 mg / 5 ml
	DUVENT	Tablet	Rupatadine 10 mg
		Syrup	Rupatadine 5 mg / 5 ml
	BILLI	Tablet	Bilastine 20 mg
MELTAB		Bilastine 10 mg	
Oral Solution		Bilastine	
Cough & Cold	DEXTRIM	Syrup	Dextromethorphan Hydrobromide 20 mg + Phenylephrine Hydrochloride 10 mg + Triprolidine Hydrochloride 2.5 mg / 5 ml
		Syrup	Guaifenesin 200 mg + Dextromethorphan Hydrobromide 15 mg + Menthol 15 mg / 5 ml
	MUCOSOL	Syrup	Ambroxol Hydrochloride 15 mg / 5 ml
		Drops	Ambroxol Hydrochloride 6 mg / ml
Anti-Hypertensives	BIZORAN	Tablet	Amlodipine 5 mg + Olmesartan Medoxomil 40 mg, Amlodipine 5 mg + Olmesartan Medoxomil 20 mg
	OLMESAN	Tablet	Olmesartan Medoxomil 10 mg, Olmesartan Medoxomil 20 mg, Olmesartan Medoxomil 40 mg
	OLMESAN PLUS	Tablet	Olmesartan Medoxomil 20 mg + Hydrochlorothiazide 12.5 mg
	AMDOCAL	Tablet	Amlodipine 5 mg, Amlodipine 10 mg
	AMDOCAL PLUS	Tablet	Amlodipine 5 mg + Atenolol 25 mg, Amlodipine 5 mg + Atenolol 50 mg
	TELMA	Tablet	Telmisartan 40 mg, Telmisartan 80 mg
	TELMACAL	Tablet	Telmisartan 40 mg + Amlodipine 5 mg, Telmisartan 80 mg + Amlodipine 5 mg
	TELMA PLUS	Tablet	Telmisartan 40 mg + Hydrochlorothiazide 12.5 mg
Lipid Lowering	ATOVA	Tablet	Atorvastatin 10 mg, Atorvastatin 20 mg, Atorvastatin 40 mg
	ROSUTIN	Tablet	Rosuvastatin 5 mg, Rosuvastatin 10 mg, Rosuvastatin 20 mg
Anti-Infectives	ARLIN	Tablet	Linezolid 400 mg, Linezolid 600 mg
		Suspension	Linezolid 100 mg / 5 ml
		Injection	Linezolid 2 mg / 2 ml IV Infusion
	TRIOCIM	Capsule	Cefixime 200 mg, Cefixime 400 mg
		Suspension	Cefixime 100 mg / 5 ml, Cefixime 200 mg / 5 ml
	TYCLAV	Tablet	Amoxicillin 250mg + Clavulanic Acid 125 mg, Amoxicillin 500 mg + Clavulanic Acid 125 mg, Amoxicillin 750 mg + Clavulanic Acid 125 mg

Anti-Infectives		Suspension	Amoxicillin 125 mg + Cavulanic Acid 31.25 mg / 5 ml, Amoxicillin 400 mg + Clavulanic Acid 57 mg / 5 ml	
		Injection	Amoxicillin 1 Gm + Clavulanic Acid 200 mg, Amoxicillin 500 mg + Clavulanic Acid 100 mg	
	TURBOCLAV	Tablet	Cefuroxime 250 mg + Clavulanic Acid 62.5 mg, Cefuroxime 500 mg + Clavulanic Acid 125 mg	
	AZITHROCIN	Tablet	Azithromycin 250 mg, Azithromycin 500 mg	
		Suspension	Azithromycin 200 mg / 5 ml	
		Injection	Azithromycin 500 mg IV	
	FILMET	Tablet	Metronidazole 200 mg, Metronidazole 400 mg, Metronidazole 800 mg	
		Syrup	Metronidazole 200 mg / 5 ml	
	NEOFLOXIN	Tablet	Ciprofloxacin 750 mg, Ciprofloxacin 500 mg, Ciprofloxacin 250 mg	
		Injection	Ciprofloxacin 250 mg / 5 ml	
	BEMSIVIR	Injection	Remdisivir Inn 100 mg	
EMORIVIR	Capsule	Monlupiravir 200 mg		
VIRAFLU	Tablet	Favipiravir 200 mg		
IVERA	Tablet	Ivarmectine 6 mg, Ivarmectine 12mg,		
Antacids	DIGECID PLUS	Suspension	Magaldrate 480 mg + Simethicone 20 mg / 5 ml	
	VISCOCID	Suspension	Sodium Alginate 500 mg + Potassium Bicarbonate 100 mg / 5 ml	
Anti-Ulcerants	ACIFIX	Tablet	Rabeprazole 20 mg	
	REMMO	Tablet	Esomeprazole 20 mg, Esomeprazole 40 mg	
		Tablet	Esomeprazole 20 mg, Esomeprazole 40 mg	
			Capsule	Esomeprazole 20 mg, Esomeprazole 40 mg
	Injection	Esomeprazole 40 mg		
		PANTOBEX	Tablet	Pantoprazole 20 mg, Pantoprazole 40 mg
			Injection	Pantoprazole 40 mg
	PROCEPTIN	Capsule	Omeprazole 20 mg, Omeprazole 40 mg	
		Injection	Omeprazole 40 mg	
YAMADIN	Tablet	Famotidine 20 mg, Famotidine 40 mg		
FAMOMAX	Suspension	Famotidine		
Enzymes	ZYMET Pro	Capsule	Pancreatin 325 mg	
Gastroprokinetics	DEFLUX	Tablet	Domperidone 10 mg, Domperidone 10 mg Meltab	
		Suspension	Domperidone 5 mg / 5 ml	
		Drops	Domperidone 5 mg / ml	
Antispasmodic	ROSTIL	Capsule	Mebeverine Hydrochloride 200 mg	
		Tablet	Mebeverine Hydrochloride 135 mg	
CNS	FRENXIT	Tablet	Flupentixol 0.5 mg + Melitracen 10 mg	
	NERVALIN	Capsule	Pregabalin 25 mg, Pregabalin 50 mg, Pregabalin 75 mg	
	EMIJOY	Tablet	Chlordiazepoxide 5 mg + Amitriptyline Hcl 12.5 mg	
Hormones	FEMZOLE	Tablet	Letrozole 2.5 mg	
	TAMONA	Tablet	Tamoxifen Citrate 10 mg, Tamoxifen Citrate 20 mg	

Laxatives	FRELAX	Suspension	Liquid Paraffin 1.25 ml + Magnesium Hydrochloride 300 mg / 5 ml
	SERELOSE	Solution	Lactulose 3.35 gm / 5 ml
Anti-Fungals	OMASTIN	Capsule	Fluconazole 150 mg, Fluconazole 200 mg, Fluconazole 50 mg
		Suspension	Fluconazole 50 mg / 5 ml
		Injection	Fluconazole 2 mg / ml Infusion
	TERBEX	Tablet	Terbinafine 250 mg
		Cream	Terbinafine HCl 1%
Respiratory	AZMASOL	MDI	Salbutamol 100 mcg / Puff
		Respirator Solution	Salbutamol 2.5 mg / 3 ml Ampoule, Salbutamol 5 mg / ml in amber glass bottle
	BEXITROL-F	MDI	Salmeterol 25 mcg + Fluticasone Propionate 125 mcg, Salmeterol 25 mcg + Fluticasone Propionate 250 mcg, Salmeterol 25 mcg + Fluticasone Propionate 50 mcg
		DPI	Salmeterol 50 mcg + Fluticasone Propionate 100 mcg, Salmeterol 50 mcg + Fluticasone Propionate 200 mcg, Salmeterol 50 mcg + Fluticasone Propionate 500 mcg
		MAXHALER	Salmeterol 50 mcg + Fluticasone Propionate 100 mcg, Salmeterol 50 mcg + Fluticasone Propionate 200 mcg, Salmeterol 50 mcg + Fluticasone Propionate 500 mcg
	DECOMIT	MDI	Beclomethasone Dipropionate (100 mcg / Puff), Beclomethasone Dipropionate (50 mcg / Puff)
	DECOMIT PLUS	MDI	Beclomethasone Dipropionate 100 mcg + Formoterol Fumarate 6 mcg, Beclomethasone Dipropionate 200 mcg + Formoterol Fumarate 6 mcg
	SYMBION	DPI	Formoterol Fumarate 6 mcg + Budesonide 100 mcg, Formoterol Fumarate 6 mcg + Budesonide 200 mcg
		MAXHALER	Formoterol Fumarate Dihydrate 12 mcg + Budesonide 400 mcg
	TIORIVA	DPI	Tritropium Bromide 18 mcg
	DECOMIT	Nasal Spray	Beclomethasone Dipropionate 100 mcg / Actua
	NASOMET	Nasal Spray	Mometasone Furoate 50 mcg / Actuation
	PERINASE	Nasal Spray	Fluticasone Propionate 50 mcg / Actuation
	DYNASE	Nasal Spray	Azelastine hydrochloride 137 mcg + Fluticasone propionate 50 mcg / Actuation
	TOFEN	Tablet	Ketotifen Fumarate 1mg
		Syrup	Ketotifen 1 mg / 5 ml
	MONOCAST	Tablet	Montelukast 4 mg, Montelukast 5 mg, Montelukast 10 mg
		Sachet	Montelukast 4 mg
	FIXOLIN	Tablet	Doxofylline 200 mg, Doxofylline 400 mg
	MUCOMIST	Tablet	Acetylcysteine 600 mg
Respirator Solution		Acetylcysteine 600 mg / 3 ml Ampoule	
TRIBREZ	Inhaler	Formoterol Fumarate BP5.5MCG+Glycopyrro	
IV Fluids	DEXAQUA	Injection	Dextrose 10% W/V, Dextrose 5% W/V
	DEXORIDE	Injection	NaCl 0.9% W/V & Dextrose 5% W/V
	SALORIDE	Injection	Sodium Chloride 0.09% W/V
Ophthalmic	ODYCIN	Eye Drops	Moxifloxacin 0.5%
	ODYCIN D	Eye Drops	Moxifloxacin Hcl

Ophthalmic	TEARON	Eye Drops	Polyethylene Glycol 400 0.4% + Propylene Glycol 0.3%
	TEARON FRESH	Eye Drops	Carboxymethyl Cellulose Sodium 1%
	VIVIS	Capsule	Antioxidants & Minerals
Urogenital	URAL-K	Solution	Potassium Citrate 1500 mg + Citric Acid Monohydrate 250 mg / 5 ml Solution
	MIRASOL	Tablet	Mirabegron INN 25 mg, Mirabegron INN 50 mg
	UROFLO	Capsule	Tamsulosin Hydrochloride 0.4 mg
	UROFLO PLUS	Capsule	Tamsulosin Hydrochloride 0.4 mg + Dutasteride 0.5 mg
Biologies	OGIVRI	Lyophilized Powder	Trastuzumab INN 440mg/Vial
	FULPHILA	Prefield Syringe	Pegfilgrastim
Vitamins & Minerals	BEXTRAM GOLD	Tablet	High Potency 32 Multivitamin-Mineral
	BEXTRAM SILVER	Tablet	High Potency 30 Multivitamin-Mineral
	D-RISE	Capsule	Cholecalciferol 20000 IU, Cholecalciferol 40000 IU
		Tablet	Cholecalciferol 2000 IU
	HEMOFIX FZ	Tablet	Elemental Iron 48 mg (Ferrous Ascorbate), Folic Acid 0.5 mg And Elemental Zinc 22.5 mg Tab
	NEUROCARE	Tablet	Vitamin B1, B6, and B12
	CALORATE	Tablet	Calcium Orotate 400 mg, Calcium Orotate 740 mg
	BECORAL D	Tablet	Coral Calcium
BECORAL DX	Tablet	Coral Calcium	

Our product portfolio color

 Anti Allergy & Cough and Cold	 Endocrine	 Others
 Analgesic & Musculoskeletal	 GI	 Respiratory
 Anti-Infective	 IV Fluids	 Anti-Fungal
 CNS	 Ophthalmics	 Vitamins
 CVS & Lipid Lowering		

Major Active Pharmaceutical Ingredients (APIs)

- APIXABAN
- LINAGLIPTIN
- RIVAROXABAN
- ROSUVASTATIN
- SITAGLIPTIN
- PENICILLINS
- DICLOFENAC

Key Products Launched

We have expanded our product portfolio with 22 generics available in 32 different presentations. **Triovix** Junior Tablet; **Symbion** 6/100 Maxhaler; **Zymet Pro** Capsule; **Remmo**, a buffered esomeprazole MUPS formulation; **Fulphila**, first Biosimilar Pegfilgrastim from Mylan are few among the new products launched during the year. Two more products have been launched post reporting period.




Our Market

We are a leading player in Bangladesh with over 9% share of country's Taka 276 billion pharma market. The Company over the years has emerged as a dominant exporter with its footprint in more than 50 countries across all continents. We are the only Bangladeshi company exporting medicines to the United States, the largest and most stringent pharma market in the world. While our current revenue predominantly comes from the domestic market, we have a strategic focus on export with an ambition to achieve export-led growth in the longer term.



Export Destinations



Our Manufacturing Capabilities





Tongi Site

Company's main manufacturing site at Tongi, Gazipur is spread over an area of 23 acres which houses a number of self-contained production units including oral solids, metered dose inhalers, intravenous fluids, liquids, ointments, creams, suppositories, ophthalmic drops, injectables, prefilled syringes, nebulizer solutions, insulin, dry powder inhaler, small scale API unit etc. The site has its own infrastructure to ensure adequate generation and distribution of electricity with an installed capacity of 15 MW. It also contains water purification, effluent treatment, liquid nitrogen and steam generation plant/facilities. There is over 2,42,000 sq ft warehouse area to accommodate materials and finished products maintaining the GMP compliance.

Kaliakoir Site

The Kaliakoir plant contains manufacturing facilities for penicillin products, both formulation and active pharmaceutical ingredients (APIs). In compliance with cGMP regulations, the penicillin production is carried out at this facility which is few miles away from the Tongi site.

All the plants are highly automated with equipment sourced from reputed suppliers based in Germany, USA, UK, Switzerland, China, India etc.

Current Production Capacity:



Oral Solid Dosage (OSD)

- Tablets, Capsules, Powder for Suspension, Sachets and Oral Soluble Films
- Capacity: Tablets-5492 million, Capsules-232 million, Powder for Suspension-1.86 million bottles, Sachets- 4.08 million and Oral Soluble Films- 0.52 million units

Semi Solid and Liquid (SSL)

- Liquids, Cream & Ointment, Shampoo & Lotion and Suppository
- Capacity: Liquids-41.25 bottles, Cream & Ointment-3.2 million Tubes, Suppository-10.20 million pieces, and Shampoo & Lotion- 0.25 million bottles




Sterile, Nasal Spray & Respiratory Solutions

- Intravenous fluid, Amino Acid, Insulin Nasal Spray and Respiratory Solutions (Non-Steroids), Nasal Spray and Respiratory Solutions (Steroids), Lyophilized Injection, Prefilled Syringe and Ophthalmic products
- Capacity: Intravenous fluids-9.84 million bottles, Amino Acid -0.96 million bottles, Insulin -3.00 million vials and cartridges, Nasal Spray and Respiratory Solutions (Non-Steroids)- 6.31 million ampules, Nasal Spray and Respiratory Solutions (Steroids)- 2.85 million HDPE containers, Lyophilized Injection -2.11 million vials, Prefilled Syringe -1.92 million units and Ophthalmic – 4.56 million LDPE containers

Inhalers

Metered Dose Inhalers (MDI), Dry Powder Inhaler(DPI)/
Multi Dose Dry Powder Inhaler (mDPI)

- Capacity: MDI- 18.10 million Cans, DPI- 108.8 million Capsules



Penicillin

- Capsules and Dry Syrups
- Capacity: Capsules – 42.24 million and Dry Syrups- 3.06 million bottles

Active Pharmaceutical Ingredients (APIs)

- Multiple APIs
- Capacity: 22MT





Unit 3

Our new state-of-the-art manufacturing facility (Unit-3) for oral solids, semi-solids and liquid products is almost complete. This multistoried facility having floor space of 49,854 m² and production area of 26,468 m² is equipped with latest machineries mostly from European sources. The facility is capable of producing of 9 billion tablet/capsules and 210 million units liquid and semi-liquid Products. Two solid lines and one liquid line are now manufacturing validation batches and is expected to go for commercial production by January 2022. The facilities will be fully operational in phases after validation of and product transfer to other lines.



Our Global Accreditations

Benchmarked to the highest global regulatory standards, Beximco Pharma's manufacturing facilities have been audited and approved by the following major global agencies:

- U.S. FDA
- Therapeutic Goods Administration (TGA), Australia
- Malta Medicines Authority (European Union)
- German Regulatory Authority (Regierungspräsidiums Tübingen)
- Gulf Central Committee (GCC)
- World Health Organization (WHO)
- ANVISA (Brazil)

Approved by the U.S. FDA
also Certified by





Research and Development

Our research and development activities are closely focused on market needs and driven by technological progress. As an emerging global generic drug company, our key strength lies in our ability to excel in developing technologically complex and differentiated products. Our state-of-the-art R&D lab facilitates the development of innovative and difficult products with a focus on creating unique market opportunities. We have given top priority in building and strengthening our capabilities to excel in formulating technologically complex products such as multi-layer tablet, sustained release formulation, dispersible tablet, metered dose inhalers, dry powder inhalers, prefilled syringes, lyophilized injectables, sterile ophthalmics, oral thin films etc. We are also pursuing research collaboration with universities and biotech companies both at home and abroad for strengthening our capabilities in selected areas.

Board and Management



Salman F Rahman MP
Vice Chairman



A S F Rahman
Chairman

The Board of Directors

A S F Rahman	Chairman
Salman F Rahman MP	Vice Chairman
Nazmul Hassan MP	Managing Director
Osman Kaiser Chowdhury	Director
Iqbal Ahmed	Director
A B Siddiqur Rahman	Director
Quamrun Naher Ahmed	Director
Reem H. Shamsuddoha	Director
Prof. Mamtaz Uddin Ahmed	Independent Director
Dr. Md. Ibraheem Hosein Khan	Independent Director

Mohammad Asad Ullah, FCS	Company Secretary
--------------------------	-------------------

Audit Committee

Prof. Mamtaz Uddin Ahmed	Chairman
Osman Kaiser Chowdhury	Member
Reem H. Shamsuddoha	Member
Mohammad Asad Ullah, FCS	Secretary

Nomination and Remuneration Committee

Dr. Md. Ibraheem Hosein Khan	Chairman
Iqbal Ahmed	Member
Osman Kaiser Chowdhury	Member
Mohammad Asad Ullah, FCS	Secretary

Executive Committee

Osman Kaiser Chowdhury	Member of the Board of Directors
Nazmul Hassan MP	Managing Director
Rabbur Reza	Chief Operating Officer
Mohammad Ali Nawaz	Chief Financial Officer
Afsar Uddin Ahmed	Director, Commercial



Directors' Profile

Ahmed Sohail Fasihur Rahman

Chairman

Mr. Ahmed Sohail Fasihur Rahman is the Chairman and founder of Beximco Group. He is a distinguished business personality of the country and has received many awards and accolades for his phenomenal contribution to the country's journey of industrial development. Mr. Rahman was instrumental in introducing best-in-class corporate practice in Bangladesh and is widely credited as the architect of Group's successful global strategy.

He graduated with Honours in Physics from the University of Dhaka in 1966, and also studied in the United Kingdom. Mr. Rahman held key positions with many well-reputed organizations, which includes Chairman of IFIC Bank Limited, Director of Industrial Promotion & Development Company Limited, Arab Bangladesh Bank Limited, Pubali Bank Limited and Investment Corporation of Bangladesh.

He is currently a member of the Board of Trustees of North South University Foundation, the first private university in Bangladesh.



Salman Fazlur Rahman MP

Vice Chairman

Mr. Salman Fazlur Rahman MP, is a distinguished industrialist, philanthropist and politician of Bangladesh. Mr Rahman is an elected Member of Parliament and currently serving as the Prime Minister's Private Industry and Investment Adviser, with the rank and status of a cabinet minister.

One of the most renowned and successful businessmen in the country, Mr. Rahman is widely recognized for his contribution to the development of the private sector in Bangladesh. He has been active with different trade bodies of home and abroad and was the President of SAARC Chamber of Commerce and Industry (SCCI); Federation of Bangladesh Chambers of Commerce and Industries (FBCCI); Metropolitan Chamber of Commerce and Industry (MCCI); Bangladesh Association of Pharmaceutical Industries (BAPI); Bangladesh Textile Mills Association (BTMA) and Association of Television Channel Owners (ATCO).

Mr. Rahman is the Chairman of IFIC Bank Limited. He is also the Chairman of the Board of Governors of Bangladesh Enterprise Institute; Board of Editors of English daily The Independent; and news channel Independent TV. He is a keen promoter of sports and is the Chairman of Abahani Ltd Dhaka, the premier sporting club of the country. He holds a degree from the University of Karachi.



Nazmul Hassan MP Managing Director

Mr. Nazmul Hassan MP is a prominent and highly respected business leader of the country. Besides being the Managing Director of Beximco Pharmaceuticals Limited, he is the Chairman of the Board of Directors of Nuvista Pharma Ltd, and Beximco Pharma API Limited and a Director of Sanofi Bangladesh Limited- the subsidiary companies of Beximco Pharma. He is also a Director of the Board of Bangladesh Antibiotic Industries Limited, Independent Television and Padma Mining and Energy Limited.

Mr. Hassan obtained his graduation degree in Public Administration from the University of Dhaka and an MBA in Marketing from Institute of Business Administration (IBA). He also received executive education from University of California Los Angeles (UCLA) and Kellogg School of Management, Chicago. He is the President of IBA Alumni Association; a Member of the American Management Association and Australian Institute of Management.

Mr. Hassan is an elected Member of Parliament (MP) of Bangladesh Since 2009. He is a Member of the Parliamentary Committee for Finance, Sports & Defense.

Mr. Hassan is passionate to sports and actively involved with Bangladesh's national cricket. He is currently the president of Bangladesh Cricket Board (BCB), elected to the position for three consecutive terms.

He is a board member of the International Cricket Council (ICC), ICC Business Corporation (IBC), and a Member of HR & Remuneration Committee, ICC. He was the elected President of Asian Cricket Council (ACC) for 2018.

Mr. Hassan is the President of Bangladesh Association of Pharmaceutical Industries (BAPI) and a member of Int'l Society for Pharmaceutical Engineering (ISPE). He is involved with various national and international committees and task forces related to formulation of healthcare and drug policy.



Osman Kaiser Chowdhury Director

Mr. Osman Kaiser Chowdhury is a member of the Institute of Chartered Accountants of England and Wales and a Fellow member of the Institute of Chartered Accountants of Bangladesh. He is involved with Beximco Group for over 40 years and is currently the Director of Group Finance and Corporate Affairs, Managing Director of Bangladesh Export Import Company (Beximco) Limited. He has over 13 years' experience working abroad, including the United Kingdom.


Mr. Chowdhury is a member of the Board of Directors of a number of listed and non-listed Companies including Beximco Synthetics Ltd., Shinepukur Ceramics Ltd. and Beximco Securities Ltd.



Abu Bakar Siddiqur Rahman

Director

Mr. Abu Bakar Siddiqur Rahman held senior positions at a number of entities within the Beximco Group of companies and has an extensive business experiences in trading, jute, textiles, pharmaceuticals and other sectors. He has been in the Board of Beximco Pharma since 1993. Mr. Rahman is also a member of the Board of Directors of Bangladesh Export Import Company Limited.



Iqbal Ahmed

Director

Mr. Iqbal Ahmed has been with the Beximco Group since 1972 and held senior positions in a number of entities within the Beximco Group of companies. He has over 45 years business experiences in trading, jute, textile, pharmaceuticals, engineering, IT and other sectors. Mr. Ahmed has been in the Board of Beximco Pharma since 1985. He is also a director of Bangladesh Export Import Company Limited, Shinepukur Ceramics Limited, and Beximco Synthetics Limited. He was the publisher of “The Independent” and “Muktakantha” an English and a Bengali national daily newspaper respectively, in Bangladesh. He received his Bachelor’s Degree in Science from the University of Dhaka in 1966.




Quamrun Naher Ahmed

Director

Ms. Quamrun Naher Ahmed is a retired civil servant. She last served as an Additional Secretary, Financial Institution Division, Ministry of Finance. Starting at an entry level of civil service, she has risen through the ranks to the senior administrative and policy level. In her career she served senior positions in different ministries including Ministry of Shipping, Commerce, Home affairs, and Fisheries & Livestock. She was also a Director of Karmasangsthan Bank for more than five years.

She had an excellent academic record with an MPhil in Social Change from the Norwegian University of Science and Technology (NTNU) and an M.S.S. in Economics from the University of Dhaka.

She attended a wide range of trainings, workshops, and conferences covering different fields including public administration, development management, law, accounts and finance, held home and abroad. Currently she is a full time member of National River Conservation Commission, a Board member of IFIC Bank Limited, IFIC Securities Ltd., IFIC Money Transfer (UK) Ltd. and Nepal Bangladesh Bank Ltd.



Reem H Shamsuddoha

Director

Ms. Reem H Shamsuddoha had her Bachelor of Science in Business Administration from Fordham University, Gabelli School of Business, New York. She has participated in professional training in Advance Management Program in the University of Hong Kong. She has a wide range of working experience in renowned local and overseas organizations including Daraz, TapFury LLC, International Quality and Productivity Center (IQPC), Opal Financing Group and had Internship experience with ASB Communications and Elida Olsen et CIE of New York.

Ms. Reem is a member of the Board of Directors of a number of listed and non-listed companies including Global Voice Holdings Limited, Global Voice Telecom Limited, Beximco IOC Petroleum & Energy Limited, and Bangladesh Export Import Co. Ltd.



Mamtaz Uddin Ahmed

Independent Director

Professor Mamtaz Uddin Ahmed joined Beximco Pharmaceuticals Limited as an Independent Director on July 2020. He is currently a professor of the Department of Accounting and Information Systems, University of Dhaka and has over 36 years of teaching experience at university level. Professor Ahmed is the Treasurer of the University of Dhaka and Chairman of the Bureau of Business Research. He is an experienced Board member, currently an Independent Director of Alhaj Textile Mills Limited and a Director of Ashuganj Power Station Company Ltd. His previous Board positions include Director of Chittagong Stock Exchange Ltd. and Dhaka Stock Exchange Ltd.

In addition, Professor Ahmed was the Vice President of the South Asian Federation of Accountants (SAFA) and President of the Institute of Cost and Management Accountants of Bangladesh (ICMAB). Professor Ahmed obtained his Bachelor and Masters in Accounting from the University of Dhaka. He also obtained MBA from University of Castle, USA and CMA degree from ICMAB, Bangladesh.



Dr. Md. Ibraheem Hosein Khan

Independent Director

Dr. Md. Ibraheem Hosein Khan is a retired civil servant, last served as the Secretary, Ministry of Cultural Affairs, Government of Bangladesh. Before his retirement from service in the Bangladesh Government, he worked in different Government departments including the Prime Minister's Office, Ministry of Land and Ministry of Cultural Affairs. Dr. Khan has also served as Administrator for the Dhaka South City Corporation. Dr. Khan holds a PhD from Jahangirnagar University, Dhaka, two master and two bachelor degrees from institutions in Bangladesh, Australia and the United Kingdom.



Company Secretary

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Mr. Mohammad Asad Ullah has been working with Beximco Group since 1983. He obtained his Bachelor of Arts and Master of Law degrees from the University of Dhaka. He also holds an MBA with major in Human Resource Management. Mr. Asad Ullah qualified as Chartered Secretary from the Institute of Chartered Secretaries of Bangladesh (ICSB) and is a Fellow Member of the institute. He was four times President of ICSB. He is a widely experienced person with long career in Company Secretarial functions.

Executive Committee

Executive Committee comprises five members- Mr. Osman Kaiser Chowdhury, Mr. Nazmul Hassan MP, Mr. Rabbur Reza, Mr. Mohammad Ali Nawaz and Mr. Afsar Uddin Ahmed. Mr. Chowdhury and Mr. Hassan are also members of the Board of Directors.



Rabbur Reza

Chief Operating Officer

Mr. Rabbur Reza is a pharmaceutical industry expert with wide experience in the areas of sales, marketing, brand management, international business development, operations management, partnerships and acquisition. In addition to his role in Beximco Pharma, he is the Managing Director of Nuvista Pharma Ltd. and Beximco Pharma API Ltd and CEO of Sanofi Bangladesh Ltd., subsidiary companies of Beximco Pharma. He had previously worked for Biotech and Milton Pharmaceuticals in Australia.

Mr. Reza holds a Bachelor of Pharmacy degree from Panjab University, India and an MBA from Queensland University of Technology (QUT), Australia. He received executive education in Strategy and Leadership at Harvard Business School and London Business School.

He is a fellow of Australian Institute of Management, a member of Pharmaceutical Society of Australia, and a member of Montreal Protocol's Medical Technical Options Committee (United Nations Environment Program-UNEP). Mr. Reza received the "Australian Alumni Excellence Awards 2014" in the category of Business and Leadership.



Mohammad Ali Nawaz

Chief Financial Officer

Mr. Mohammad Ali Nawaz is a well-rounded finance professional with extensive exposures in corporate finance and restructuring, merger and acquisitions, project management, supply chain and operations management. After joining Beximco Group as a Management Trainee in 1990, he worked for different entities within the group, in varying capacities. He was appointed Chief Financial Officer of Beximco Pharma in 2009. He is also a Director of Nuvista Pharma Ltd., Sanofi Bangladesh Ltd., and Beximco Pharma API Ltd.

Mr. Nawaz qualified as a CMA from the institute of Cost and Management Accountants of Bangladesh, and is currently a Fellow Member of the Institute. He also obtained an MBA from the Institute of Business Administration, University of Dhaka.



Afsar Uddin Ahmed

Director Commercial

Mr. Afsar Uddin Ahmed completed his MBA from the Institute of Business Administration (IBA), University of Dhaka, with a major in Marketing. He also received advanced management training at International Management Centre, Ilkley College, Yorkshire, UK. Mr. Ahmed has worked in and supervised a number of operational areas of BPL including Marketing, Sales, Distribution, Exports, Planning, Procurement, MIS, Business Development, Project Management and API business.

He is a Director of Beximco Pharma API Ltd. and BioCare Manufacturing Sdn Bhd, Malaysia, an associate company of Beximco Pharma. He served Sanofi-Aventis as Director Marketing of its Bangladesh business overseeing the marketing operations of several business units. Mr. Ahmed also worked as the Country Manager of BPL's Pakistan operation.



We strive to convert every possibility into a reality. We continue to develop capabilities and build scale in order to meet the challenges of the future.

Management Committee



Nazmul Hassan MP
Managing Director



Osman Kaiser Chowdhury
Member of the Board of Directors



Rabbur Reza
Chief Operating Officer



Mohammad Ali Nawaz
Chief Financial Officer



Afsar Uddin Ahmed
Director, Commercial



Lutfur Rahman
Director, Manufacturing



Zakaria Seraj Chowdhury
Head of Distribution Services &
Director, International Marketing



Shamim Momtaz
Director, Manufacturing



Mohd. Tahir Siddique
Director, Quality



Rizvi Ul Kabir
Director, Marketing



Jamal Ahmed Choudhury
Director, Accounts & Finance



Ms. Roksana Hassan
Executive Director, Financial Compliance
Audit and Internal Control



Dr. Selina Akter
Executive Director
Department of Medical Affairs



Shawkat Haider, PhD
Executive Director, Business Development
& Corporate Affairs



M A Arshad Bhuiyan
General Manager
Human Resource

Financial Highlights 2020-21

Consolidated

Net sales revenue increased  **15.2% - BDT 29,493.6m**
(2019-20: BDT 25,611.9m)

Domestic sales revenue increased  **15.4% - BDT 26,369.6m**
(2019-20: BDT 22,860.1m)


Export sales increased  **13.5% - BDT 3,124.0m**
(2019-20: BDT 2,751.8m)

Profit after tax increased  **45.7% - BDT 5,165.7m**
(2019-20: BDT 3,544.4m)

EPS increased  **45.8% - BDT 11.49**
(2019-20: BDT 7.88)

Recommended **35% cash dividend** (BDT 3.5 per share)

Beximco Pharma Standalone



Net sales increased **14.4% - BDT 26,949.4m**
(2019-20: BDT 23,557.8m)

Domestic sales increased **14.5% - BDT 23,825.3m**
(2019-20: BDT 20,806.0m)

Export sales increased **13.5% - BDT 3,124.0m**
(2019-20: BDT 2,751.8m)


Profit after tax increased **47.0% - BDT 4,943.5m**
(2019-20: BDT 3,363.4m)

EPS increased **46.9% - BDT 11.08**
(2019-20: BDT 7.54)

Beximco Pharma introduces
World's first generic Molnupiravir,
an oral antiviral drug for **COVID-19** treatment

Emorivir[®]
Molnupiravir 200 mg Capsules

Saves life by inhibiting viral replication at early stage



**BEXIMCO
PHARMA**

here's to life

Operational Highlights

Product Portfolio

24 new generics (2 post-period) in **34** different presentation forms in domestic market

- **4** for the First Time in Bangladesh
- **Remmo**, a buffered esomeprazole MUPS formulation of Esomeprazole
- **Fulphila**, a USFDA and EMA approved first Biosimilar Pegfilgrastim from Mylan
- The world's **FIRST** generic **Molnupiravir**, an oral antiviral drug for COVID-19 treatment (Post period).

10 new products from subsidiary Nuvista Pharma

International Market

- Completed **25** registrations for **22** products in **14** countries
- Entered **8** new countries: **Oman, Lebanon, Venezuela, Bolivia, Kosovo, Mexico, Congo, Mongolia**
- US FDA approval for **Flecainide Acetate** an antiarrhythmic drug
- US FDA approval for muscle relaxant drug **Baclofen** (post period)

Acquisition & Partnerships

- Acquired **54.6% stake** in Sanofi Bangladesh Limited from May & Baker Limited and Fisons Limited, UK (Post period)
- Appointed as the exclusive distributor of Serum Institute of India Pvt. Ltd (SII), for the distribution of Oxford's AstraZeneca COVID-19 vaccine in Bangladesh
- Signed the "Open pledge from Global Manufacturers of Generic Medicines against COVID-19"

Awards & Accreditation

- CPhI Pharma Award in the category of 'Innovation in Response to COVID-19'
- Global Generics & Biosimilars Awards 2021 in the category of "Company of the year, Asia Pacific" (post period).
- ANVISA (Brazil) approval for OSD (T-II), MDI and Sterile unit

Accolades and Awards

CPHI Pharma Awards 2020



Received highly prestigious CPhI Pharma Award in the category of 'Innovation in Response to COVID- 19'

Bangladesh Business Innovation Award 2021



Won "Public Service-Best COVID-19 Response awards" at the 3rd edition of the Bangladesh Innovation Award 2021

Global Generics & Biosimilars Awards 2021



Won the Global Generics & Biosimilars Awards 2021 in the category of “Company of the year, Asia Pacific”

Our People







At Beximco Pharma, we firmly believe that our greatest resource is our people. We consider our people as the catalyst behind our progress and value contribution of each and every employee towards achieving our goals. Throughout the ongoing pandemic disruptions our people have shown unwavering dedication, agility and resilience. Their committed effort has enabled us to serve our patients and other stakeholders and helped continue uninterrupted operations of our business. We believe, with the accumulated strength of our people, we can reach to a greater height in the days ahead.

Our commitment is to ensure the highest level of employee engagement by providing a congenial environment, competitive remuneration packages, end-service benefits, and importantly, career progression in the organization. BPL's HR policy is designed to attract committed and talented resources with ability to get aligned with the Company's mission, vision, values and goals and drive the value chain of the Company. The Company adopts objective, fair and unbiased evaluation criteria in the selection and recruitment process.

Our people is well composed with adequate diversity in terms of education, age, experience, and gender. We try to hire people from diversified fields of expertise. We focus on gender diversity and prefer female candidates where male and female are found equally qualified for any position. Currently, Beximco Pharma employs 210 full time permanent female employees at different levels, two of them are members of the Company's Management Committee. Employment of woman is increasing gradually across all levels of organization and in 2020-21, the number of female employees has risen by 31% over last year. The Company does not make any discrimination in terms of gender, religion, faith, color or nationality in the selection and recruitment process.


The Company is creating new employment opportunities and during the year under review, we recruited 718 employees in permanent positions befitting our business growth. There was a net addition of 349 employees in 2020-21 against 266 in 2019-20.





Training and Development:

Despite the disruptive pandemic situation, we arranged several training programs for different level of employees to equip them with right knowledge and update their skills. The Company has dedicated departments both at factory level and head office who carried out need based and tailored training programs throughout the year for employees across the organization. Besides our own expertise, we invite local and international trainers and experts to conduct trainings. Selected employees get overseas training. During the year, 252 employees received specialized training in areas such computerized system validation, brand management, strategy formulation and WHO GSDP implementation, arranged by external organizations home and abroad.





Learning and Development Centre at our Plant



The unwavering commitment of our people-their energy and enthusiasm-remain the driving force that leads us towards achieving newer milestones.

Covid-19 Support to Employee



At the beginning pandemic in 2020, we initiated package of COVID-19 support services for our employees which include 24 hours hotline services for the employees and their family members; free medical tests; free medicine and ambulance services; isolation and quarantine centers; oxygen cylinder supports; emergency food supply; hassle and risk free COVID-19 sample collection centers at convenient places; and 24/7 medical consultation services by our dedicated medical service team; and mental health care. These supports for the employees and their families continued this year as well. We continued preventive measures such as use of masks all times, temperature screening, sanitization, and wearing of personal protective equipment where necessary.

Our HR department issued different guidelines for the employees including restriction on outside travelling, attending at public gatherings etc. to minimize the risk of COVID-19 infections.

In collaboration with NOVUS Clinical Research Services, Beximco Pharma established a dedicated isolation center equipped with high flow oxygen facility for emergency use by employees in emergency cases of unavailability of hospital facilities. The center is manned with doctors, nurses and other medical staffs.

Environment, Health and Safety

Beximco Pharma cares for environment and we are mindful of our responsibilities to protecting the environment and promoting sustainable eco-friendly operations. The Company endeavors to provide a safe and healthy workplace, promote environmental excellence in our operations, and meet global EHS standards.

We consciously select technologies that meet environmental standard and use state of art machineries and equipment in our manufacturing operation. Our facilities and processes are designed to keep the environmental effects of the manufacturing activities to a practicable minimum level. Liquid and solid wastes and gaseous emissions generated from our operations controlled, disposed, and managed in the best practicable means. We actively comply with relevant government regulations and industry standards and all our manufacturing facilities have got the relevant certifications from the Department of Environment.

Beximco Pharma has stringent Occupational Health and Safety System in place to ensure the health and safety of the employees, contractors, visitors and neighbors who may be affected by its operations. The Company has a separate Environment, Health and Safety (EHS) Department manned with qualified personnel to look after EHS compliance issues. The Company also has an EHS committee composed of high-level management employees. The committee meet once in every two months to evaluate overall EHS situation and resolve identified issues. Beximco Pharma conducts EHS audit once every year. The Company also has an “Environment Health and Safety” policy which is binding for all.

Environment Sustainability Measures

Solid, Liquid Waste and Gaseous Emission Control and Conduction

The solid wastes generated from the manufacturing operation are appropriately managed complying to regulations and have no degrading effect on the environment and ecological system. The entire waste management is handled with the Best Available Technologies (BAT) that include incineration plant, dust control units and scrubber to ensure zero discharge of solid waste that may harm the surrounding ecological system. Beximco Pharma has its own incineration unit, having a capacity of 250kg per hour depending on calorific value of the products and appropriate system for the purification of generated smoke. As per international guideline, the height of the chimney is more than 30 meter. The quality of gas finally discharged from the incinerator is well within acceptable standard set by the Directorate of Environment (DoE).

Proper filter in the exhaust has been implemented to prevent dust flowing outside the building and is controlled by Building Atomization System (BAS). We installed in High-Efficiency Particulate Air (HEPA) filters and proper scrubber for enhanced protection in manufacturing areas. Dust particles collected from the filters are incinerated. There is treatment device to purify the vapour before discharging into atmosphere. Quality of air emission from Incinerator, Boiler and Generator etc. are regularly monitored.

A considerable amount of wastewater is generated mainly from washing and cleaning of machineries, empty bottles, utensils, floors, etc., The other source of liquid waste consists of dissolved and suspended API, excipients, laboratory re-agents; water from the cooling tower. The Company has adequate control over managing the liquid waste and has its own effluent treatment plant. No toxic wastewater is discharged into the open land or water bodies without treatment. About 50% of this water is recycled and used for gardening, car washing and water scrubber of incinerator while the settled sludge is incinerated.

The work of setting new generation wastewater treatment process (PLC based Membrane Bioreactor technology) considering the future load of wastewater generation has significantly progressed. This turnkey project having a treatment capacity of 605 m³/day is being implemented by Envision Enviro Technologies of India. The Submerged Membrane Unit (SMU) is being procured from KUBOTA Corporation, Japan.

Carbon Footprints

Beximco Pharma measures the carbon footprint in the factory surroundings once in every three years as per government regulations. The results have always been well below the standard limit set by DoE. The latest 2021 findings are as below:

	CO2	CO	NO2	NO	TVOC	PM10	SPM
	ppm	ppm	ppm	ppm	ppb	µg/m3	µg/m3
Government Standard	5,000	50	5	25	1,000	150	200
Result in company surroundings	425	0	0.14	1.70	0.96	31.51	192

Saving Water and Energy

We inspire the reduced use of natural resources and endeavor to use system, process or technology that helps saving water and energy. In this context we installed sensor based water taps in our facilities to reduce social water consumption. We are re-using the waste water of our WFI (water for injection) treatment plant to clean cooking utensils of used in canteen.

Beximco Pharma has introduced Economizer in the exhaust line of boiler to preheat feed water and also uses condensate recovery system to utilize hot water as a feed water of boiler. Moreover, Exhaust Gas Boiler (EGB) has been installed near the power generation unit to utilize the exhaust heat being exposed in the atmosphere to produce steam. This in one hand is thus protecting atmospheric air heat and saving energy on the other hand.

Beximco Pharma's new Learning and Development Center has been designed and built with using steel sheets and glass panels for maximum use of daylight.

Different parameters of the treated water of the plant as on September, 2021 is:

Tests	Specification	Results
pH	6.0 to 9.0	7.39
TDS	NMT 2,100 ppm	533
Dissolved Oxygen	4.5 to 8.0 ppm	5.1
COD	NMT 200 ppm	131.85
BOD	NMT 50 ppm	41.75
Arsenic	NMT 0.2 ppm	0.005

Noise, Odor And Vibration Management

Noise and certain vibrations generally produced by the electromechanical equipment may affect the surrounding. The noise requires no mitigation step as the factory is located in a non-residential/commercial area falling under 'Ga' area (mixed) as per standard. Our machineries are sound efficient and has very insignificant effect in the sound level. Machine cover in required cases are also installed to muffle the sound level. The working personnel inside the plant are provided with Personal Protective Equipment (PPE). Vibration problems are mitigated as the reactors are located at a proper distance from the boundary level. There is no major odor problem as the factory premises are regularly disinfected and scrubbers are installed in the main header of gas emission line. Latest measures of Noise level around the factory is:

	Sound dBa (2021)	Sound dBa (2020)	Sound dBa (2019)
Government Standard	75	75	75
Result in company surroundings	57	54	59

Child Labour

Beximco Pharma firmly follows the codes of Bangladesh Labor Act in all respects including restrictive provisions relating to "Employment of Adolescent". The Company does not employ any Child labour directly or indirectly.

Our CSR Initiatives

CSR is an integral part of our business. As a responsible business entity, Beximco Pharma undertakes different CSR programs aiming at serving the community at large. We are focused especially at three key areas- healthcare, education for the underprivileged children, and research. Our major CSR initiatives throughout the year include:

Free Remdesivir Injection



Beximco Pharma continues to supply Remdesivir injection free of cost to all government hospitals across the country for COVID-19 treatment. Beximco also donated 10,000 vials of Remdesivir to India through the government's medical assistance program. The supplies also included oral anti-viral, PPE kits and zinc, calcium, vitamin C tablets.

Mask Awareness Campaign



Beximco Pharma sponsored country's largest mask awareness campaign in partnership with Jaago Foundation, a leading volunteer organization in Bangladesh. The campaign took place during Durga Puja festival under the title "Mask Pori Pujay Ghuri"— aimed to inspire and create awareness among people to wear masks during the pandemic. Large quantities of masks, sanitizers and leaflets were provided for this campaign.



Support to the Government Vaccination Program

Beximco Pharma has been providing full logistics support to the government's COVID-19 vaccination program in terms of storage and nationwide distribution of Sinopharm, Moderna and AstraZeneca vaccines totally free of cost. The company has also purchased several ultra-cold freezers for supporting the storage of Pfizer vaccine received through COVAX.



Donation of Female Hygiene Products



Beximco Pharma handed over menstrual hygiene products to Sarkari Shishu Paribar (Girls) authorities on June 30, 2021. These hygiene products were distributed among 1786 girls aged above 13 years living in 42 Sarkari Shishu Paribar (Girls) orphanages across the country.

Support to IEDCR


Beximco Pharma has provided logistics and transportation support throughout the year to the Institute of Epidemiology, Disease Control and Research (IEDCR) for sample collection from various parts of the country. IEDCR is the national reference laboratory, which accounts for disease surveillance and disease outbreak investigation.

COVID-19 Equipment to Dhaka Medical College Hospital (DMCH)

Beximco Pharma handed over large quantities of COVID-19 equipment, including PPE, ceiling fans and face masks to support the frontline health workers of Dhaka Medical College Hospital. It was part of the company's continued initiatives to combat COVID-19 pandemic.



Central Oxygen Plant at Dohar and Nawabganj




Beximco Pharma has been at the forefront of the fight against COVID-19. The company provided full support to set up an oxygen plant at the Nawabganj Health Complex and Dohar Health Complex with central refillable oxygen storage capacity of 254 cubic meters and 431 cubic meters respectively to ensure uninterrupted supply of oxygen for the COVID-19 patients.

Support to Jaago's "Back To School- Education Program"



Schools in Bangladesh remained closed for long eighteen months due to COVID-19. Beximco Pharma extended support through Jaago Foundation to ensure health and safety of the returning students on reopening of the schools. The company donated COVID-19 hygiene products including sanitizer, spray bottle, masks, PPE etc to the underprivileged kids.

Donation of Medical Equipment to Charitable Dental Clinic



Donated medical equipment to a charitable dental clinic founded by Dr. Osama Bin Noor in Raipura, Narsingdi to provide quality oral health care for around half a million people living in the village. Dr. Osama Bin Noor is well known for winning Queen's Young Leaders 2016 award.

Corporate Events

Sanofi Acquisition: Deal Closing Ceremony



Beximco Pharmaceuticals Limited acquired 54.6% stake in Sanofi Bangladesh Limited. A brief ceremony on the occasion took place at a hotel in Dhaka. The event was attended by Beximco Pharma Managing Director Nazmul Hassan MP, BCIC Chairman Shah Md Imdadul Haque, Secretary to the Ministry of Industries, SM Alam, and other senior officials from both Sanofi and Beximco.



Launching of World's First Generic Molnupiravir



Beximco Pharmaceuticals Limited, launched the world's first generic Molnupiravir on 9th November 2021, following the Emergency Use Authorization by the Directorate General of Drug Administration (DGDA). Molnupiravir is an oral antiviral drug for symptomatic COVID-19 recently developed by Merck, Sharp & Dohme (MSD) and Ridgeback Bio-therapeutics. Beximco Pharma's branded generic version of Molnupiravir is being marketed as Emorivir.

We continuously review, update and expand our product portfolio in order to ensure that patients have access to newer generics and better treatment options at an affordable price.



Announcement of the Preliminary Findings of icddr,b's Clinical Trial of Ivermectin



Beximco Pharma funded the clinical trial conducted by internationally renowned research organization icddr,b to evaluate the efficacy of Ivermectin in COVID-19 patients. The randomized, double-blind, placebo-controlled clinical trial aims at evaluating the safety and efficacy of anti-parasitic medicine Ivermectin in combination with antibiotic doxycycline or Ivermectin alone. It was conducted in hospitalized adults diagnosed with COVID-19. The participating hospitals were Mugda Medical College and Hospital; Kurmitola General Hospital, and Dhaka Medical College & Hospital, Dhaka. The study findings have been published in the International Journal of Infectious Diseases (IJID) on December 2, 2020.


On December 7, 2020, icddr,b organized a dissemination seminar to share preliminary findings of the concluded study that was held in a local Hotel. National public health experts, representatives from the DGHS, DGDA, BMRC, icddr,b, Beximco Pharma and media were also present at the seminar.

About the trial, Beximco Pharma managing director Nazmul Hassan MP said, “We are pleased to sponsor the first randomized, well designed clinical trial of Ivermectin in COVID-19 patients in Bangladesh. Should the outcomes be positive from this trial, as well as other ongoing trials in different countries, Ivermectin can offer itself as a highly affordable and readily available solution for the COVID-19 pandemic.”

Media Spotlights



Forbes Singapore featured Beximco Pharma.



Beximco Pharma's Learning and Development Center was featured in The Business Standard- a popular news portal of Bangladesh.

THURSDAY, NOVEMBER 25, 2021

HOME ECONOMY STOCKS ANALYSIS WORLD+BIZ SPORTS GLITZ FEATURES VIDEOS LONG READ

বাংলা

PANORAMA

Inam Ahmed
29 July, 2021, 11:05 am
Last modified: 29 July, 2021, 10:04 pm

Facebook, Messenger, Twitter, WhatsApp, Print, Share

“If we can develop skilled manpower, we can enter any market of the world”

Rabbur Reza is the Chief Operating Officer (COO) of Beximco Pharmaceuticals Ltd--one of the largest pharmaceutical companies of Bangladesh. The Business Standard editor Inam Ahmed recently conversed with Reza about Beximco’s success in the US drugs market, and the overall export potentials of Bangladesh’s pharmaceutical industry.


3 white men convicted of murdering Ahmaud Arbery in Georgia

US weekly jobless claims hit 52-year low, economy regaining speed

China denounces US for inviting Taiwan to democracy summit

Supply shortages are easing in US and worsening in Europe

India and US aim to expand farm trade, resolve market access issues



Rabbur Reza, COO of Beximco Pharmaceuticals Ltd

Chief Operating Officer (COO) of the Company, Mr. Rabbur Reza was interviewed by The Business Standard about Beximco Pharma’s success in the US drugs market, and the overall export potentials of Bangladesh’s pharmaceutical industry.

LEASING MONEY Investing Retirement Credit Cards Loans Banking Personal Finance Careers Real Estate Advisors

Home / Money / Investing / Investing News

Bangladesh's Beximco to Sell First Generic Version of Merck COVID-19 Pill

By **Beutika** | Nov 9, 2021, at 2:30 a.m.

Share Facebook Twitter YouTube Print



FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 28, 2021. Merck & Co Inc/Handout via REUTERS

The Financial Express

Thursday, 25 November 2021 | Today's FE | e-Paper

HOME ECONOMY STOCK TRADE NATIONAL WORLD EDITORIAL VIEWS MORE T20 WORLD CUP INTO 25TH YEAR OF PUBLICATION

Health

Bangladesh okays production of Merck's COVID pill by Beximco Pharma

FE ONLINE DESK | Published: November 09, 2021 10:35:10 | Updated: November 10, 2021 17:58:54



Media coverage of the manufacture of Molnupiravir.

Chairman's Statement



A S F Rahman
Chairman

I am delighted to report yet another year of excellent performance of Beximco Pharmaceuticals Limited. Amidst pandemic-hit economic and social onslaught, we ended the year with commendable operational and financial performance. We not only achieved our targets but also set few milestones, delivered results and progressed towards successful accomplishment of our strategic goals to strengthen the shareholders' value.

Economic and social life in Bangladesh throughout 2020-21 remained volatile because of the pandemic. Despite constraints and disruptions, we attained impressive sales growth in domestic and international markets, achieved remarkable profit growth and further reinforced our market position. Our overall sales increased by 15.2% with domestic market growing by 15.4% and export by 13.5% over prior year. Pre-tax and post-tax profit recorded 37.1% and 45.7% YoY growth, respectively. This is indeed an appreciable achievement and manifest our strength to withstand challenges and uncertainties to achieve business goals.

As part of our strategy to diversify, expand and reinforce our market position, we completed our second strategic acquisition within three years following the successful acquisition of Nuvista Pharma in 2018. Beximco Pharma acquired 54.6% stake in Sanofi Bangladesh Limited, the Bangladesh operation of the multinational pharmaceutical company Sanofi S.A. We acquired the foreign shareholding in the Company from May & Baker Limited and Fisons Limited, UK while the remaining 45.4% remains with the government of Bangladesh represented through the Ministry of Industries and Bangladesh Chemical Industries Corporation. This acquisition is a strategic fit for Beximco Pharma and I believe, it will generate opportunities for long-term value creation for the Company.

We introduced the world's first generic remdesivir in 2020. This year we set yet another milestone and drew global attention when Beximco Pharma launched a generic copy of molnupiravir, the first oral antiviral drug for the symptomatic treatment of COVID-19.

Our pioneering roles and initiatives to innovate and deliver high-quality medicines to the people have continued to earn recognitions from home and abroad. This year we won the CPhI Pharma Awards 2020 for "Innovation in Response to COVID-19". We also won the Global Generics & Biosimilars Awards 2021 in the category of "Company of the year, Asia Pacific" for the second time.

To sustain the growth momentum, we made significant investment in our Unit-3 manufacturing facilities. The project is almost complete and few of the manufacturing lines are now producing validation batches, while the rest will be operational in phases after validation and product transfer. This facility, once fully operational, will significantly increase our production capacity, ease our manufacturing constraints and secure our future growth.

Mr. Shah Monjurul Hoque, an Independent Director of the Board and a member of the Audit Committee, retired on completion of his tenure of office for two consecutive terms. On behalf of the Board, I thank Mr. Hoque for his guidance and valuable contribution as a director of the Company.

Mr. Hoque has been replaced by Dr. Md. Ibraheem Hosein Khan. Dr. Khan is a retired Civil Servant and last served as the Secretary, Ministry of Cultural Affairs, Government of Bangladesh. I welcome Dr. Khan in the Beximco Pharma family. The Board has appointed him as the Chairman of the Nomination and Remuneration Committee (NRC). I assure Dr. Khan all necessary co-operation in discharging his duty as an Independent Director and Chairman, Nomination and Remuneration Committee (NRC).

The Audit Committee and the Nomination and Remuneration Committee have carried out their respective responsibilities with utmost sincerity and diligence. On behalf of the Board, I like to thank the Chairman and members of both the committees for their sincere efforts and valued contribution.

I am truly proud of our devoted people, who showed strong resilience and commitment during this period of pandemic turmoil. It's because of their unwavering dedication we could continue seamless operations and steady supply of medicines to the people of home and abroad. I extend my sincere gratitude to each of our employees.

I also note with gratitude the contributions of all healthcare professionals and workers especially, the doctors, nurses, and other medical caregivers, for their invaluable services to the pandemic stricken people.

Finally, I express my thanks to you, respected shareholders, for extending invaluable support at all times. I wish you all good health and safe life.

Thanking you



A S F Rahman
Chairman

চেয়ারম্যানের প্রতিবেদন

সম্মানিত শেয়ারহোল্ডারবৃন্দ,

বেক্সিমকো ফার্মাসিউটিক্যালস লিমিটেড তার ধারাবাহিক সাফল্যের আরো একটি বছর সুসম্পন্ন করেছে। মহামারীর কারণে সারা বছর জুড়ে দেশের অর্থনৈতিক ও সামাজিক পরিবেশ ছিল প্রতিকূল। এতদসত্ত্বেও আমরা আমাদের ব্যবসায়িক লক্ষ্যমাত্রা অর্জনের পাশাপাশি কোম্পানীর আর্থিক প্রবৃদ্ধি অর্জনের মাধ্যমে শেয়ারহোল্ডারদের দীর্ঘমেয়াদী স্বার্থ সংরক্ষণের সাথে সংশ্লিষ্ট কৌশলগত লক্ষ্য বাস্তবায়নে কিছু নতুন মাইলফলক স্থাপন করতে সক্ষম হয়েছি।

প্রতিকূল ও অনিশ্চিত পরিস্থিতি বিরাজমান থাকা সত্ত্বেও ২০২০-২১ইং সালে আমরা আভ্যন্তরীণ বিক্রয় ও রপ্তানীর ক্ষেত্রে লক্ষ্যনীয় প্রবৃদ্ধি অর্জন করেছি, আমাদের মুনাফা উল্লেখযোগ্য পরিমাণ বৃদ্ধি পেয়েছে এবং বাজারে আমাদের অবস্থান আরো সুসংহত ও সুদৃঢ় হয়েছে।

গত বছরের তুলনায় এ বছর আমাদের সার্বিক বিক্রয় রাজস্ব ১৫.২% বেড়েছে। দেশীয় বাজারে এই প্রবৃদ্ধির হার ১৫.৪% এবং রপ্তানীর ক্ষেত্রে এই প্রবৃদ্ধির হার ১৩.৫%। আমাদের কর পূর্ব ও কর পরবর্তী মুনাফা যথাক্রমে ৩৭.১% ও ৪৫.৭% বৃদ্ধি পেয়েছে। আলোচ্য বছরে আমাদের ব্যবসায়িক সাফল্য কৃতিত্বের দাবী রাখে। যেকোন চ্যালেঞ্জ ও অনিশ্চয়তা মোকাবেলায় আমাদের যে সার্বিক সামর্থ্য রয়েছে এটি তার পরিচয় বহন করে।

বহুমুখীকরণ এবং বাজার সম্প্রসারণের মাধ্যমে কোম্পানীর অবস্থানকে আরো সুদৃঢ় ও সুসংহত করার কৌশলগত লক্ষ্যে এ বছর আমরা Sanofi Bangladesh Ltd. এর ৫৪.৬% শেয়ার অধিগ্রহণ করেছি। ২০১৮ সালে নুভিস্তা ফার্মা লিমিটেড এর অধিগ্রহণের তিন বছরের মধ্যে এটি আমাদের দ্বিতীয় গুরুত্বপূর্ণ কৌশলগত অধিগ্রহণ। Sanofi Bangladesh Ltd. বিশ্বখ্যাত ফার্মাসিউটিক্যাল কোম্পানী Sanofi SA এর একটি অঙ্গ প্রতিষ্ঠান। বেক্সিমকো ফার্মা Sanofi Bangladesh Ltd. এর বিদেশী মালিকানাধীন অংশ May and Baker Ltd. এবং Fisons Ltd., UK এর নিকট থেকে ক্রয় করে। অবশিষ্ট ৪৫.৪% শেয়ার বাংলাদেশ সরকার তথা বাংলাদেশ শিল্প মন্ত্রণালয় ও বাংলাদেশ কেমিক্যাল ইন্ডাস্ট্রিজ কর্পোরেশনের মালিকানায় রয়েছে। এই অধিগ্রহণ বেক্সিমকো ফার্মার কৌশলগত লক্ষ্যের সাথে যথাযথভাবে সামঞ্জস্যপূর্ণ। আমার বিশ্বাস, এটি কোম্পানির দীর্ঘ-মেয়াদী লক্ষ্য অর্জনে একটি গুরুত্বপূর্ণ ভূমিকা পালন করবে।

২০২০ সালে বিশ্বে আমরাই প্রথম জেনেরিক রেমডেসিভির (remdesivir) উৎপাদন ও বাজারজাত করেছিলাম। এবছর আবারও আমরা সারা বিশ্বে প্রথম কোম্পানী হিসাবে Molnupiravir এর জেনেরিক ভার্সন বাজারজাত করে নতুন মাইলফলক স্থাপন করেছি, বিশ্বব্যাপী যা নজর কেড়েছে। Molnupiravir কোভিড-১৯ চিকিৎসায় মুখে গ্রহণযোগ্য প্রথম অ্যান্টিভাইরাল ঔষধ।

ঔষধ উৎপাদনে আমাদের উদ্ভাবনী সক্ষমতা এবং মানুষের কাছে তা সহজলভ্য করার ক্ষেত্রে আমাদের প্রচেষ্টা, দেশে বিদেশে ক্রমাগত স্বীকৃতি পাচ্ছে। এরই ধারাবাহিকতায় এ বছর আমরা CPhI Pharma Award in the category of 'Innovation in Response to COVID -19' এবং দ্বিতীয়বারের মত Global Generics & Biosimilars Awards 2021 in the category of "Company of the year, Asia Pacific" অর্জন করেছি।

দীর্ঘমেয়াদে প্রবৃদ্ধি ধরে রাখার জন্য আমাদের উৎপাদন সক্ষমতা বৃদ্ধি অত্যন্ত জরুরী এবং এ লক্ষ্যে আমরা আমাদের ইউনিট-৩ উৎপাদন প্রকল্পে উল্লেখযোগ্য পরিমাণ বিনিয়োগ করেছি। প্রকল্পটি প্রায় সম্পূর্ণের পথে। ইতিমধ্যে এর কয়েকটি উৎপাদন লাইন validation batch তৈরি শুরু করেছে, বাকিগুলি validation ও product transfer কার্যক্রম সম্পন্নের মাধ্যমে পর্যায়ক্রমে উৎপাদনের জন্যে প্রস্তুত হবে। এই উৎপাদন প্রকল্পটি সম্পূর্ণভাবে চালু হলে আমাদের উৎপাদন সক্ষমতা উল্লেখযোগ্যভাবে বৃদ্ধি পাবে যা ভবিষ্যত প্রবৃদ্ধি অর্জনে সহায়ক হবে।

পরিচালনা পর্ষদের স্বতন্ত্র পরিচালক এবং অডিট কমিটির সদস্য জনাব শাহ মঞ্জুরুল হক পর পর দুই মেয়াদে দায়িত্ব পালন শেষে এবছর পরিচালনা পর্ষদ থেকে অবসর গ্রহণ করেছেন। আমি পরিচালকমণ্ডলীর পক্ষ থেকে জনাব শাহ মঞ্জুরুল হককে কোম্পানীর পরিচালনা কার্যক্রমে গুরুত্বপূর্ণ অবদান রাখার জন্য ধন্যবাদ জানাচ্ছি।

ডঃ মোঃ ইব্রাহিম হোসেন খান একজন স্বতন্ত্র পরিচালক হিসাবে জনাব শাহ মঞ্জুরুল হক এর স্থলাভিষিক্ত হয়েছেন। ডঃ খান একজন অবসরপ্রাপ্ত সরকারি কর্মকর্তা। তিনি গণপ্রজাতন্ত্রী বাংলাদেশ সরকারের সংস্কৃতি মন্ত্রণালয়ের সচিব হিসেবে অবসর গ্রহণ করেন। আমি ডঃ খানকে বেঞ্জিমকো ফার্মা পরিবারে স্বাগত জানাই। পরিচালনা পর্ষদ তাকে Nomination and Remuneration কমিটির চেয়ারম্যান হিসেবে দায়িত্ব প্রদান করেছে। একজন স্বতন্ত্র পরিচালক এবং Nomination and Remuneration কমিটির চেয়ারম্যান হিসেবে দায়িত্ব পালনে সর্বাত্মক সহযোগিতার ব্যাপারে আমি ডঃ খানকে পূর্ণ আশ্বাস প্রদান করছি।

অডিট কমিটি এবং Nomination and Remuneration কমিটি অত্যন্ত আন্তরিকতার সাথে তাদের দায়িত্ব যথাযথভাবে পালন করেছেন। আমি পরিচালনা পর্ষদের পক্ষ থেকে উভয় কমিটির চেয়ারম্যান এবং সদস্যদেরকে তাদের মূল্যবান অবদানের জন্য ধন্যবাদ জানাচ্ছি।

আমি আমাদের নিবেদিতপ্রাণ কর্মীদের নিয়ে অত্যন্ত গর্বিত। তারা এই মহামারীকালীন সময়ে অত্যন্ত দৃঢ় মনোবল দেখিয়েছেন এবং তাদের স্বস্থ দায়িত্ব নিষ্ঠার সাথে পালন করেছেন। তাদের আনুগত্য এবং দায়িত্বপূর্ণ আচরনের ফলে কোম্পানীর ব্যবসায়িক কার্যক্রম এবং দেশ বিদেশে ওষুধের নিরবিচ্ছিন্ন সরবরাহ সম্ভব হয়েছে। আমি এজন্য তাদের প্রত্যেককে আমার আন্তরিক কৃতজ্ঞতা ও ধন্যবাদ জানাচ্ছি।

আমি স্বাস্থ্যসেবার সাথে সংশ্লিষ্ট ডাক্তার, নার্সসহ স্বাস্থ্য ও চিকিৎসা সেবা প্রদানকারী সকলকে আমার আন্তরিক কৃতজ্ঞতা জানাচ্ছি। মহামারী আক্রান্ত মানুষের পাশে থেকে তারা তাদের অক্লান্ত সেবা প্রদান অব্যাহত রেখেছেন।

পরিশেষে, আমাদেরকে সার্বিক সহায়তা প্রদান এবং সবসময় আমাদের উপর আস্থা রাখার জন্য আমি আমাদের সম্মানিত শেয়ারহোল্ডারদের ধন্যবাদ জানাই।

আমি সকলের সুস্বাস্থ্য এবং দীর্ঘজীবন কামনা করছি।

ধন্যবাদান্তে,

X. L. P. Lalund.

এ এস এফ রহমান
চেয়ারম্যান





Nazmul Hassan MP
Managing Director

Management Discussion and Analysis

We completed yet another challenging year amidst the ongoing pandemic that continued to disrupt business and economic activities around the world. Global Covid-19 deaths have now surpassed five million and countries are still battling the highly infectious delta strain of the virus. The biggest vaccination campaign in history is currently underway but there remains a wide gap in vaccine access. Out of 7.86 billion doses of vaccine administered worldwide, only 5.1% have been in low-income countries and this vaccine inequity remains the biggest obstacle to ending this pandemic.

Bangladesh started its nationwide vaccination in early February with AstraZeneca/Covishield vaccine from Serum Institute India (SII), even ahead of many developed nations. But an unforeseen export restriction on vaccine imposed by the Indian Government due to their worsening pandemic situation, badly disrupted Bangladesh's vaccination program. The country has so far received 8 million doses of Covishield vaccine out of contracted 30 million doses being purchased under a tripartite agreement among Beximco Pharma, GoB and SII. However, as the Covid vaccine manufacturers in developed nations ramped up their production with large proportion of their populations already vaccinated, some rich countries namely US, Canada, UK, Japan, Germany began donating surplus vaccines to low and middle-income countries through the WHO-led Covax initiative. The country till to date has administered 92 million doses with 21% population fully vaccinated. Majority of the vaccines are currently being supplied under GoB's commercial deal with Chinese firm Sinopharm, while large quantities are committed through Covax to vaccinate almost 70% our population by the first quarter of 2022.

On the economic front, as the pandemic headwinds ease and economic activities are returning to normal, Bangladesh achieved GDP growth of 5.4% in 2020-21 with per capita income rising to \$2,227. According to the latest World Bank projection, Bangladesh's GDP will grow by 6.4% in the 2021-22 driven by export and remittance. As Bangladesh celebrates the golden jubilee of its independence, the country has achieved another historic milestone in its pursuit of development when it received the final recommendation from UN to graduate from the LDC category. Bangladesh was set to leave the LDC group in 2024. However, in view of the COVID-19 pandemic and, as per the request from Bangladesh government, the graduation year is now deferred to 2026.

Global pharma industry remains at the forefront in the fight against the pandemic and Bangladesh is no exception. Despite facing all the pandemic challenges, Bangladesh pharma industry maintained double digit growth. Pharmaceutical export from Bangladesh also grew by 25% to \$169 million in the last fiscal. Export of COVID-19 drugs, especially remdesivir and Favipiravir, played an important part in achieving this growth. Government supportive policy towards the industry remains unchanged.

Review of Operations

Sales, Products and Markets

Beximco Pharma continued to perform strongly maintaining its growth momentum with remarkable increase in sales, operating, pre-tax and post-tax profit- all attaining impressive double digit growth. Our domestic sales revenue grew by 15.4% to reach at Taka 26,369 million. Defying the supply chain and logistic challenges, we managed to maintain the growth trajectory of our export. During the year, our export revenue fetched Taka 3,124 million registering a 13.5% increase over last year, with over 50% of the total export shipped to highly regulated developed markets. Beximco Pharma alone now contributes 22% of the country's total export of pharmaceutical products.

We expanded our product portfolio with 24 new generics available in 34 different presentations, 4 of them for the first time in Bangladesh. We have maintained our leadership positions in key therapy areas, namely cardiovascular, respiratory and analgesic. We also performed exceptionally well with diabetes, anti-infective and CNS categories. During the year, we introduced buffered Esomeprazole MUPS Brand - Remmo® which has been well accepted by the market. We also launched Fulphila® (6 mg/ 0.6 ml prefilled syringe), the first USFDA and EMA approved biosimilar pegfilgrastim from Mylan for supportive treatment of chemotherapy. Fulphila is our second biosimilar product launched under the Mylan deal.

In November 2021, Beximco Pharma became the first in the world to launch a generic copy of molnupiravir, the first oral antiviral drug for the symptomatic Covid-19, which was originally developed by Merck Sharp & Dohme (MSD) and Ridgeback Biotherapeutics. Molnupiravir is being hailed as a game changer which reportedly cut the risk of hospitalisation and death by half. Beximco Pharma's branded generic version of molnupiravir is being marketed as Emorivir. Mentionable that, Beximco Pharma made global headlines with the launch of the world's first generic version of remdesivir, under the brand name bemsivir, in May 2020.

In the international market, we completed 25 registrations for 22 products in 14 countries and entered eight new markets, namely Oman, Lebanon, Venezuela, Bolivia, Kosovo, Mexico, Congo, and Mongolia. Beximco Pharma remains the country's lone exporter of medicines to the US and this year the Company launched its 7th product an anti histamine drug cyproheptadine, in this important market. We received the US FDA approval for antiarrhythmic drug flecainide acetate (50, 100, and 150 mg tablets) and muscle relaxant drug baclofen (10 and 20 mg tablets). As of today, we have nine ANDAs approved in the US market that have been fully developed in-house besides eight ANDAs acquired from Sandoz in 2019.

Acquisition of Sanofi Bangladesh

After the successful acquisition of Nuvista Pharma in 2018, this year we acquired a majority stake (54.6 percent) in Sanofi Bangladesh Limited (SBL) a multinational pharmaceutical company operating in Bangladesh since 1958. This acquisition is a major milestone for us and in line with our strategy to further consolidate our domestic market position and accelerate growth. SBL produces over 100 generic brands with strong footings in cardiology, diabetes, oncology, dermatology and CNS. SBL also sells Sanofi's global brands of vaccines, insulins and chemotherapy drugs in Bangladesh through direct imports. SBL's rich product offerings will largely supplement our product portfolio and reinforce our strategy to diversify into new and expanding specialty therapy areas. We believe leveraging our robust product development skills & strong sales-marketing infrastructure and utilizing the manufacturing platforms of SBL, we will be able to generate substantial opportunities for long-term value creation for Beximco Pharma.

Support to Community

Ensuring uninterrupted supply of quality medicines during lockdowns and supply chain disruptions was more than just a business to us. Our dedicated and committed team successfully accomplished this goal. Beximco Pharma took several initiatives to support the community throughout the pandemic. Notable among them, were donating negative pressure isolation canopies to leading hospital, supplying remdesivir free of cost to Government designated COVID-19 hospitals, providing PPE and masks for the health professionals, giving logistics support to DMCH and IEDCR, sponsoring country's biggest mask awareness campaigns etc. Beximco Pharma offered full support to the country's vaccination program by providing free of charges storage and nationwide distribution services of all COVID-19 vaccines namely Sinopharm, Moderna, AstraZeneca procured by the Government from different sources other than the supply under contract with SII. As on the reporting date, we have distributed 90 million doses, almost all of the country's COVID19 vaccines nationwide.

Awards and Recognitions

This year we won the prestigious CPhI Pharma Awards 2020 for "Innovation in Response to COVID-19" which is a clear testimony of our initiatives and capabilities to face challenging situations. The Company also won the Global Generics & Biosimilars Awards 2021 in the category of "Company of the year, Asia Pacific" for the second time. This prestigious award recognizes the tremendous achievements made by the global generics and biosimilar industries in delivering high-quality medicines to those who need them most.

Beximco Pharma received Special Appreciation as one of the Top Taxpayer Companies from the Large Taxpayer Unit of the National Board of Revenue. It became one of the top income tax payers in the manufacturing sector category.

Accounting Policies and Estimates

Bangladesh has adopted International Financial Reporting Standards (IFRS)/International Accounting Standards (IAS). Beximco Pharma has been consistently applying these standards in preparation of its financial statements. Management has the discretion to decide on the accounting policies within the financial reporting framework and make estimates and provisions in preparing those financial statements. The Company's accounting policies remain consistent with those of the previous year and there has been no changes in the accounting policies that could materially impact the financial statements. The accounting estimates and provisions are based on prudent judgments.

Risks Related to the Financial Statements

The Company has a robust system of internal control and well-designed accounting reporting process. The Company's accounting and finance functions are manned with adequate experienced professionals. Appropriate policies and procedures, as well as adequate review and control mechanisms are in place in every steps of the financial reporting value chain to avoid, eliminate or reduce the risk of errors, omissions or material misstatements in the financial reports. Moreover, quarterly and annual public reports are subject to rigorous review by the Board's audit committee in addition to the annual accounts being audited by independent external auditors.

Looking Forward

We started 2021-22 with a positive outlook amidst the uncertainties and challenges emanating from any new wave of the pandemic. However, gaining from our experience over the last two years and relying on our strength of resilience, we remain confident to explore the maximum business potentials in any challenging situation.

Acquisition of Sanofi Bangladesh is an important strategic step to reinforce our market position through diversified portfolio and expanded market reach. This year, one of our key priorities would be to realign and restructure the business and operating model of SBL and ensure its successful integration to build strong foundation for a sustainable growth of business.

Ensuring safety of our employees remains our top priority. We will take all possible measures to keep them safe. I am immensely proud of our dedicated people who demonstrated exceptional resilience in the face of this global pandemic. It's because of their unwavering commitment and courage we could continue our operations and ensure uninterrupted supply of medicines to every corner of the country even during lockdowns.

Throughout the pandemic, Beximco Pharma has stood by the healthcare professionals of the country. In addition to our various initiatives for supporting them, we want to express our gratitude saying 'Thank you' to each and every frontline health worker who puts their lives at stake in order to save countless lives.

My heartfelt gratitude to all our employees for their hard work and dedication in this extremely difficult time.

Finally, I would like to extend my sincere thanks to all our stakeholders for showing their confidence and trust on us.

Nazmul Hassan

Nazmul Hassan MP
Managing Director



Report of the Directors to the Shareholders

I am pleased to place before you the Directors' Report and the Audited Accounts of the Company for the year ended 30 June 2021 along with the report of the auditors thereon.

General Economic Overview

With some ease of the pandemic following substantial vaccination progress in advanced countries and its rollout in other countries, the global economy is gradually rebounding although the risk of another wave of the pandemic remains a concern. The world economy, as per OECD, is projected to grow 5.7 percent in 2021 and 4.5 percent in 2022, as against a 3.5 percent contraction in the pandemic hit 2020. The global trade and supply chain severely affected during the peak of the pandemic has improved showing the signs of returning to normalcy.

Bangladesh detected its first case of Covid-19 in March 2020. Since then, responding to the varying severity of surge of the virus, Government intermittently imposed lockdowns and other restrictive measures to contain its spread. Throughout the year, the industry and business passed difficult time especially in the first and fourth quarter, when Bangladesh faced two surges of Covid-19 upsetting the life and livelihood of the people. With the emergence of the delta variant, almost a quarter of FY 2020-21 was under lockdowns and restrictions of varying degrees, adversely affecting the economic activities of the country. Alongside the vaccination program, Government took up several fiscal and non-fiscal measures to support business and keep the economy afloat. It has so far announced 28 stimulus packages worth Taka 1.35 trillion for mitigating the adverse impact of the pandemic and to facilitate faster recovery of the economy. Other supporting measures include relaxation of interest rates, relaxed repayment schedule and loan classification rules, extended settlement time in foreign trade, duty and tax waivers for import and sale of all Covid-19 related medicines, supplies and equipment.


Bangladesh economy relying on robust inflows of wage earner's remittances and rebound of export, bounced back and grew by 5.47% during FY 2020-21, a strong turnaround from 3.51% of prior year. The inflation rate remained stable at around 5.6%. Low import payment, higher foreign remittance helped reach the forex reserve at 46.39 billion and the exchange rate of Taka against its intervening currency the USD, remained broadly stable throughout 2020-21. However, with the ease of pandemic and unwinding of disrupted supply chain, import of raw materials and capital machinery significantly rose. The Inflow of wage earners' remittance on the other hand, in recent months has declined. These caused depreciation of Taka against US Dollar by around 1% during the first quarter of the new fiscal year.

The economic outlook of Bangladesh in the prevailing global context appears encouraging with Government projecting a 7.2% growth in 2021-22. The World Bank and multilateral agencies however projects 6.4% to 6.8% growth for Bangladesh.

Review of Financial Performance

Impressive sales and Profit Growth

The Company despite a challenging market condition prevailing throughout the fiscal period, achieved remarkable progress in all parameters of financial performance. Our consolidated sales registered a 15.2% increase to reach at Taka 29,494 million from Taka 25,612 million of previous year. Sales in the domestic market increased by 15.4% while our export rose by 13.5% to Taka 3,124 million. The operating profit rose by 18.6% to Taka 6,651 million, while the pre-tax profit increased by 37.1% to Taka 6,378 million. The net profit after tax reached to Taka 5,166 million with remarkable 45.7% YoY growth. Earnings per share rose by 45.8% to Taka 11.49 from Taka 7.88 of prior year. Improved sales mix and relatively stable exchange rate coupled with leverage effect of higher sales volume has helped maintain the gross margin at 47.2%, marginally higher over 46.5% of last year. The operating expenses remained contained at 24.6% of sales.



Improved Operating Cash flow

Strong sales and profit growth enabled to generate a healthy cash flow. Our Net Cash from Operating Activities increased to Taka 6,023 million against Taka 5,542 million of prior year, registering an 8.7% YoY increase. The Company used cash of Taka 2,521 million for acquisition of property, plant and equipment compared to TK 2,243 million of previous year. The Company also repaid long term borrowing of Taka 505 million and short term borrowing of Taka 2,375 million during the year. These resulted a decline in Company's bank borrowings by Taka 2,873 million to Taka 7,631 million from Taka 10,504 million of prior year. Net Operating Cash Flows Per Share (NOCFPS) however, slightly dropped to Taka 13.50 against Taka 13.67 of prior year due to increase in the number of shares declared as stock dividend for the year 2019-20.

Subsidiary Companies

Nuvista Pharma Limited

Nuvista Pharma Limited (NPL) has almost doubled its revenue in a short span of three years since acquisition by Beximco Pharma. Along with sales, the company made strong improvements in other areas of operating and financial performance, especially in prescription share, product portfolio, operating and net profit.

In FY 2020-21, it registered 24.0% growth in sales to reach at Taka 2,572 million. Profit after tax stood at Tk. 300 million, a 22.9% increase over the prior year. Because of strong cash flow resulting from impressive sales growth, NPL is now meeting its working capital requirements from its own cash flow with insignificant or no use of bank credit facilities.

	Taka in million			
	2020-21	2019-20	2018-19	2017-18
Total Sales	2,572	2,074	1,669	1,320
Profit Before Tax	421	334	108	(59)
Net Profit	300	244	90	(95)
Earnings Per Share	25.51	20.75	7.62	-8.06
Net Operating Cash Flows Per Share	34.76	28.23	19.87	14.33
Dividend (Cash)	40%	35%	20%	5%

Sanofi Bangladesh Limited

Beximco Pharma completed the acquisition of 54.6% stake in Sanofi Bangladesh Limited (SBL) at a consideration of approximately Taka 469.62 crore (equivalent £39.35 million) pending final closing adjustments, if any. The transfer of ownership was completed by end of business day of September 30, 2021 and SBL effectively became a subsidiary of Beximco Pharma from October 1, 2021. Sanofi Bangladesh, therefore, has not been consolidated in the current reporting period. The acquisition of Sanofi Bangladesh has been disclosed in the annual report as an event after reporting period.

Beximco Pharma API Limited

This company was formed with an intent to set up a facility at API industrial park being developed by the government of Bangladesh, to manufacture Active Pharmaceutical Ingredients (APIs) for domestic and international market. However, the company is still in the initial phase and has carried out no operational activities during the year.

Continuity of Other Income

The Company reports Cash Incentives on Exports on submission of claims fulfilling the eligibility criteria. Claims for export incentives are to be made after receipts of the export proceeds. Companies are allowed six-month time from the date of receipts of the export proceeds to claim incentives. Income from this source for the period 2020-21 was Taka 310 million as against Taka 140 million of 2019-20. The Cash Incentive on Export recorded a significant increase over the comparable prior period because of lower submission of application in the initial period of the introduction of the incentive scheme in 2019-20 fiscal year. Moreover, Company's export is mostly on deferred payment basis. As such, application against the export of a particular year may be stretched over the next financial year. Income from cash incentive is dependent on the value of export made and the amount of proceeds remitted in a particular year.

The Company earned a net amount of Taka 542 million as Vaccine Distribution Fee under a tripartite agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Pvt. Ltd ('SII') for the supply of Oxford University /AstraZeneca SARS-CoV-2 AZD 1222 Vaccine in Bangladesh. The Company delivered seven million vaccines out of contracted thirty million doses during the reported period. Any future earning from this source is dependent on the delivery of the committed quantity of the vaccine under the agreement.

We have royalty income from our subsidiary Nuvista Pharma and overseas partners for the sale of few selected products. The royalty earned from Nuvista Pharma has been eliminated as inter-company transactions in the consolidated financials. Royalty income linked to the volume of sale of the particular products.

Forfeited PF Refund of Taka 11 million included in other income relates to the refund made by the Provident Fund Trusts as per directive of Financial Reporting Council (FRC) vide their notification No 179/FRC/FRM/Notification/2020/2 dated July 7, 2020. This represents the accumulated balance of the forfeited amount since 2015 and future income from this source will either be insignificant or none. The other items under the head “Other Income” are either insignificant or inherent to normal business operations.

Profit and its Appropriation

Directors propose the appropriation of profit as follows:

Amount in Taka'000

Particulars	BPL (Stand-alone)	
	2020-21	2019-20
Net Profit After Tax	4,943,488	3,363,400
Adjustment for depreciation of Revalued Assets	7,180	8,114
Profit Brought Forward	18,906,148	16,548,524
Profit Available for Appropriation	23,856,816	19,920,038
Proposed Dividend:		
Cash Dividend	(1,561,392)	(608,334)
Stock Dividend	----	(405,556)
Profit Carried Forward	22,295,424	18,906,148

Dividend

The Board of Directors recommends 35% Cash Dividend i.e. Tk. 3.50 per share for the year ended 30 June 2021 for onward approval at the Annual General Meeting. The Company has declared no interim dividend during the year.

Risks and Concerns

Every business operates in a volatile, uncertain, complex and ambiguous environment. Organizations thus are exposed to risks that might arise from internal or external sources. Recent pandemic has shattered global supply system and disrupted trade, communication and usual movements of people. Businesses, irrespective of nature, size and geographic location, have been adversely affected at varying degrees. The unpredicted and uncontrollable challenges of this type have brought the necessity of robust risk management into forefront.

Beximco Pharma, like any other business or industry, is operating in a dynamic and competitive market and thus exposed to risks that may affect its business. The senior management of the Company oversees risk management processes on a continual basis. Management of risks involves identification and assessment of risks; setting standards on company's risk appetite; and designing, implementing and monitoring policies to address various financial and non-financial risks. While the Company has robust policies and procedures in place at functional, operational and strategy level to mitigate risks from internal and external sources, there are uncertainties beyond control of the Company which might adversely affect its business and deter achievement of its targets.

Economic Risks

Any decline in economic growth could, as for any other industry, impact the future demand for pharmaceutical products. Thus company might not meet its expected growth in revenue. Bangladesh, however, maintained steady economic progress over the years with substantial uplift in all socio-economic indices and it is anticipated that trend will continue in the near future.

Market Risk

The Company has borrowings from local and overseas sources. Interest rates are variable and any significant rise in interest rates might impact the financial results of the Company. Foreign borrowings, in addition to interest rate are subject to foreign exchange risk. Company however, has strong revenue and cash flow stream to meet its financial obligations. Domestic interest rate remains

more or less stable due to intervention by government. Moreover, government has capped the maximum lending interest rate at 9%, which mitigates the risk of any abrupt increase in the rate of interest. Additionally, the interest rate of major foreign loan is based on Euribor which is currently negative. The Company has growing export proceeds that give a natural hedge to partially neutralize the adverse impact of the exchange rate fluctuations. Government intervenes in the market through its monetary and fiscal measures to keep the forex market stable, which is another protection for the Company.

Interest Rate and Foreign Exchange Risk

Other market risks are interest rate risk and foreign exchange risk. The Company has borrowings from local sources and abroad. Local borrowings are on variable interest rate. Rise of interest rates will impact the financial results of the Company. However, considering the finance expenses in contrast with total revenue and expense of the Company, the impact is not that much. Moreover, this risk is greatly mitigated due to intervention of the Govt by capping the maximum interest rate which is currently 9%. Foreign borrowings are subject to both interest rate risks and foreign exchange risks. Rise of interest rates and appreciation of currency have adverse impact on company's profitability. The Company's main foreign loan is based on Euribor which is negative thus not to impact on borrowing costs. Exchange rate between USD and BDT remained broadly stable during the year under review. Moreover, the company, having export proceeds, has a natural hedging for a certain portion of foreign exchange transaction especially repayment against foreign loan and other overseas expenses. Government intervenes in the market through its monetary and fiscal measures to keep the market stable which is another projection for the Company. Due to absence of derivatives market in the country, the Company remain exposed to some foreign exchange risks mainly for its payment against import. However, impact shall not be severe considering the low volume of open foreign exchange exposure compared to total operations of the Company.

Input price and Supply Chain Risk

Pharmaceutical companies in Bangladesh are largely dependent on imported APIs. Any substantial increase in prices of materials and disruptions in the supply chain may affect the cost of production. Because of regulatory control and sensitivity to public health, prices of pharmaceutical products can't be promptly adjusted responding to the rise in cost and thus the attainment of the profit target might be hindered. To mitigate the risk, Beximco Pharma imports raw materials from multiple sources, both local and international, at competitive prices. The Company is not reliant on any single supplier for its materials and this therefore, reduces the individual supplier's influence on procurement prices. Most of the suppliers have their local agent and the Company maintains close relationship with them. Moreover, BPL manufactures few of the APIs and steadily building up its API manufacturing capabilities to lessen dependency on import. The regulatory authority in the past has always responded positively to any upward adjustment of price for increased costs.

Product Liability Risk

Pharmaceutical products are usually exposed to high product quality risk. Each product is required to be manufactured and marketed through a stringent compliance procedure. Manufacturing of products requires the flexibility to accommodate the changing local and global regulatory needs. Any deviation from the standard may result in serious market reputational damages and might also create a regulatory barrier. Over the years, Beximco Pharma has been recognized locally and globally for its quality products and manufacturing excellence. Our manufacturing facilities are certified by leading global regulatory agencies. As such, Beximco Pharma is less exposed to product quality risk. Additionally, the Company has taken adequate insurance cover to minimize the product liability risk.

Technology Risk

The pharmaceutical industry is a technology and research driven industry. Failure to adapt to innovation and technological advancement might affect Company's future growth. Beximco Pharma continues to invest in state-of-the-art manufacturing technologies, R&D and laboratory infrastructure to strengthen its manufacturing and innovation capabilities. It maintains close ties with leading global companies and organizations to remain updated on the changes taking place in the industry.

Regulatory Risk

Uncertainties emanating from significant changes in the pharmaceutical policy, regulations, tax regime or other business laws having a bearing on the pharmaceutical sector may also threaten the growth potential of the business. Government policy for the Pharmaceutical sector remains supportive of its growth. Existing fiscal and non-fiscal incentives enjoyed by the industry are expected to continue in the future. No significant changes in policy, regulation or tax regime that can adversely affect the business are foreseen.

Retirement and Re-election of Directors

Mr. Iqbal Ahmed and Mr. O. K. Chowdhury, Directors of the Company retire by rotation as per Articles 126 and 127 of the Articles of Association of the Company and being eligible, offer themselves for re-election.

Ms. Reem H. Shamsuddoha and Ms. Quamrun Naher Ahmed have been appointed as Directors of the Company on December 19, 2020. As per Article 131 of the Articles of Association of the Company they retire and being eligible, offer themselves for re-election.

Detailed bio-data of the Directors are available in the Directors' Profile section of this Annual Report.

Appointment of Independent Director

In compliance to the provisions of Corporate Governance Code issued by Bangladesh Securities and Exchange Commission (BSEC) dated June 03, 2018, Dr. Md. Ibraheem Hosein Khan was appointed as Independent Director of the Company on January 17, 2021 for a period of 3 years, subject to the approval of the Shareholders in the Annual General Meeting. Proposal is placed for the approval of his appointment.

Detailed bio-data of Mr. Khan is available in the Directors' Profile section of this Annual Report.

Auditors

The existing Auditors, M. J. Abedin & Co., Chartered Accountants, National Plaza, 109, BirUttam C. R. Datta Road, Dhaka-1205 who were appointed as Auditors of the Company in the 44th Annual General Meeting of the Company has carried out the audit for the year ended 30 June 2021. M. J. Abedin & Co., Chartered Accountants, National Plaza, 109, BirUttam C.R. Datta Road, Dhaka-1205, the Auditors of the Company retires at this meeting and has expressed their willingness to continue in office for the year 2021-22. The Board after due consideration recommends for the reappointment of M. J. Abedin & Co., Chartered Accountants as auditors for the year 2021-22.

Related Party Disclosure

The Company has a number of transactions between its subsidiaries and other related parties. The transactions are carried out on an arm's length basis. The Audit Committee periodically reviews these transactions. The full disclosure of all related party transactions is provided in the notes to the accounts.

Remuneration to Directors

All the Directors in the Board except the Managing Director are non-executive and receive no remuneration or benefits from the Company other than the Board Meeting attendance fee. The salary and other perquisites paid to the Managing Director for his service has been disclosed in the notes to the accounts.

Compensation Policy for Top Executives

The Company offers industry competitive compensation packages to the employees. Managing Director and all other senior management team members are full-time employees of the Company and receive fixed monthly salary. They are also entitled to certain perquisites as per the terms of their employment contract. Additionally, Beximco Pharma has defined contribution plan (Provident Fund) and a defined benefit Plan (Gratuity) for employees irrespective of their positions. Company has a rigorous performance evaluation and appraisal system linked to KPIs. Employee salary and allowance are reviewed once in every year and revised based on individual performance. The Nomination and Remuneration Committee is entrusted with the responsibility of reviewing and appraising the salary of the senior executives and making an appropriate recommendation to the board. Senior management is not entitled to any performance linked variable incentive scheme other than the benefits of statutory Workers' Profit Participation Fund.

Directors' Statement on Financial Reports

Directors are pleased to report the following:

- The financial statements together with the notes thereon have been drawn up in conformity with the Companies Act, 1994 and Securities and Exchange Rules, 2020. These statements present fairly the Company's state of affairs, the result of its operations, cash flow and changes in equity.
- Proper books of accounts of the Company have been maintained.

- Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment.
- The International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs) have been followed in preparation of the financial statements.
- Internal Control System is sound in design and has been effectively implemented and monitored.
- Interests of the minority shareholders have been duly protected.
- There is no significant doubt about the ability of the Company to continue as a going concern.

Declaration by CEO and CFO

Declaration by CEO and CFO on the Financial Statement of the Company is attached as Annexure- 1

Key Operating and Financial Data

The summarized key operating and financial data for 2020-21 and immediately preceding five years is provided in Annexure- 2

Management Discussion and Analysis

Detailed discussion on the Operating and Financial performance of the Company along with other disclosures as required under Corporate Governance Code issued by Bangladesh Securities and Exchange Commission through Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated June 3, 2018 has been separately reported by the Managing Director.

Board Meetings and Attendance

Twelve Board meetings were held during the year under review. The attendance records of the Directors are as follows:

Name of the Directors	Representation in the Board	Attendance in Board Meeting
Mr. A S F Rahman	Chairman	6
Mr. Salman F Rahman MP	Vice Chairman	12
Mr. Nazmul Hassan MP	Managing Director	12
Mr. Iqbal Ahmed	Director	10
Mr. O K Chowdhury	Director	12
Mr. A B Siddiquir Rahman	Director	12
Ms. Reem H. Shamsuddoha	Director	7
Ms. Quamrun Naher Ahmed	Director	7
Mr. Shah Monjurul Hoque	Independent Director (outgoing)	6
Mr. Mamtaz Uddin Ahmed	Independent Director	12
Dr. Md. Ibraheem Hosein Khan	Independent Director	3

The Pattern of Shareholding

The Shareholding of Directors, CEO, CFO, Company Secretary, Key Executives and their spouses and children are provided in Annexure- 3.

Corporate Governance Compliance Report

In accordance with the requirement of Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, dated 3 June 2018, Report on "Corporate Governance Compliance" is provided in Annexure- 4.

On behalf of the Board,



A S F Rahman
Chairman

The Board of Directors
Beximco Pharmaceuticals Limited

Subject: Declaration on Financial Statements for the year ended on 30 June 2021

Dear Sirs,

Pursuant to the condition No. 1(5) (xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2016-158/207/Admin/80, Dated June 03, 2018 & under section 2CC of the Securities and Exchange Ordinance 1969, we do hereby declare that:

1. The Financial Statements of Beximco Pharmaceuticals Limited for the year ended on 30 June 2021 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
2. The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
3. The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
4. To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
5. Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
6. The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that:

We have reviewed the financial statements for the year ended on 30 June 2021 and that to the best of our knowledge and belief:


- a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
- b) These statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.

There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,



Nazmul Hassan MP
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer

Key Operating and Financial Data

	30 June 2021	30 June 2020	30 June 2019	30 June 2018	30 June 2017	30-Jun-16
	Taka in Thousand					
Authorized Capital	15,000,000	15,000,000	15,000,000	9,100,000	9,100,000	9,100,000
Paid up Capital	4,461,121	4,055,564	4,055,564	4,055,564	4,055,564	3,862,442
Shareholders' Equity	37,364,865	32,797,450	29,864,324	27,351,837	25,072,426	23,059,412
Fixed Assets (Gross)	47,887,415	45,615,625	43,454,027	39,081,675	31,692,789	28,756,326
Net Asset Value (NAV) Per Share -Taka	83.01	80.12	72.96	66.78	61.82	59.7
Market Price Per Share	177.3	69.20	83.50	93.90	113.00	83.5
Price Earning Ratio (Time)	15.43	8.8	11.16	15.02	20.58	17.47

Number of Shareholders	55,248	56,101	56,177	57,982	62,741	67,679
Foreign Investors	71	71	77	90	92	83
ICB including ICB Investors Account	871	882	881	879	874	878
Sponsors, General Public & Other Institutions	54,306	55,148	55,219	57,013	61,775	66,718

Number of employees	5104	4,755	4,489	4,256	3,833	3,515
---------------------	------	-------	-------	-------	-------	-------






	2020-21	2019-20	2018-19	2017-18	2016-17	2015-16
	Taka in Thousand					
Total Sales	29,493,574	25,611,947	22,816,630	17,716,717	15,508,777	13,785,325
Export Sales	3,124,001	2,751,790	2,502,633	1,476,978	1,078,472	861,653
Gross Profit	13,923,502	11,899,100	10,620,343	8,285,979	7,184,882	6,408,857
Profit Before Tax	6,377,548	4,653,440	3,946,065	3,361,334	2,891,482	2,564,267
Net Profit	5,165,750	3,544,483	3,040,403	2,532,654	2,226,695	1,938,894
EPS/Restated EPS- Taka	11.49	7.88	7.48	6.25	5.49	4.78
Net Operating Cash Flow Per Share	13.50	13.67	7.30	4.49	6.49	8.21
New Product Launched-numbers	22	26	20	16	15	21

Cash Dividend	35%	15%	15%	12.50%	12.50%	15%*
Stock Dividend	-	10%	-	-	-	5%*

*18 months period.

Graphical View of Selected Growth Indicators

Taka in million



The Pattern of Shareholding

Name-wise details	Shares held
Parent/Subsidiary/Associate Companies and Other Related Parties:	
Beximco Holdings Ltd.	24,897,715
Bangladesh Export Import Company Ltd.	3,189,926
New Dacca Industries Ltd.	10,345,757
Beximco Engineering Ltd.	965,206
National Investment & Finance Company Ltd.	1,308,505
Directors, CEO, Company Secretary, CFO, Head of Internal Audit and their Spouses and Minor Children:	
A S F Rahman, Chairman	9,058,888
Salman F Rahman, Vice Chairman	9,080,095
Nazmul Hassan, Managing Director	14,657
Company Secretary, Spouse and Minor Children	-
Chief Financial Officer, Spouse and Minor Children	-
Head of Internal Audit, Spouse and Minor Children	-
Executives	-
Shareholders holding 10% or more voting interest in the Company	-

Corporate Governance Compliance Report

As per condition No. 1(5)(xxvii)

Status of compliance with the conditions imposed by the Commissions Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, dated 3 June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969

(Report under Condition No. 9)

Condition No.	Title	Compliance Status ("√" in appropriate Column)		Remarks (if any)
		Complied	Not Complied	
1	Board of Directors (BOD)			
1(1)	Board's Size [number of Board members to be 5 – 20]	√		
1(2)	Independent Directors (ID)			
1(2)(a)	Number of Independent Directors [at least 1/5th of the Board members shall be the Independent Directors]	√		
1(2)(b)(i)	Holding no share or holding less than 1% shares	√		
1(2)(b)(ii)	Not being a sponsor and connected with any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries, and parents or holding entities who holds 1% or more shares of the total paid-up shares of the Company on the basis of family relationship and his or her family members are also not allowed to hold more than 1% shares of the total paid-up shares of the Company	√		
1(2)(b)(iii)	Not an executive of the company in immediately preceding 2 (two) financial years	√		
1(2)(b)(iv)	Not having any pecuniary or otherwise relationship with the company or its subsidiary/ associated companies	√		
1(2)(b)(v)	Not a member or TREC (Trading Right Entitlement Certificate) holder, director or officer of any stock exchange	√		
1(2)(b)(vi)	Not a shareholder, director excepting independent director or officer of any member or TREC holder of any stock exchange or an intermediary of the capital market	√		
1(2)(b)(vii)	Not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance	√		
1(2)(b)(viii)	Not an Independent Director in more than 5 listed companies	√		
1(2)(b)(ix)	Not been convicted by a court as defaulter in any loan of a bank or NBF	√		
1(2)(b)(x)	Not been convicted for a criminal offence	√		
1(2)(c)	To be appointed by BOD and approved by the shareholders in the AGM	√		
1(2)(d)	The post cannot remain vacant for more than 90 days	√		
1(2)(e)	Office tenure of Independent Director	√		
1(3)	Qualification of Independent Director			
1(3)(a)	Knowledgeable, having integrity, ability to ensure compliance with relevant laws and make meaningful contribution to the business	√		
1(3)(b)(i)	Business Leader: Promoter/director of an unlisted company having minimum paid up capital of Taka 100.00 mil. or any listed company or a member of any national or international chamber of commerce/business association, or	√		
1(3)(b)(ii)	Corporate Leader: who is or was a top level executive not lower than CEO/ MD/AMD/DMD/ COO/ CFO/CS or Head of Finance or Accounts or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Taka 100.00 mil. or of a listed company, or			
1(3)(b)(iii)	Former official of Govt./statutory/autonomous/regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics/commerce/business or law, or			
1(3)(b)(iv)	University Teacher having educational background in Economics or Commerce or Business Studies or Law, or			

Condition No.	Title	Compliance Status ("√" in appropriate Column)		Remarks (if any)
		Complied	Not Complied	
1(3)(b)(v)	Practicing advocate at least in the High Court Division of Bangladesh Supreme Court or a CA/CMA/CFA/CCA/CPA or CS			
1(3)(c)	Having at least 10 (ten) years of experiences in any field mentioned in clause (b)			
1(3)(d)	Qualification of Independent Directors may be relaxed subject to prior approval of the Commission.	N/A		
1(4)	Duality of Chairperson of the Board and MD or CEO			
1(4)(a)	The positions of the Chairperson of the Board and MD and/or CEO of the company shall be different individuals	√		
1(4)(b)	MD and/or CEO of a listed company shall not hold the same position in another listed company	√		
1(4)(c)	Chairperson shall be a non-executive directors of the company	√		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the MD and/or CEO	√		
1(4)(e)	In the absence of the Chairperson of the Board, the remaining members may elect from non-executive directors as Chairperson for that particular Board's meeting	√		
1(5)	Inclusions in Director's Report to Shareholders			
1(5)(i)	Industry outlook and possible future developments	√		
1(5)(ii)	Segment-wise or product-wise performance	√		Company operates in a single product segment.
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any	√		
1(5)(iv)	Discussion on COGS, Gross Profit and Net Profit Margins	√		
1(5)(v)	Discussion on continuity of Extra-Ordinary gain or loss	√		
1(5)(vi)	A detailed discussion on related party transactions	√		
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments	N/A		
1(5)(viii)	Explanation, if the financial results deteriorate after going for IPO, RPO, Right Offer, Direct Listing, etc.	N/A		
1(5)(ix)	Explanation about significant variance between Quarterly Financial performance and Annual Financial Statements	N/A		
1(5)(x)	Remuneration paid to directors including Independent Directors	√		
1(5)(xi)	Statement on fair presentation in the financial statements	√		
1(5)(xii)	Maintaining proper books of accounts	√		
1(5)(xiii)	Consistent application of appropriate accounting policies, and accounting estimates being reasonable and prudent	√		
1(5)(xiv)	IAS/IFRS applied and adequate disclosure made	√		
1(5)(xv)	Soundness of internal control system and it's monitoring	√		
1(5)(xvi)	A statement that minority shareholders have been protected from abusive actions by, or controlling shareholders acting either directly or indirectly	√		
1(5)(xvii)	Statement regarding ability to continue as going concern	√		
1(5)(xviii)	Significant deviations from last year's operating results	√		
1(5)(xix)	Summary of key operating/financial data of last 5 years	√		Annexure- 2
1(5)(xx)	Reason for non declaration of Dividend	N/A		
1(5)(xxi)	Board's statement on interim bonus share or stock dividend	N/A		
1(5)(xxii)	Number of Board meetings and attendance of directors	√		
1(5)(xxiii)	Pattern of shareholding (along with name wise details)			
1(5)(xxiii)(a)	Parent/Subsidiary/Associate Companies & related parties	√		Annexure-3
1(5)(xxiii)(b)	Directors, CEO, CS, CFO, HOIA, their spouses & children	√		
1(5)(xxiii)(c)	Executives (Top 5 salaried employees other than above)	√		
1(5)(xxiii)(d)	Shareholders holding 10% or more voting interest	√		

Condition No.	Title	Compliance Status (“√” in appropriate Column)		Remarks (if any)
		Complied	Not Complied	
1(5)(xxiv)	Appointment/re-appointment of a director			
1(5)(xxiv)(a)	A brief resume of the director	√		
1(5)(xxiv)(b)	Nature of his/her expertise in specific functional areas	√		
1(5)(xxiv)(c)	Names of companies in which he/she holds directorship and the membership of committees of the board	√		
1(5)(xxv)	A Management’s Discussion and Analysis signed by CEO or MD focusing on:			
1(5)(xxv)(a)	Accounting policies and estimation	√		
1(5)(xxv)(b)	Changes in accounting policies and estimation	√		
1(5)(xxv)(c)	Comparative analysis of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof	√		Annexure-2
1(5)(xxv)(d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario	√		
1(5)(xxv)(e)	Briefly explain the financial and economic scenario of the country and the globe	√		
1(5)(xxv)(f)	Risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company	√		
1(5)(xxv)(g)	Future plan or projection or forecast for company’s operation, performance and financial position	√		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure- 1	√		Annexure- 1
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-5 and Annexure-4.	√		
1(6)	Meetings of the Board of Directors			
1(6)	Shall conduct Board meetings and record the minutes of the meetings as per the provisions of the relevant Bangladesh Secretarial Standards (BSS)	√		
1(7)	Code of Conduct for the Chairperson, other Board members and Chief Executive Officer			
1(7)(a)	A code of conduct for the Chairperson of the Board based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6.	√		
1(7)(b)	The code of conduct as shall be posted on the website of the company	√		
2	Governance of Board of Directors of Subsidiary Company			
2(a)	Composition of BOD to be similar to holding company	√		
2(b)	One Independent Director to be in both holding and subsidiary company	√		
2(c)	Minutes of Board meetings of subsidiary company to be placed at following Board meeting of holding company	√		
2(d)	Minutes of respective Board meeting of holding company to state that affairs of subsidiary company be reviewed	√		
2(e)	Audit Committee of holding company to review financial statements/investments of subsidiary company	√		
3	Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS)			
3(1)	Appointment			
3(1)(a)	Appointment of MD or CEO, CS, CFO and a HIAC	√		
3(1)(b)	The positions of the MD or CEO, CS, CFO and HIAC shall be different individuals	√		
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time	√		
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS	√		
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board	√		
3(2)	The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board	√		
3(3)	Duties of MD or CEO and CFO			

Condition No.	Title	Compliance Status ("√" in appropriate Column)		Remarks (if any)
		Complied	Not Complied	
3(3)(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year	√		
3(3)(a)(i)	Financial statements do not contain anything which is materially untrue or misleading	√		
3(3)(a)(ii)	Financial statements present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws	√		
3(3)(b)	The MD or CEO and CFO shall also certify that there are no transactions entered during the year which are fraudulent, illegal or in violation of the code of conduct	√		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report	√		Annexure-1
4	Board of Directors' Committee			
4(i)	Audit Committee	√		
4(ii)	Nomination and Remuneration Committee	√		
5	Audit Committee			
5(1)(a)	Having Audit Committee as a sub-committee of the BOD	√		
5(1)(b)	Assist the BOD in ensuring fairness of financial statements and a good monitoring system	√		
5(1)(c)	Duties of Audit Committee clearly set out in writing	√		
5(2)(a)	Audit Committee composition	√		
5(2)(b)	Audit Committee members to be non-executive	√		
5(2)(c)	Members to be "financially literate" and at least one to have 10 years of accounting/ financial management experience	√		
5(2)(d)	Vacancy in Audit Committee to be filled up immediately or no later than 1 month	√		
5(2)(e)	The CS to act as the secretary of the Audit Committee	√		
5(2)(f)	No quorum in Audit Committee meeting without one Independent Director	√		
5(3)(a)	Chairperson to be an Independent Director, selected by the BOD	√		
5(3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting	√		
5(3)(c)	Chairperson of audit committee to remain present in AGM	√		
5(4)(a)	The Audit Committee shall conduct at least its four meetings in a financial year	√		
5(4)(b)	The meeting of the Audit Committee shall be constituted in presence of either two members or two-third of the members of the Committee, whichever is higher, where presence of an Independent Director is a must	√		
5(5)	Role of Audit Committee			
5(5)(a)	Oversee the financial reporting process	√		
5(5)(b)	Monitor choice of accounting policies and principles	√		
5(5)(c)	Monitor Internal Audit and Compliance process, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report	√		
5(5)(d)	Oversee hiring and performance of external auditors	√		
5(5)(e)	Meeting with the external auditors for review of the annual financial statements	√		
5(5)(f)	Review the annual financial statements	√		
5(5)(g)	Review the quarterly and half yearly financial statements	√		
5(5)(h)	Review the adequacy of internal audit function	√		
5(5)(i)	Review the Management's Discussion and Analysis before disclosing in the Annual Report	√		
5(5)(j)	Review statement of significant related party transactions	√		
5(5)(k)	Review Letter of Internal Control weakness issued by statutory auditors	√		
5(5)(l)	Oversee the determination of audit fees and time required for effective audit and evaluate the performance of external auditors	√		
5(5)(m)	Review disclosures/statements/ declarations about uses of funds Raised through IPO/ RPO/Rights Issue	-	-	No such IPO/RPO/ Right Issue occurred during FY 2020-21.
5(6)(a)	Reporting to the Board of Directors			
5(6)(a)(i)	Reporting on the activities of Audit Committee	√		

Condition No.	Title	Compliance Status ("√" in appropriate Column)		Remarks (if any)
		Complied	Not Complied	
5(6)(a)(ii)(a)	Reporting on conflicts of interests	-	-	Audit Committee found no such issue or activity.
5(6)(a)(ii)(b)	Reporting on suspected/presumed fraud or irregularity or material defect in the internal control system	-	-	
5(6)(a)(ii)(c)	Reporting on suspected infringement of laws	-	-	
5(6)(a)(ii)(d)	Reporting on any other matter to disclose immediately	-	-	
5(6)(b)	Reporting to BSEC	-	-	
5(7)	Reporting to the Shareholders and General Investors	√		
6	Nomination and Remuneration Committee (NRC)			
6(1)	Responsibility to the Board of Directors			
6(1)(a)	Shall have a NRC as a sub-committee of the Board	√		
6(1)(b)	Assists the Board in formulation of the NRC policy	√		
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing	√		
6(2)	Constitution of the NRC			
6(2)(a)	At least three members including an Independent Director	√		
6(2)(b)	All Committee members shall be non-executive directors	√		
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board	√		
6(2)(d)	The Board reserve the authority to remove and appoint any member of the Committee	√		
6(2)(e)	The Board shall fill the vacancy in case of death, resignation, disqualification, or removal of any member	-	-	No such instance occurred during the period.
6(2)(f)	The Chairperson of the Committee may appoint external expert for advice or suggestion	-	-	No such instance occurred during the period.
6(2)(g)	The company secretary shall act as the secretary of the Committee	√		
6(2)(h)	Quorum of the NRC meeting shall not constitute without attendance of at least an Independent Director	√		
6(2)(i)	No remuneration other than director fees/honorarium for any member	√		
6(3)	Chairperson of the NRC			
6(3)(a)	Board shall select 1 (one) member of the NRC to be Chairperson who shall be an ID	√		
6(3)(b)	In the absence of regular Chairperson, the position may elect from the remaining members of the committee	√		
6(3)(c)	Chairperson shall attend the AGM	√		
6 (4)	Meeting of the NRC			
6(4)(a)	At least one meeting in a financial year	√		
6(4)(b)	Any emergency meeting upon request by any member of the NRC	-	-	No such instance happened during the period.
6(4)(c)	Quorum: Higher of two members or 2/3 of total members including at least one independent director	√		
6(4)(d)	The proceedings of each meeting shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of NRC	√		
6(5)	Role of the NRC			
6(5)(a)	Shall be independent and responsible or accountable to the Board and to the shareholders	√		
6(5)(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board:			
6(5)(b)(i)	Formulation of the nomination criteria and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:			
6(5)(b)(i)(a)	The level and composition of remuneration shall be reasonable and sufficient to attract, retain and motivate suitable directors	√		
6(5)(b)(i)(b)	Clear relationship among remuneration, performance & benchmarks	√		

Condition No.	Title	Compliance Status ("√" in appropriate Column)		Remarks (if any)
		Complied	Not Complied	
6(5)(b)(i)(c)	Balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals	√		
6(5)(b)(ii)	Devising a policy on Board's diversity	√		
6(5)(b)(iii)	Identification of qualification of directors and recommendation for their appointment and removal to the Board	√		
6(5)(b)(iv)	Evaluating the performance of independent directors and the Board	√		
6(5)(b)(v)	Identifying needs for employees and determine their selection, transfer or replacement and promotion criteria	√		
6(5)(b)(vi)	Developing, recommending and reviewing annually the company's human resources and training policies	√		
6(5)(c)	Disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report	√		
7	External or Statutory Auditors			
7(1)(i)	Non-engagement in appraisal/valuation/fairness opinions	√		
7(1)(ii)	Non-engagement in designing & implementation of Financial Information System	√		
7(1)(iii)	Non-engagement in Book Keeping or accounting	√		
7(1)(iv)	Non-engagement in Broker-Dealer services	√		
7(1)(v)	Non-engagement in Actuarial services	√		
7(1)(vi)	Non-engagement in Internal Audit services or special audit services	√		
7(1)(vii)	Non-engagement in services determined by Audit Committee	√		
7(1)(viii)	Not involved in audit or certification services on compliance of corporate governance	√		
7(1)(ix)	Not involved in any other service that creates conflict of interest	√		
7(2)	No partner or his/her family or employees of the external audit firms hold any share at least during the tenure of their audit assignment	√		
7(3)	Representative of external auditors shall remain present in the AGM	√		
8	Maintaining a website by the Company			
8(1)	An official website linked with the website of the stock exchange	√		
8(2)	Website shall keep functional from the date of listing	√		
8(3)	Shall make available the detailed disclosures on website as required under the listing regulations of the concerned stock exchanges	√		
9	Reporting and Compliance of Corporate Governance			
9(1)	Compliance certificate on Corporate Governance Code of the Commission shall be disclosed in the Annual Report	√		
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the AGM	√		
9(3)	The directors shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not	√		



Suraiya Parveen & Associates

(Chartered Secretaries, Financial & Management Consultants)

[Certificate as per condition No.1 (5) (XXVII)]

Report to the Shareholders of Beximco Pharmaceuticals Limited on compliance on the Corporate Governance Code

We have examined the compliance status to the Corporate Governance Code by Beximco Pharmaceuticals Limited for the year ended on 30 June 2021. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June, 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- (a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission;
- (b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;
- (c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws; and
- (d) The Governance of the company is satisfactory.

Dhaka, Dated
November 10, 2021



For Suraiya Parveen & Associates
Chartered Secretaries

Suraiya Parveen, FCS
Chief Executive Officer

Avalon Serabella, (5th Floor), 09, Dilu Road, New Eskaton, Ramna, Dhaka-1000

Cell : 01911 421 998, 01713 110 408

E-mail : suraiyaparveenfcs@gmail.com, musfiquefcs@gmail.com

Report of the Audit Committee

I am pleased to present the report of the Audit Committee of Beximco Pharmaceuticals Limited in compliance to the provisions of the Corporate Governance Codes issued by Bangladesh Securities and Exchange Commission (BSEC). A competent audit committee is important to insure accounting and reporting transparency and promote good governance. The Audit Committee of Beximco Pharma as a sub-committee of the Board plays a vital role in effective discharge of the Board's oversight responsibilities. The Committee has distinct Terms of Reference (ToR) developed conforming to the Code of Corporate Governance which includes but not confined to overseeing the financial reporting process, evaluating internal control system, reviewing significant related party transactions, assessing potential conflict of interests, and reviewing the financial statements of the Company and its subsidiaries. This report gives a brief on the activities performed by the Audit Committee throughout the year.

Changes in the Committee

Mr. Shah Monjurul Hoque, an Independent Director of the Board and a member of the Audit Committee retired on completion of his tenure of office for two consecutive terms of three years each. Mr. Hoque was an important member of the committee and made appreciable contribution during his tenure. I express my heartfelt thanks for his valuable service.

Ms. Reem H. Shamsuddoha a Director of the Board was nominated as a member of the Audit Committee on January 18, 2021 in replacement of Mr. Hoque. Following the changes the Committee has been reconstituted as below:

Name	Representation in the Board	Position in the Committee
Prof. Mamtaz Uddin Ahmed	Independent Director	Chairman
Mr. Osman Kaiser Chowdhury, FCA	Director	Member
Ms. Reem H. Shamsuddoha	Director	Member
Mr. Mohammad Asad Ullah, FCS	Company Secretary	Secretary

Meetings and Attendance

The Committee held four meetings to carry out its business during the period under review. Records of attendance in the meetings are as below:

Name	Representation in the Board	Position in the Committee	Attendance in Meeting
Prof. Mamtaz Uddin Ahmed	Independent Director	Chairman	4/4
Mr. Shah Monjurul Hoque	Independent Director	Member (outgoing)	2/4
Mr. Osman Kaiser Chowdhury, FCA	Director	Member	4/4
Ms. Reem H. Shamsuddoha	Director	Member	2/4
Mr. Mohammad Asad Ullah, FCS	Company Secretary	Secretary	4/4

* Ms. Reem H. Shamsuddoha replaced Mr. Shah Monjurul Hoque who retired on 17 January 2021

Review of Financial Statements

The Audit Committee reviewed the annual audited financial statements of the Company for the year 2020-21 in its meeting held on October 19, 2021. The annual financial reports of the subsidiary companies, namely Nuvista Pharma Limited and Beximco Pharma API Limited, were also placed for review and approval of the Committee during the meeting. Mr. Mohammad Ali Nawaz, the Chief Financial Officer (CFO) of the Company presented the annual accounts along with the independent auditor's report. The Committee had detailed discussion with the representative of the management on different aspects of the financial statements particularly on compliance with IFRS/IAS, adequacy of disclosures made, consistency of the accounting policies applied and prudence of the estimates and judgements made in preparation of the financial statements.

The Committee carefully examined the related party transactions carried out among different associated companies, including the subsidiaries. The Committee was well satisfied that the related party transactions were made on an arm's length basis in the normal course of business and the transactions have been appropriately disclosed in the financial statements as per IAS 24: 'Related Party



Disclosures'. The Committee evaluated the report of the independent auditor on the annual financial statements and found no material audit observation.

Besides the review of annual financials, the Committee met on three other occasions to review the interim un-audited financial statements of the Company and its subsidiaries. They carried out in-depth review of each of the quarterly financial statements with due care to ensure that the financial statements give a true and fair view of the state of affairs of the company and are free from any material error. During the evaluation process, relevant queries were raised and explanations were sought from the management on accuracy of the reported numbers and adequacy of the information disclosed in the financial statements. The Committee, where applicable, gave necessary feedback and guidance. In each case Committee being satisfied authorized for onward submission of the financial reports for the approval of Board.

Other Reviews and Activities

The Committee assessed the independence, objectivity and expertise of the independent auditors engaged to carry out the audit for the year ended 30 June 2021 and found their performance meeting the standard. Based on the evaluation, the Committee recommended for the re-appointment of the existing auditor for the year 2021-22.

The Committee appraised the financial reporting process and the adequacy of the internal control system of the Company and found them satisfactory. They noted that internal audit team enjoy full, free and unrestricted access to all activities, records, property. They also noted that internal audit and compliance team has been further strengthened with professionally qualified personnel.

The Committee noted no material deviations or non-compliance or adverse audit finding that calls for board or shareholders' attention during the year under review.

Mamtaz Uddin Ahmed
Chairman
Audit Committee

Activities and Other Details of Nomination and Remuneration Committee (NRC)

The Nomination and Remuneration Committee (NRC) is one of the two sub-committees of the Board formed in Compliance to the Corporate Governance Code issued by Bangladesh Securities and Exchange Commission.

Composition of the NRC

There have been some changes in the Committee during the year under review. Mr. Shah Monjurul Hoque, an Independent Director of the Board and the Chairman of the NRC retired from the Committee and the Board on completion of his tenure of office for two consecutive terms. Dr. Md. Ibraheem Hosein Khan an Independent Director of the Board has replaced Mr. Hoque. The Board has appointed Dr. Khan as the Chairman of the Committee. The Committee comprises as follows:

Name	Representation in the Board	Position in the Committee
Dr. Md. Ibraheem Hosein Khan	Independent Director	Chairman
Mr. Iqbal Ahmed	Director	Member
Mr. Osman Kaiser Chowdhury, FCA	Director	Member
Mr. Mohammad Asad Ullah, FCS	Company Secretary	Secretary

Summary of Activities of NRC

The Nomination and Remuneration Committee (NRC) had one meeting during the year. Dr. Md. Ibrahim Hosein Khan, Chairman of the NRC, presided over the meeting. All the members, except Mr Iqbal Ahmed, attended the meeting. Mr. Md. Ali Nawaz, Chief Financial Officer, Mr. Jamal Ahmed Choudhury, Director (F&A), and Mr. M A Arshad Bhuiyan, General Manager, HRM attended the meeting as representatives of the management on invitation.

The Committee dealt with two agendas namely, Employee Recruitment and Selection Process of the Company; and the Policy on Composition of Board and Appointment of Directors. The proceedings of the meeting were appropriately recorded. No member of the Committee received any remuneration other than the meeting attendance fee.

Review of Employee Recruitment and Selection Process of the Company

Head of HRM presented the process of recruiting and selecting employees for different positions and grades of the Company before the members of the Committee. The presentation outlined the method of assessing the HR needs; determining the qualification criteria; and the steps adopted to searching, screening, evaluating and recruiting appropriate candidate for positions at different tiers of the organization. The Company adopts objective, fair and unbiased evaluation criteria in the selection process. Recruitments are principally based on education, experience and defined skills for any particular position.

The Committee conducted in-depth review of the existing policy and concluded that the current recruitment and selection process of the Company is well designed in terms of assessing the need, interacting with the potential candidates and hiring talented human resource for the Company.

Review of Policy on Composition of Board and Appointment of Directors

The Committee thoroughly reviewed the Company's policy on Composition of Board and Appointment of Directors. Representative of management presented in detail the composition of the Board, policy on board diversity, evaluation criteria of the board members and their appointment process. The Committee noted that the policy is well defined and appropriately accommodates the statutory and regulatory requirements. They made few minor suggestions which were duly accommodated. In this context, the Committee evaluated the current composition of the Board and observed that the Board is well composed with adequate diversity in terms of age, experience, gender, etc. The current Board also adequately fulfills the condition of a minimum number of Independent Directors statutorily required to be included in the Board.



Nomination and Remuneration Policy

The Company has a written policy on nomination and appointment of directors in the Board. The policy sets out the detail qualification and other eligibility norms for the members and the process of their nomination, which is rightly aligned with the Corporate Governance Code of Bangladesh Securities and Exchange Commission.

While Directors, as per Bangladesh Companies Act, are to be elected by the shareholders in the annual general meeting, the Board of Directors makes the recommendation for appointment or re-appointment of Directors. NRC plays an important role in assisting the Board to identify persons fitting the qualifying criteria as a Director. The Person (s) identified for the proposed appointment as director is evaluated in terms of the requirements laid down in prevailing legislation; specific regulations applicable to the public listed companies both in Bangladesh and the United Kingdom; the Bylaws and the policies of the Company. NRC makes an independent evaluation of his/her experience, capability and competence to make a meaningful contribution as a Board member to achieve Company's mission and goals. Additionally, to comply with the regulations of the Alternative Investment Market (AIM) of London Stock Exchange, a clearance from the Company's Nominated Advisor (NOMAD) is required before the appointment of any director, including the Independent Director. NOMAD conducts independent third party verification of the eligible candidates before their appointment as Directors.

The Company shall appoint adequate number of directors, including independent directors, and shall endeavor to nominate or appoint directors from diversified fields of experience and specialties. From the perspective of gender diversity, preference shall be given to the female candidates where male and female are found equally qualified for the membership of the Board. The Company does not make any discrimination in terms of religion, faith, color, gender or nationality while considering the appointment as a Director. All the Directors of the Board except the Managing Director are non-executive. The Company pays no remuneration to them other than the fees for attending the Board and other committee meetings.

The Company has a well-structured policy on selection, recruitment and promotion of the senior level executives which is duly authorized by the Board. The Managing Director and all other top-level executives are full-time employee of the Company. They get a fixed monthly salary and allowances as per terms of their service contracts. The Company has a robust performance appraisal system linked to KPI. Performances are reviewed on an annual basis. Further details on the remuneration policy are available in the report of Directors.

Investor Relations

Communication with Shareholders and Investors

Beximco Pharma recognizes the investors' right to remain informed about the Company, its operating and financial results, and other material information that are relevant to their investment decisions. The country's legislation and regulations sets out the rights and privileges of the shareholders and the nature, timing and means of communicating information to the shareholders and investors.

The Company without failure complies with all regulatory provisions and communicates information in effective and timely manner. The Company regularly holds its Annual General Meeting as required by the Companies Act, 1994 to appraise the shareholders about the overall affairs of the Company. The AGM deals with specific agenda to be approved by the Shareholders. Interested shareholders may take part in the discussion and raise queries about the affairs of the Company. Extra-ordinary General Meeting (EGM) is also held in cases that require calling of a meeting. The board members and senior management of the Company remain present in those meetings to answer queries and address any concerns of the shareholders.

Considering pandemic, like prior year, this year's AGM will also be held on virtual platform.

The Company updates the market with all price sensitive information as soon as it becomes available through the stock exchanges and company's own website. In applicable cases such information are also published in the print media and online portals.

The senior management of the Company occasionally meets its overseas investors to update them about the business. The local and overseas fund managers and analysts also hold pre-arranged meeting at home and abroad with our top management to know the present and future potentials of the Company. During the year the meetings were held mostly online.

Beximco Pharma has a distinct Company Secretarial Department adequately manned with qualified professionals to carry out the regulatory secretarial functions and to meet administrative enquiries from the shareholders and investors. There is also an investor relation team within accounting and finance function to deal with queries and information requests from investors, regulators etc.


Beximco Pharma is the only company in Bangladesh listed with Alternative Investment Market (AIM) of London Stock Exchange. In compliance to AIM regulation, the Company has engaged SPARK Advisory Partners Limited as Nominated Advisor (NOMAD), SP Angel Corporate Finance LLP as designated Broker and FTI Consulting LLP as Public Relations agent. Analyst of SP Angel publishes report on the Company for the investors.

Reporting to the Shareholders

Financial Reports and Reporting Calendar


The Company publishes three quarterly financial reports prepared in a condensed form. These reports are un-audited. The Company's Annual Audited Financial Accounts are however, audited by independent external auditors and prepared complying with international accounting standards and other statutory requirements. Such Reports are available in the Company's website.

Latest timing of release of the financial statements are:




Website Communication:

The Company has a rich website (www.beximcopharma.com) that contains historical as well as latest information about the Company and its operation. The website is well organized to meet information requirement of different stakeholders and updated on a regular basis. The investors' relation segment of the website has been further reorganized for easy search of information and to make it convenient to the users. In addition to accessing information through website, investors and other report users may contact the Company for additional information. The contact details are available on the Company's website.



Five Year Dividend History



* In addition to Cash, 10% Stock Dividend was declared in 2019-20

Stock Market Performance

Dhaka Stock Exchange (DSE)

Particulars	30 June 2021	30 June 2020	30 June 2019	30 June 2018	30 June 2017
Share Price- Dhaka	BDT 177.3	BDT 69.2	BDT 83.5	BDT 93.9	BDT 113.0
Share Price- AIM	GBP 0.860	GBP 0.355	GBP 0.389	GBP 0.510	GBP 0.605
Market Capitalization- Dhaka Price	BDT 79.1bn	BDT 28.1bn	BDT 33.9bn	BDT 38.1bn	BDT 45.8bn
EPS- Taka	11.49	7.88	7.48	6.25	5.49
P/E Ratio (Dhaka Price)	15.4	8.8	11.2	15.0	20.6
Dividend (Cash)	35% (Proposed)	15%	15%	12.5%	12.5%
Stock Dividend	--	10%	-	-	-

GDRs Information

Nominated Advisor

SPARK Advisory Partners Limited
5 St. John's Lane, EC1M 4BH, London, UK
No.1 Aire Street, Leeds, LS1 4PR, UK

Broker

SP Angel Corporate Finance LLP
Prince Frederick House 35-39 Maddox Street
London W1S 2PP, United Kingdom

Custodian



HSBC

Level 4, Shanta Western Tower
186 Bir Uttam Mir Shawkat Ali Road
Tejgaon Industrial Area Dhaka- 1208, Bangladesh

Depository

The Bank of New York Mellon
240 Greenwich Street, 22W New York
NY 10286- USA

Snapshots of 44th Annual General Meeting (Held on virtual platform)



Dividend Policy Statement

Introduction

Bangladesh Securities and Exchange Commission (BSEC) through a Directive, made it mandatory for a listed company to formulate its Dividend Distribution Policy and disclose the policy in the company's annual report and official website. In compliance to this directive, Beximco Pharmaceuticals Limited ("Beximco Pharma" or the "Company") publishes this statement as a guiding framework for the shareholders with regards to the Company's Dividend Policy.

This statement provides a brief outline of the legal and regulatory provisions relating to dividend, key issues in dividend considerations and the procedure for the declaration, approval and payment of dividend.

Relevant Laws and Regulations

Different legal and regulatory provisions have bearings on dividend decisions of the Company. The paragraphs below provide a brief overview of the provisions relating to dividend:

Companies Act

The Companies Act 1994, the primary legislation regulating the affairs of a company, gives power to the directors to recommend the dividend to be declared by the company which is to be approved by the shareholders in the Annual General Meeting (AGM). The shareholders however, cannot approve any dividend more than what has been recommended by the directors. It also authorizes the directors to pay from time to time, interim dividends to the shareholders if so appears to be justified by the profits of the company. The directors may, before recommending any dividend, set aside out of the profits of the company, such sums as they deem appropriate, as reserve or reserves which shall at the discretion of the directors, be applied for meeting contingencies, or for equalizing dividends or for any other purpose of the company appropriate for utilization of such profits or may employ such profits in the business of the company or otherwise as they think fit.

The law further provides that dividends are to be paid out of profits of the year or any other undistributed profits.

Listing Regulations of Stock Exchanges

There has been a number of listing regulations that have direct or indirect impact on dividend decisions of the company. Shares of a company is traded under different trading categories depending on payment or non-payment of dividend by a company. According to the regulations, a company shall be traded in the "Z Category" (a category with a longer trading settlement time and other restrictive conditions) if it fails to declare cash dividend for two consecutive years. Moreover, a company may among other reasons, be de-listed from the stock exchange if it fails to pay cash/stock dividend for a consecutive period of five years. The listing regulations also require a company to declare in its annual general meeting the reasons, if any for partial or non-distribution of profits as dividend and the plan for utilization of the undistributed profits if there be any.

Income Tax Law

Bangladesh Income Tax law, provides for additional tax charges to a listed company that retains more than 70% of its net after-tax profit earned in any year. According to the said provision if a company retains or transfers more than 70% of its after tax profit to reserve or any other fund, an additional 10% tax shall be payable on such retained or transferred fund. Moreover, in order to encourage cash dividend, the tax law requires that if in any income year, the stock dividend declared by a company exceeds the cash dividend, an additional 10% tax shall be imposed on the whole amount of stock dividend declared or distributed.

Key Considerations in dividend decisions

The company shall endeavour to maintain a consistent dividend over the year with appropriate consideration of factors relevant to such decisions. It is the Company's practice to declare dividend on annual basis based on annual financial performance. However, the Board may also declare interim dividend based on periodic financial results. Historically the Company declared dividend in either cash or stock or in judicious combination of cash and stock. The company intends to pursue the same policy in future depending on the operating and financial context prevailing at that time.

Multiple internal and external factors might affect Company's dividend decisions. While recommending dividend the Board of directors shall consider among others:

- Company's current net earnings, accumulated distributable reserves/surplus and availability of free cash flow
- Potential growth opportunities and investment requirements; assessment of benefits of retention vs pay-out
- Legal and Regulatory compulsion and tax implication of retention and payout
- Any debt/loan covenants restricting dividend announcements
- Persuasion of a target capital structure
- Cost of external finance
- Policy on consistency of the dividend over reasonable and foreseeable future years

Additionally, the Board may consider other factors or circumstances to decide on distribution of dividend for a particular year.

Eligibility of shareholders for dividend

Dividend is declared on the face value of each Equity Share. Unless otherwise stated, all holders of Equity Share and GDR (Global Depository Receipts) whose names appear on the registrar of the Company on the Record Date declared by the Company for entitlement of dividend, are eligible to get the dividend.

Timing of Dividend Announcement and Payment

Annual dividend decision is taken in the Board meeting to be held within 120 days from the date of closing of the financial year. Such decisions are based on the results of the audited financial statements. The dividend recommendations made by the directors are notified to the shareholders through stock exchanges, website and public announcements.

Dividend recommended by the Directors are to be placed in the Annual General meeting of the Company for the Shareholders' approval. Dividend are transferred to the respective shareholders' account within 30 days from the date of its approval. Interim Dividend if any declared by the Company, are paid within 30 days from the Record Date fixed by the Company for the entitlement of such dividend.

Policy Review and Amendment

Apart from mandatory revision, modification or amendment as necessitated by the legal and regulatory requirements, the company shall review this policy on periodic basis and make necessary revision or amendment to keep the policy relevant and up to date. The Board of Directors of the company shall approve the revision and/or amendment as it deems fit.

Disclaimer


The above Policy Statement neither gives a guarantee of dividend to be declared by the Company nor does it constitute a commitment for any future dividend and thus be read as a general guidance on different dividend related issues. The policy upholds the Board's absolute/complete liberty to recommend any dividend in deviation of the policy.

Value Added Statement

For the Year Ended 30 June 2021

Taka in thousand

	Taka	%
Value Added :		
Sales & Other Income	34,901,684	
Bought-in-Materials & Services	(16,537,596)	
	18,364,088	100
Applications :		
Retained by the Company	4,496,664	24.5
Salaries and Benefits to Employees	4,799,451	26.1
Interest to Lenders	858,685	4.7
Dividend to Shareholders	1,608,393	8.8
Duties & Taxes to Govt. Exchequer	6,600,895	35.9
	18,364,088	100





The combined force of our product development, manufacturing skills and also our marketing expertise will yield definitive results not just for investors but also for patients in need.

**Consolidated Financial Statements
Beximco Pharmaceuticals Ltd. and Its Subsidiaries**

Independent Auditor's Report
To the Shareholders of

Beximco Pharmaceuticals Limited and its Subsidiaries

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Beximco Pharmaceuticals Limited (the "Company"), which comprise the Consolidated Statement of Financial Position as at June 30, 2021 and Consolidated Statement of Profit or Loss and Other Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Statement of Cash Flows for the year then ended, and notes to the Consolidated Financial Statements, including a summary of significant accounting policies.

The Accounting year of the subsidiary companies- Beximco Pharma API Limited and Nuvista Pharma Limited, ends on the same date as of the Company. We have audited the Financial statements of Beximco Pharma API Limited and expressed our unmodified opinion on those statements vide our report dated October 21, 2021. The Financial Statements of Nuvista Pharma Limited was audited by A. Qasem & Co. Chartered Accountants, who through their report dated October 18, 2021 have also expressed unmodified opinion on those statements.

In our opinion, the accompanying consolidated financial statements of the Company give a true and fair view of the consolidated financial position of the Company as at June 30, 2021, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 2020 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Risk	Our response to the risk
Valuation of Property, Plant and Equipment (PPE)	
<p>The carrying value of the PPE was Tk. 36,211,375,594 as at June 30, 2021.</p> <p>Expenditures are capitalized if they create new assets or enhance the existing assets, and expensed if they relate to repair or maintenance of the assets. Classification of the expenditures involves judgment. The useful lives of PPE items are based on management's estimates regarding the period during which the assets or its significant components will be used. The estimates are based on historical experience and market practice and take into consideration the physical condition of the assets.</p> <p>The valuation of PPE was identified as a key audit matter due to the significance of this balance to the consolidated financial statements and that there is significant measurement uncertainty involved in this valuation.</p> <p>See Note No. 4 to the consolidated financial statements</p>	<p>Our audit included the following procedure:</p> <ul style="list-style-type: none"> • We assessed whether the accounting policies in relation to the capitalization of expenditures are in compliance with IFRS and found them to be consistent. • We inspected a sample of invoices and L/C documents to determine whether the classification between capital and revenue expenditure was appropriate. • We evaluated whether the useful lives determined and applied by the management were in line with historical experience and the market practice. • We checked whether the depreciation of PPE items was commenced timely, by comparing the date of the reclassification from capital work in progress to ready for use, with the date of the act of completion of the work.

Risk	Our response to the risk
------	--------------------------

Valuation of Inventory

<p>The inventory of Tk. 7,142,863,477 as at June 30, 2021 was held at different locations across the country.</p> <p>Inventories are carried at the lower of cost and net realizable value. As a result, the management apply judgment in determining the appropriate values for slow-moving or obsolete items.</p> <p>Since the value of Inventory is significant to the consolidated Financial Statements and there is significant measurement uncertainty involved in this valuation, the valuation of inventory was significant to our audit.</p> <p>See Note No. 8 to the consolidated financial statements.</p>	<p>We verified the appropriateness of management's assumptions applied in calculating the value of the inventory by:</p> <ul style="list-style-type: none"> • Evaluating the design and implementation of key inventory controls. • Attending inventory counts on sample basis and reconciling the count results to the inventory listing to test the completeness of data. • Reviewing the requirement of inventory provisioning and action there upon by the management. • Comparing the net realizable value obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories.
---	---

Related party transactions

<p>The Company has related party transactions as described in Note No. 36 of the Consolidated Financial Statements.</p> <p>We focused on identification of related parties and disclosure of related party transactions in accordance with relevant accounting standards.</p>	<p>Our audit procedures amongst others included the following:</p> <ul style="list-style-type: none"> • Evaluated the design and tested the operating effectiveness of controls over identification and disclosure of related party transactions. • Evaluated the transactions among the related parties and tested material accounts balances. • Evaluated the disclosures in the Consolidated financial statements in compliance with IAS 24.
---	--

Other Information

Management is responsible for the other information. The other information comprises all of the information in the Annual Report other than the consolidated financial statements and our auditor's report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on such work we perform, we conclude that there is a material misstatement of this other information, we are required to communicate the matter to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the consolidated Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the consolidated financial statements of the Company in accordance with IFRSs, The Companies Act 1994, The Securities and Exchange Rules 2020 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal controls of the Company.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, The Securities and Exchange Rules 2020 and relevant notifications issued by Bangladesh Securities and Exchange Commission, we also report that:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of those books;
- c) The Company's Consolidated Statement of Financial Position (Balance sheet) and Consolidated Statement of Profit or Loss and Other Comprehensive Income (Profit & Loss Account) dealt with by this report are in agreement with the books of accounts and;
- d) The expenditures incurred and payment made were for the purpose of the Company's business for the year.

Dhaka
October 21, 2021

M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A



Hasan Mahmood FCA
Enrollment No : 0564
DVC :N/A

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Financial Position
As at June 30, 2021

	Notes	June 30, 2021	June 30, 2020
Amount in Taka			
ASSETS			
Non-Current Assets		38,475,237,847	37,069,663,021
Property, Plant and Equipment- Carrying Value	4	36,211,375,594	35,000,809,631
Right-of-use Assets	4(a)	319,884,849	240,163,919
Intangible Assets	5	1,380,693,809	1,275,560,330
Goodwill	6	546,691,213	546,691,213
Other Investments	7	16,592,382	3,751,551
Other Non-current Assets		—	2,686,377
Current Assets		13,770,846,179	13,049,078,919
Inventories	8	7,142,863,477	5,944,769,057
Spares & Supplies	9	661,722,724	775,528,787
Accounts Receivable	10	2,873,844,874	3,305,451,434
Loans, Advances and Deposits	11	2,416,948,496	2,388,313,122
Cash and Cash Equivalents	12	675,466,608	635,016,519
TOTAL ASSETS		52,246,084,026	50,118,741,940
EQUITY AND LIABILITIES			
Equity Attributable to the Owners of the Company		37,030,558,202	32,495,120,607
Issued Share Capital	13	4,461,120,890	4,055,564,450
Share Premium		5,269,474,690	5,269,474,690
Excess of Issue Price over Face Value of GDRs		1,689,636,958	1,689,636,958
Capital Reserve on Merger		294,950,950	294,950,950
Revaluation Surplus		1,121,824,646	1,125,767,451
Unrealized Gain/(Loss)		13,767,206	926,375
Retained Earnings		24,179,782,862	20,058,799,733
Non-Controlling Interest	14	334,306,627	302,329,006
TOTAL EQUITY		37,364,864,829	32,797,449,613
Non-Current Liabilities		5,531,540,789	5,963,327,323
Long Term Borrowings-Net of Current Maturity	15	1,206,717,094	1,651,590,390
Liability for Gratuity and WPPF & Welfare Funds	16	2,335,257,766	2,144,053,434
Deferred Tax Liability		1,989,565,929	2,167,683,499
Current Liabilities and Provisions		9,349,678,408	11,357,965,004
Short Term Borrowings	17	5,023,181,128	7,398,361,360
Long Term Borrowings-Current Maturity	18	1,401,406,013	1,454,311,995
Creditors and Other Payables	19	1,965,048,180	1,397,817,066
Accrued Expenses	20	619,399,363	739,512,826
Dividend Payable / Unclaimed Dividend	21	118,137,390	82,075,347
Income Tax Payable		222,506,334	285,886,410
TOTAL EQUITY AND LIABILITIES		52,246,084,026	50,118,741,940

The Notes are an integral part of the Financial Statements.

Approved and authorised for issue by the Board of Directors on October 21, 2021 and signed for and on behalf of the Board :



Osman Kaiser Chowdhury
Director


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Per our report of even date

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A

Hasan Mahmood FCA
Enrollment No : 0564
DVC : N/A

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the Year ended June 30, 2021

		Amount in Taka	
	Notes	July 2020- June 2021	July 2019 - June 2020
Net Revenue	22	29,493,573,869	25,611,947,655
Cost of Goods Sold	23	(15,570,071,581)	(13,712,847,509)
Gross Profit		13,923,502,288	11,899,100,146
Operating Expenses		(7,272,794,940)	(6,289,606,032)
Administrative Expenses	26	(896,648,965)	(792,951,709)
Selling, Marketing and Distribution Expenses	27	(6,376,145,975)	(5,496,654,323)
Profit from Operations		6,650,707,348	5,609,494,114
Other Income	28	908,275,284	293,558,304
Finance Cost	29	(858,685,146)	(1,013,804,085)
Profit Before Contribution to WPPF & Welfare Funds		6,700,297,486	4,889,248,333
Contribution to WPPF & Welfare Funds		(322,749,293)	(235,808,378)
Profit Before Tax		6,377,548,193	4,653,439,955
Income Tax Expenses	30	(1,211,798,461)	(1,108,956,854)
Current Tax		(1,386,678,310)	(1,086,668,418)
Deferred Tax Income/ (Expense)		174,879,849	(22,288,436)
Profit After Tax		5,165,749,732	3,544,483,101
Profit/(Loss) Attributable to:			
Owners of the Company		5,127,693,711	3,514,687,301
Non-Controlling Interest		38,056,021	29,795,800
		5,165,749,732	3,544,483,101
Other Comprehensive Income/(Loss)	31	12,840,831	(1,577,828)
Total Comprehensive Income		5,178,590,563	3,542,905,273
Total Comprehensive Income Attributable to:			
Owners of the Company		5,140,534,542	3,513,109,473
Non-Controlling Interest		38,056,021	29,795,800
		5,178,590,563	3,542,905,273
Earnings Per Share (EPS)/ Restated EPS	32	11.49	7.88

The Notes are an integral part of the Financial Statements.

Approved and authorised for issue by the Board of Directors on October 21, 2021 and signed for and on behalf of the Board :



Osman Kaiser Chowdhury
Director



Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Per our report of even date

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A


Hasan Mahmood FCA
Enrollment No : 0564
DVC : N/A

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Changes in Equity
For the Year Ended June 30, 2021

Amount in Taka

As at June 30, 2021

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to Owners of the Company	Non-Controlling Interests	Total Equity
Balance as on July 01, 2020	4,055,564,450	5,269,474,690	1,689,636,958	294,950,950	1,125,767,451	926,375	20,058,799,733	32,495,120,607	302,329,006	32,797,449,613
Total Comprehensive Income:										
Profit for the Year	—	—	—	—	—	—	5,127,693,711	5,127,693,711	38,056,021	5,165,749,732
Other Comprehensive Income/(Loss)	—	—	—	—	—	12,840,831	—	12,840,831	—	12,840,831
Transactions with the Shareholders:										
Cash Dividend	—	—	—	—	—	—	(608,334,668)	(608,334,668)	(6,078,400)	(614,413,068)
Stock Dividend	405,556,440	—	—	—	—	—	(405,556,440)	—	—	—
Adjustment for Depreciation on Revalued Assets	—	—	—	—	(7,180,526)	—	7,180,526	—	—	—
Adjustment for Deferred Tax on Revalued Assets	—	—	—	—	3,237,721	—	—	3,237,721	—	3,237,721
Balance as on June 30, 2021	4,461,120,890	5,269,474,690	1,689,636,958	294,950,950	1,121,824,646	13,767,206	24,179,782,862	37,030,558,202	334,306,627	37,364,864,829

Net Asset Value (NAV) Per Share (Note-33)

Tk. 83.01

As at June 30, 2020

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to Owners of the Company	Non-Controlling Interests	Total Equity
Balance as on July 01, 2019	4,055,564,450	5,269,474,690	1,689,636,958	294,950,950	1,131,853,004	2,504,203	17,144,333,029	29,588,317,284	276,006,553	29,864,323,837
Total Comprehensive Income:										
Profit for the Year	—	—	—	—	—	—	3,514,687,301	3,514,687,301	29,795,800	3,544,483,101
Other Comprehensive Income/(Loss)	—	—	—	—	—	(1,577,828)	—	(1,577,828)	—	(1,577,828)
Transactions with the Shareholders:										
Cash Dividend	—	—	—	—	—	—	(608,334,668)	(608,334,668)	(3,473,347)	(611,808,015)
Adjustment for Depreciation on Revalued Assets	—	—	—	—	(8,114,071)	—	8,114,071	—	—	—
Adjustment for Deferred Tax on Revalued Assets	—	—	—	—	2,028,518	—	—	2,028,518	—	2,028,518
Balance as on June 30, 2020	4,055,564,450	5,269,474,690	1,689,636,958	294,950,950	1,125,767,451	926,375	20,058,799,733	32,495,120,607	302,329,006	32,797,449,613

Net Asset Value (NAV) Per Share (Note-33)

Tk. 80.12

The Notes are an integral part of the Financial Statements.

Approved and authorised for issue by the Board of Directors on October 21, 2021 and signed for and on behalf of the Board :



Osman Kaiser Chowdhury
Director


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Per our report of even date

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A


Hasan Mahmood FCA
Enrollment No : 0564
DVC : N/A

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Cash Flows
For the Year ended June 30, 2021


		Amount in Taka	
	Notes	July 2020-June 2021	July 2019-June 2020
Cash Flows from Operating Activities :			
Receipts from Customers and Others		30,833,168,257	25,934,454,695
Payments to Suppliers and Employees		(22,500,770,314)	(18,467,458,543)
Cash Generated from Operations		8,332,397,943	7,466,996,152
Interest Paid		(861,452,888)	(1,012,519,091)
Interest Received		2,377,286	20,409,291
Income Tax Paid		(1,450,058,386)	(932,399,131)
Net Cash Generated from Operating Activities	35	6,023,263,955	5,542,487,221
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(2,520,682,923)	(2,243,555,782)
Intangible Assets		(37,734,793)	(31,745,002)
Disposal of Property, Plant and Equipment		32,831,171	3,646,251
Dividend Received		940,700	1,427,930
Decrease in Short Term Investment		—	323,364,536
Net Cash Used in Investing Activities		(2,524,645,845)	(1,946,862,067)
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		(504,636,764)	(1,000,373,112)
Net Increase/(Decrease) in Short Term Borrowings		(2,375,180,232)	(1,970,741,462)
Dividend Paid		(578,351,025)	(601,957,017)
Net Cash (Used in) / from Financing Activities		(3,458,168,021)	(3,573,071,591)
Increase/(Decrease) in Cash and Cash Equivalents		40,450,089	22,553,563
Cash and Cash Equivalents at Beginning of Year		635,016,519	610,494,299
Effect of Exchange Rate Changes on Cash and Cash Equivalents	35	—	1,968,657
Cash and Cash Equivalents at End of Year	12	675,466,608	635,016,519
Net Operating Cash Flows Per Share	34	13.50	13.67

The Notes are an integral part of the Financial Statements.

Approved and authorised for issue by the Board of Directors on October 21, 2021 and signed for and on behalf of the Board :



Osman Kaiser Chowdhury
Director


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Per our report of even date

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A

Hasan Mahmood FCA
Enrollment No : 0564
DVC : N/A

Beximco Pharmaceuticals Limited and its Subsidiaries

Notes to the Financial Statements

As at and for the year ended June 30, 2021

1. The Reporting Entity

1.1 About the Company

Beximco Pharmaceuticals Limited (BPL/ the Company) is a public limited company incorporated in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). In 2018, BPL acquired 85.22% shares of Nuvista Pharma Limited – a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs and took over control of its management. Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 The Subsidiaries

Nuvista Pharma Limited

Nuvista Pharma, formerly Organon (Bangladesh) Ltd., was a subsidiary of Netherlands based Organon International. The Company has been operating in Bangladesh since 1964, with a local manufacturing facility at Tongi, Dhaka. In the post-independent Bangladesh, it was incorporated as Organon (Bangladesh) Limited under Bangladesh Companies Act as a private limited company. In 2006 the foreign shareholding was sold out to Bangladeshi management and was renamed as Nuvista Pharma Limited. The Company through amendments to its memorandum of association in 2011 converted it into a public limited company. In 2018, Beximco Pharmaceuticals Limited acquired majority shareholdings in Nuvista Pharma and became the immediate and ultimate parent of the company.

Beximco Pharma API Limited

Beximco Pharma API Limited was formed as a private limited company in December 2017 with a paid up capital of Taka 20 million divided into 2 million shares of Taka 10 each, fully held by BPL (excepting 10 shares). The Company intends to set up a facility at API Industrial Park to manufacture Active Pharmaceutical Ingredients (APIs) for domestic and international markets. The Company is still in the initial phase of establishment.

1.3 Nature of Business

BPL is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable, Large Volume Intravenous Fluids. Besides formulation products, BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets.

NPL produces various pharmaceutical products including oral contraceptives, hormone, steroid, anti-histamine, anti-fibrinolytic, anti-infective, gastrointestinal, musculoskeletal, respiratory, vitamin & mineral supplement and women's health products which are sold in the domestic market.

Both BPL and NPL provide contract manufacturing services.

2. Basis of Preparation of Financial Statements

2.1 Statement of Compliance

The financial statements have been prepared in compliance with the requirements of the Companies Act 1994, the Securities & Exchange Rules 2020, the Listing Regulations of Dhaka and Chittagong Stock Exchanges and other relevant local laws as applicable and in accordance with the International Financial Reporting Standards (IFRSs).

2.2 Basis of Measurement

The financial statements have been prepared on Historical Cost basis except for certain Property, Plant and Equipment measured at revalued amount (revaluation carried out in 2008). The Tangible and Intangible Assets and Liabilities of the acquired subsidiary has been reported at their fair values at the date of acquisition. Investment in Shares of listed companies have been valued at the year- end quoted prices. Cash flow statement has been prepared on cash basis.

2.3 Reporting Period

Financial year of Beximco Pharmaceutical Limited (BPL) and its subsidiaries Nuvista Pharma Limited (NPL) and Beximco Pharma API Limited begins on July 1 and ends on June 30. The Financial Statements cover 12 months period starting from July 01,2020 to June 30,2021.

2.4 Comparative Information

Figures for earlier year have been re-arranged wherever considered necessary to ensure better comparability with the current year.

3. Significant Accounting Policies

3.1 Basis of Consolidation

The financial statements of the subsidiaries-Nuvista Pharma Limited and Beximco Pharma API Limited, have been consolidated with those of Beximco Pharmaceuticals Limited in accordance with IFRS 10: Consolidated Financial Statements.

The Company acquired 85.22% shares of the issued and paid up capital of Nuvista Pharma Limited. This ownership interest is adequate enough to establish control over NPL and thus BPL meets the conditions as stated in IFRS 10: Consolidated Financial Statements to consider NPL as a subsidiary.

Beximco Pharma API Limited (BPAL) was formed with a paid up capital of Tk.20,000,000 divided into 2,000,000 shares of Tk.10 each, all of which excepting 10 shares are held by Beximco Pharmaceuticals Ltd (BPL). Beximco Pharma API Ltd. thus meets the conditions stated in IFRS 10: Consolidated Financial Statements to consider it as a subsidiary.

3.2 Inter-Company Transactions

Assets, Liabilities, Equity, Income, Expenses and Cash Flows arising out of transactions between the Company and the subsidiaries have been eliminated in full in the Consolidated Financial Statements.

3.3 Non-Controlling Interests (NCIs)

Non-Controlling Interests (NCIs) at the date of acquisition has been measured at fair value of the net assets of the acquired company in proportion to the shares of the entitled holders. Profit or Loss and Other Comprehensive Income subsequent to the acquisition has been allocated to the Owners of the Company and to the NCIs and also disclosed in the financial statements.

3.4 Valuation of Goodwill

Goodwill has been determined in accordance with IFRS 3: Business Combination. This represents the excess of the aggregate of Purchase Consideration and the acquisition-date fair value of NCI's share in the net assets over the acquisition-date fair value of the net assets of the subsidiary.

3.5 Investment in Associates

Investment in Associates has been accounted for using the Equity method as per IAS 28: Investment in Associates and Joint Ventures

This represents value of 3,900,000 Ordinary Shares of Malaysian Ringgit (RM) 1 each issued to Beximco Pharmaceuticals Ltd. by BioCare Manufacturing Sdn Bhd ("BioCare"), Malaysia. Beximco Pharmaceuticals Ltd. was issued 30% of the equity share of the Malaysian based company for providing technical support to set up a manufacturing facility to produce specialized pharmaceutical products in Seri Iskandar Pharmaceutical Park, Perak, Malaysia. BioCare is considered to be an associate of BPL as per IAS 28: Investment in Associates and Joint Ventures.

Accounting year of BioCare ends on December 31 which is different from the date of preparation of this Consolidated Statement of Financial Positions. BioCare has provided unaudited interim financial statements as of June 30, 2021. Beximco Pharma has not recognized 30% share of the accumulated loss of the company exceeding the value of investment of Tk. 29,325,720 by an amount of Tk. 29,517,257 following IAS 28: Investment in Associates and Joint Ventures as the Company has no obligation for any liability beyond the value of its investment in associates.

Amount in Taka

4. Property Plant and Equipment

As on June 30, 2021

Particulars	Land	Building and Other Constructions	Plant and Machinery	Furniture and Fixtures	Transport and Vehicle	Office Equipment	Total Property Plant & Equipment	Right-of-use Assets	Total
Cost									
As on July 01, 2020	4,067,829,596	7,822,270,536	15,766,994,486	330,453,956	827,287,026	616,852,214	29,431,687,814	394,467,696	29,826,155,510
Additions	—	8,243,322	153,224,100	21,758,200	—	36,310,323	219,535,945	130,204,714	349,740,659
Transferred in & Capitalized	—	298,207,642	965,316,704	1,558,986	—	2,848,259	1,267,931,591	—	1,267,931,591
Transferred from Right-of-use Assets	—	—	—	—	4,275,000	—	4,275,000	(4,275,000)	—
Disposal during the Year	—	—	(38,321,632)	(896,228)	(22,436,699)	(2,195,320)	(63,849,879)	—	(63,849,879)
Cost as on June 30, 2021	4,067,829,596	8,128,721,500	16,847,213,658	352,874,914	809,125,327	653,815,476	30,859,580,471	520,397,410	31,379,977,881
Accumulated Depreciation									
As on July 01, 2020	—	2,180,089,177	6,847,744,824	159,947,178	613,234,361	419,332,553	10,220,348,093	154,303,777	10,374,651,870
Depreciation Charged	—	188,605,759	667,088,924	17,065,904	52,082,266	32,205,427	957,048,280	47,420,034	1,004,468,314
Fair Value Depreciation	—	2,363,364	9,652,060	—	—	—	12,015,424	—	12,015,424
Transferred from Right-of-use Assets	—	—	—	—	1,211,250	—	1,211,250	(1,211,250)	—
Adjustment for Assets disposed off	—	—	(17,098,214)	(264,188)	(15,567,741)	(2,050,991)	(34,981,134)	—	(34,981,134)
Accumulated Depreciation as on June 30, 2021	—	2,371,058,300	7,507,387,594	176,748,894	650,960,136	449,486,989	11,155,641,913	200,512,561	11,356,154,474
Net Book Value June 30, 2021	4,067,829,596	5,757,663,200	9,339,826,064	176,126,020	158,165,191	204,328,487	19,703,938,558	319,884,849	20,023,823,407
Capital Work in Progress							16,507,437,036	—	16,507,437,036
Carrying Value as on June 30, 2021							36,211,375,594	319,884,849	36,531,260,443
Carrying Value as on June 30, 2020							35,000,809,631	240,163,919	35,240,973,550

Amount in Taka

	June 30, 2021	June 30, 2020
--	---------------	---------------

4 (a). Right-of-use Assets

At Cost	520,397,410	394,467,696
Accumulated Depreciation	200,512,561	154,303,777
	319,884,849	240,163,919

5. Intangible Assets

Particulars	Product Development, Licensing and Marketing Rights	ERP System	Trade Name & Trade Marks	Total
Cost				
As on July 01, 2020	1,349,055,417	169,745,334	54,000,000	1,572,800,751
Addition / Transferred in & Capitalized	165,102,296	22,864,119	14,870,674	202,837,089
As on June 30, 2021	1,514,157,713	192,609,453	68,870,674	1,775,637,840
Amortization				
As on July 01, 2020	276,210,051	16,710,370	4,320,000	297,240,421
Amortized During the year	78,461,481	16,710,362	2,531,767	97,703,610
As on June 30, 2021	354,671,532	33,420,732	6,851,767	394,944,031
Balance as on June 30, 2021	1,159,486,181	159,188,721	62,018,907	1,380,693,809
Balance as on June 30, 2020	1,072,845,366	153,034,964	49,680,000	1,275,560,330

6. Goodwill

This is carried forward from the previous year and relates to acquisition of Nuvista Pharma Limited (Note 3.4). There has been no indication of impairment of goodwill during the year.

Amount in Taka

7. Other Investments

a. Investment Details (Taka)

	July 01, 2020	Unrealised Gain/(Loss)	June 30, 2021
Bangladesh Export Import Co. Ltd.	2,182,101	12,840,831	15,022,932
Central Depository Bangladesh Ltd. (CDBL)	1,569,450	—	1,569,450
	3,751,551	12,840,831	16,592,382

b. Number of Shares:

	July 01, 2020	June 30, 2021
Bangladesh Export Import Co. Ltd.	167,854	167,854
Central Depository Bangladesh Ltd. (CDBL)	571,182	571,182

c. The shares of Bangladesh Export Import Co. Ltd. are listed in Dhaka and Chittagong Stock Exchanges. The market value of each share of Bangladesh Export Import Co. Ltd. as on June 30, 2021 was Tk. 89.50 (June 30, 2020: Tk.13.00). The fair value gain of Tk. 12,840,831 has been accounted for as Other Comprehensive Income following IFRS 9: Financial Instruments.

d. Shares of Central Depository Bangladesh Ltd.(CDBL) are not traded . The value at acquisition is considered to be the fair value as on the Balance Sheet date.

Amount in Taka

June 30, 2021 June 30, 2020

8. Inventories

This consists of as follows :

Finished Goods	1,299,682,358	1,128,728,172
Work in Process	340,572,871	294,258,178
Raw Materials	3,234,868,408	3,089,296,983
Packing Materials	1,134,669,306	960,326,569
Laboratory Chemicals	82,829,613	64,584,938
Physician Samples	79,764,262	69,468,235
R&D Materials	22,520,999	15,232,992
Materials in Transit	947,955,660	322,872,990
	7,142,863,477	5,944,769,057

9. Spares & Supplies

This consists of as follows :

Spares & Accessories	553,939,317	660,313,987
Stock of Stationery	16,841,919	14,209,600
Literature & Other Materials	90,941,488	101,005,200
	661,722,724	775,528,787

	Amount in Taka	
	June 30, 2021	June 30, 2020
10. Accounts Receivable		
This consists of :		
Trade Receivable	2,725,572,936	3,088,509,497
Other Receivable	148,271,938	216,941,937
	2,873,844,874	3,305,451,434

Accounts Receivable is reported net of provision for bad debts of Tk. 10,054,213. It includes an amount of Tk. 840,777,271, equivalent USD 9,985,468 (June 30, 2020: Tk. 817,658,851, USD 9,710,913) receivable against export sales. Part of the export sales receivables are against Letter of Credit while the rest are unsecured but considered good.

Accounts Receivable also includes Tk.1,401,534,613 due from I & I Services Ltd., who provides distribution service to the Company and a "Related Party". The maximum amount due from the company during the year was Tk.1,695,026,636 on 31 May 2021.

No amount was due from the directors, managing agent, managers and other officers of the company and any of them severally or jointly with any other person.

Aging of Trade Receivables :

Amount due within 6 months	2,658,627,358	3,036,824,038
Amount due for 6 months & above	66,945,578	51,685,459
	2,725,572,936	3,088,509,497

11. Loans, Advances and Deposits

This is unsecured, considered good and consists of as follows :		
Clearing & Forwarding	249,538,566	281,675,299
VAT	488,144,349	441,074,569
Claims Receivable	25,777,861	6,636,489
Security Deposit & Earnest Money	167,929,080	83,541,576
Lease Deposit	2,650,135	10,821,850
Capital Expenditure/ Project	128,076,779	209,723,000
Expenses	295,859,623	264,086,628
Bank Guarantee Margin	20,831,185	35,585,120
Salary Advance / Loan	186,444,554	161,306,524
Rent Advance	34,886,833	29,898,335
Motor Cycle	148,885,137	154,443,129
Raw & Packing Material	460,856,879	442,658,728
Prepaid Insurance	36,030,920	155,346,536
Overseas Liaison Office	58,207,996	40,724,614
Others	112,828,599	70,790,725
	2,416,948,496	2,388,313,122

No amount was due from the directors, managing agent, managers and other officers of the company and any of them severally or jointly with any other person, except as stated above.

Amount in Taka

	June 30, 2021	June 30, 2020
--	---------------	---------------

12. Cash and Cash Equivalents

This consists of as follows :		
a. Cash in Hand (including Imprest Cash)	164,562,735	170,478,822
b. Cash at Bank :		
(i) Current & FC Account	470,765,642	426,156,203
(ii) FDR Account	40,138,231	38,381,494
	675,466,608	635,016,519

13. Issued Share Capital

A. Authorized :		
1,000,000,000 Ordinary Shares of Tk. 10 each	10,000,000,000	10,000,000,000
50,000,000 fully convertible 5 % Preference Shares of Tk. 100 each	5,000,000,000	5,000,000,000
	15,000,000,000	15,000,000,000
B. Issued, Subscribed and Paid-up :		
51,775,750 Shares fully paid-up in cash	517,757,500	517,757,500
357,093,942 Ordinary Shares issued as stock dividend	3,570,939,420	3,165,382,980
5,951,250 Ordinary Shares issued in exchange of Shares of Beximco Infusions Ltd.	59,512,500	59,512,500
31,291,147 Ordinary Shares issued on conversion of Preference Shares	312,911,470	312,911,470
	4,461,120,890	4,055,564,450

5,951,250 Ordinary Shares of Tk. 10 each were issued to the shareholders of Beximco Infusions Ltd. on its merger with Beximco Pharmaceuticals Ltd. in 2005.

41,000,000 fully convertible 5% preference shares of Tk. 100 each were issued in 2009. 50% of the preference shares were converted into 16,169,191 ordinary shares of Tk. 10 each on February 1, 2010. The rest 50% were converted into 15,121,956 ordinary shares of Tk. 10 each on May 2, 2010.

100,037,989 Shares have been issued as underlying shares for the GDRs listed with AIM of London Stock Exchange.

	June 30, 2021		June 30, 2020	
	Number of Shares	% of Share Capital	Number of Shares	% of Share Capital
C. Composition of Shareholding :				
Sponsors/Directors:				
A S F Rahman	9,058,888	2.03	8,235,353	2.03
Salman F Rahman	9,080,095	2.04	8,254,632	2.04
Other Directors and Associates	116,517,180	26.11	37,019,789	9.13
	134,656,163	30.18	53,509,774	13.20
Other Shareholdings:				
Foreign Portfolio Investors (DSE/CSE)	51,907,674	11.64	48,720,273	12.01
Holders of GDRs (excluding Board Director)	84,386,054	18.92	90,943,627	22.42
Institutions (ICB, ICB Investors' Accounts & Others)	87,784,924	19.68	148,762,402	36.68
Individual Shareholders	87,377,274	19.58	63,620,369	15.69
	311,455,926	69.82	352,046,671	86.80
Total	446,112,089	100.00	405,556,445	100.00

	Amount in Taka	
	June 30, 2021	June 30, 2020
14. Non-Controlling Interest		
Non-Controlling Interest (Opening)	302,329,006	276,006,553
Proportionate profit/loss (NPL)	38,056,021	29,795,800
Less Cash Dividend (NPL)	(6,078,400)	(3,473,347)
	334,306,627	302,329,006

15. Long Term Borrowings - Net of Current Maturity

This is arrived at as follows :

Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	972,696,465	1,437,978,890
Lease Liability	234,020,629	208,860,444
Dhaka Bank Limited	—	4,751,056
	1,206,717,094	1,651,590,390

Lease Liability

This consists of as follows:

Within one year	113,976,268	108,115,288
Within two to five years	234,020,629	208,860,444
	347,996,897	316,975,732

16. Liability for Gratuity and WPPF & Welfare Funds

Gratuity Payable	1,322,046,817	1,185,669,111
Workers Profit Participation and Welfare Fund	1,013,210,949	958,384,323
	2,335,257,766	2,144,053,434

17. Short Term Borrowings

Janata Bank Limited	3,077,454,947	3,963,918,204
AB Bank Limited	1,014,765,029	1,106,352,880
First Security Islamic Bank Limited	510,141,234	510,491,234
Liability for UPAS Letter of Credit	254,745,071	1,406,768,304
Dhaka Bank Limited	166,074,847	410,830,738
	5,023,181,128	7,398,361,360

18. Long Term Borrowings-Current Maturity

This consists of as follows:

Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	1,287,429,745	937,110,252
Lease Liability	113,976,268	108,115,288
AB Bank Limited	—	377,802,906
Dhaka Bank Limited	—	31,283,549
	1,401,406,013	1,454,311,995

	Amount in Taka	
	June 30, 2021	June 30, 2020
19. Creditors and Other Payables		
Goods & Services	769,204,884	575,012,150
Provident Fund	800,770,806	726,878,755
Advance Against Sales	298,396,187	12,393,114
Others	96,676,303	83,533,047
	1,965,048,180	1,397,817,066

20. Accrued Expenses

This is unsecured, falling due within one year and consists of as follows :

For Expenses	296,650,070	503,704,448
Workers' Profit Participation and Welfare Funds -(current year)	322,749,293	235,808,378
	619,399,363	739,512,826

21. Dividend Payable / Unclaimed Dividend

The Dividend Payable/Unclaimed dividend as on June 30, 2021 includes prior years' dividend of Tk. 81,481,571 unclaimed to date. The unclaimed dividend reported under Creditors and Other Payables in the prior period has been reclassified in this financial statement. Subsequent to the Balance Sheet date an amount of Tk 64,297,249 has been paid to the Capital Market Stabilization Fund (CMSF) in compliance to BSEC directive no. BSEC/CMRRCD/2021-386/03 dated January 14, 2021.

	July 2020- June 2021	July 2019- June 2020
22. Net Revenue		
Domestic Sales	26,331,187,249	22,808,998,367
Export Sales	3,124,001,260	2,751,790,244
Toll Income	38,385,360	51,159,044
	29,493,573,869	25,611,947,655

23. Cost of Goods Sold

This is made-up as follows :

Work-in-Process (Opening)	294,258,178	455,530,899
Materials Consumed (Note: 24)	12,108,082,703	10,054,371,739
Factory Overhead (Note: 25)	3,958,532,311	3,623,979,789
Total Manufacturing Cost	16,360,873,192	14,133,882,427
Work-in-Process (Closing)	(340,572,871)	(294,258,178)
Cost of Goods Manufactured	16,020,300,321	13,839,624,249
Finished Goods (Opening)	1,128,728,172	1,255,181,983
Purchase (Imported and processed products)	9,718,528	—
Finished Goods available	17,158,747,021	15,094,806,232
Cost of Physician Sample transferred to Sample Stock	(288,993,082)	(253,230,551)
Finished Goods (Closing)	(1,299,682,358)	(1,128,728,172)
	15,570,071,581	13,712,847,509

Amount in Taka

	July 2020- June 2021	July 2019- June 2020
--	----------------------	----------------------

24. Materials Consumed

	July 2020- June 2021	July 2019- June 2020
This is made-up as follows :		
Opening Stock	4,114,208,490	3,854,012,150
Purchase	12,446,241,540	10,314,568,079
Closing Stock	(4,452,367,327)	(4,114,208,490)
	12,108,082,703	10,054,371,739

25. Factory Overhead

Salary & Allowances	1,533,120,357	1,345,684,174
Repairs and Maintenance	446,218,960	391,224,077
Insurance Premium	39,656,024	36,933,338
Municipal Tax & Land Revenue	9,759,175	9,034,338
Registration & Renewals	17,174,084	19,443,939
Travelling & Conveyance	34,900,276	27,128,815
Entertainment	4,199,173	2,801,983
Research and Development	313,009,068	272,389,951
Rent	13,524,226	4,756,535
Printing & Stationery	32,694,658	30,094,938
Telephone, Cellphone, Internet & Postage	10,791,816	9,599,588
Toll Expense	235,447,825	231,429,690
Electricity, Gas & Water	296,679,254	252,097,664
Training & Conference	9,614,915	6,129,368
Plant Certification and Regulatory Approvals	15,156,941	37,358,555
Depreciation	910,223,457	920,137,361
Security Expenses	27,880,157	21,979,283
Other Expenses	8,481,945	5,756,192
	3,958,532,311	3,623,979,789

26. Administrative Expenses

Salary & Allowances	504,500,078	458,035,801
Rent	27,676,800	23,948,000
Repairs and Maintenance	68,232,587	58,709,365
Registration & Renewals	6,299,916	5,019,043
Travelling & Conveyance	28,167,143	29,587,058
Entertainment	7,455,924	6,881,179
Printing & Stationery	6,803,770	5,572,906
Audit Fee	2,420,000	2,195,000
Telephone, Cellphone, Internet & Postage	6,376,660	5,927,093
Electricity, Gas & Water	16,306,564	13,770,520
Legal & Consultancy	10,632,552	15,823,054
Business Acquisition Cost	18,208,232	—
Company Secretarial, Regulatory Fee and AGM Expense	37,042,133	34,599,077
Municipal Tax & Land Revenue	1,333,030	700,698
Training & Conference	2,825,669	6,630,474
Depreciation	34,843,193	35,015,790
Meeting Fee	3,416,000	2,301,650
Security Expenses	14,112,817	11,209,371
Other Expenses	99,995,897	77,025,630
	896,648,965	792,951,709

Amount in Taka

	July 2020- June 2021	July 2019- June 2020
27. Selling, Marketing and Distribution Expenses		
Salary & Allowances	2,439,081,146	2,092,122,649
Rent	90,481,862	82,034,461
Repairs and Maintenance	38,956,827	15,310,108
Travelling & Conveyance	643,683,075	567,898,731
Entertainment	66,513,698	56,439,513
Printing & Stationery	41,586,524	37,381,062
Telephone, Cellphone, Internet & Postage	77,159,670	58,915,054
Software & Licences	33,596,270	26,876,458
Electricity, Gas & Water	21,142,416	15,361,760
Market Research & New Products	82,002,039	69,374,568
Training & Conference	127,964,742	112,364,209
Insurance Premium	34,805,887	29,966,989
Sample Expense	361,952,879	315,070,105
Advertisement	7,220,379	2,555,997
Field Operation	51,707,425	44,293,568
Events, Programs & Campaigns	274,549,019	186,559,672
Brand Development	146,192,749	106,570,287
CSR Expenses	11,036,539	81,344,051
Sales Promotion Expenses	152,775,395	138,324,168
Books, Journals and Periodicals	10,988,156	8,705,778
Salesforce Logistics	42,891,362	32,042,162
Clinical Studies and Research	6,488,050	5,002,419
Pharmacovigilance	27,087,836	14,768,459
Literature and News Letter	254,964,214	209,372,035
Registration & Renewals	140,902,326	62,603,853
Export Insurance, Freight and C&F Expenses	158,409,899	225,789,212
Distribution Commission	437,367,829	376,830,927
Delivery Expense	385,580,530	335,270,945
Depreciation & Amortization	169,120,696	158,799,273
Security Expenses	20,158,622	19,941,269
Bad Debts	3,499,431	3,692,812
Other Expenses	16,278,483	5,071,769
	6,376,145,975	5,496,654,323

28. Other Income

Interest Income	2,377,286	20,409,291
Dividend Income	940,700	1,427,930
Royalty	40,529,949	151,552,031
Cash Incentive on Export	309,745,032	139,620,667
Exchange Rate Fluctuation Gain / (Loss)	(3,716,895)	13,196,829
Vaccine Distribution Fee	542,265,041	—
Forfeited PF Refund	10,722,438	—
Profit/(Loss) on Sale of Fixed Assets	3,962,426	(33,797,892)
Miscellaneous Income	1,449,307	1,149,448
	908,275,284	293,558,304

	Amount in Taka	
	July 2020- June 2021	July 2019- June 2020
29. Finance Cost		
Interest on Bank Borrowings	578,560,598	787,650,804
Interest on Lease Liability	36,342,986	28,711,869
Interest on Loan from PF, WPPF & Welfare Fund	190,970,118	166,837,043
Other Bank Charges	52,811,444	30,604,369
	858,685,146	1,013,804,085

30. Income Tax Expenses

This consists of as follows :

(a) Current Tax	1,386,678,310	1,086,668,418
(b) Deferred Tax Expense	(174,879,849)	22,288,436
	1,211,798,461	1,108,956,854

31. Other Comprehensive Income/(Loss)

Fair Value Gain/(Loss) on Investment in Listed Shares	12,840,831	(1,577,828)
	12,840,831	(1,577,828)

32. Earnings Per Share (EPS)/ Restated EPS

(a) Earnings attributable to the Owners of the Company	5,127,693,711	3,514,687,301
(b) Weighted average number of Shares outstanding during the year	446,112,089	446,112,089
Earnings Per Share (EPS)/ Restated EPS	11.49	7.88

	June 30, 2021	June 30, 2020
33. Net Asset Value (NAV) Per Share		
Total Assets	52,246,084,026	50,118,741,940
Less Total Liabilities	(14,881,219,197)	(17,321,292,327)
Less Non-controlling Interest	(334,306,627)	(302,329,006)
Equity Attributable to the Owners of the Company	37,030,558,202	32,495,120,607
Number of Ordinary Shares	446,112,089	405,556,445
Net Asset Value (NAV) Per Share	83.01	80.12

	July 2020- June 2021	July 2019- June 2020
34. Net Operating Cash Flows Per Share (NOCFPS)		
Net Cash Generated from Operating Activities	6,023,263,955	5,542,487,221
Number of Ordinary Shares	446,112,089	405,556,445
Net Operating Cash Flows Per Share (NOCFPS)	13.50	13.67

Amount in Taka

July 2020- June 2021

July 2019- June 2020

35. Reconciliation of Net Profit with Cash Flows from Operating Activities

	July 2020- June 2021	July 2019- June 2020
Profit after Tax	5,165,749,732	3,544,483,101
Adjustment to reconcile net profit to net cash provided by operating activities :		
(a) Non-cash Expenses :	1,137,369,317	1,409,987,996
Depreciation	1,016,483,738	1,022,846,054
Amortization	97,703,610	91,106,370
Gratuity & WPPF	191,204,332	283,148,438
Exchange rate fluctuation (Gain) / Loss on Foreign Currency Bank Loan	6,857,486	(9,401,302)
Deferred Tax	(174,879,849)	22,288,436
(b) Non-operating Items	(4,903,126)	30,401,305
Dividend Income	(940,700)	(1,427,930)
(Profit) / Loss on sale of Fixed Assets	(3,962,426)	33,797,892
Effect of exchange rate changes on Cash and Cash Equivalents *	—	(1,968,657)
(c) Changes in working Capital	(274,951,968)	557,614,819
(Increase)/Decrease in Inventories	(1,198,094,420)	(20,737,379)
(Increase)/Decrease in Spares & Supplies	113,806,063	(49,401,525)
(Increase)/Decrease in Accounts Receivable	431,606,560	29,507,471
(Increase)/Decrease in Advance Income Tax	—	35,681,115
(Increase)/Decrease in Loans, Advances & Deposits	(28,635,374)	(78,809,375)
(Increase)/Decrease in Other Non-current Assets	2,686,377	3,634,939
Increase/(Decrease) in Creditors and Other Payables	587,172,366	370,996,478
Increase/(Decrease) in Accrued Expenses	(120,113,463)	148,154,924
Increase/(Decrease) in Income Tax Payable	(63,380,076)	118,588,172
Net cash Generated from Operating Activities	6,023,263,955	5,542,487,221

*The Company used Janata Bank's applicable (US Dollar-Taka) exchange rate as on June 30, 2021 which remained unchanged with the exchange rate as on June 30, 2020. As such, there was no effect of exchange rate on Cash and Cash Equivalents.

36. Related Party Disclosures

a. Following transactions were carried out with related parties in the normal course of business on arms length basis:

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at year end
(i) I & I Services Ltd.	Delivery of Products Distribution Commission	27,348,232,493 437,367,829	1,401,534,613


b. Related party transaction between the Company and its subsidiaries have been eliminated in the consolidation.



Osman Kaiser Chowdhury
Director



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer

Dhaka
October 21, 2021

Financial Statements
Beximco Pharmaceuticals Limited

Independent Auditor's Report
To the Shareholders of
Beximco Pharmaceuticals Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Beximco Pharmaceuticals Limited (the "Company"), which comprise the Statement of Financial Position as at 30 June 2021 and Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements of the Company give a true and fair view of the financial position of the Company as at 30 June 2021, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 2020 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Risk	Our response to the risk
Valuation of Property, Plant and Equipment (PPE)	
<p>The carrying value of the PPE was Tk. 34,501,205,124 as at 30 June, 2021.</p> <p>Expenditures are capitalized if they create new assets or enhance the existing assets, and expensed if they relate to repair or maintenance of the assets. Classification of the expenditures involves judgment. The useful lives of PPE items are based on management's estimates regarding the period during which the assets or its significant components will be used. The estimates are based on historical experience and market practice and take into consideration the physical condition of the assets.</p> <p>The valuation of PPE was identified as a key audit matter due to the significance of this balance to the financial statements and that there is significant measurement uncertainty involved in this valuation.</p> <p>See Note No. 4 to the financial statements</p>	<p>Our audit included the following procedure:</p> <ul style="list-style-type: none"> • We assessed whether the accounting policies in relation to the capitalization of expenditures are in compliance with IFRS and found them to be consistent. • We inspected a sample of invoices and L/C documents to determine whether the classification between capital and revenue expenditure was appropriate. • We evaluated whether the useful lives determined and applied by the management were in line with historical experience and the market practice. • We checked whether the depreciation of PPE items was commenced timely, by comparing the date of the reclassification from capital work in progress to ready for use, with the date of the act of completion of the work.

Risk	Our response to the risk
Valuation of Inventory	
<p>The inventory of Tk. 6,693,894,021 as at 30 June, 2021 was held at different locations across the country.</p> <p>Inventories are carried at the lower of cost and net realizable value. As a result, the management apply judgment in determining the appropriate values for slow-moving or obsolete items.</p> <p>Since the value of Inventory is significant to the Financial Statements and there is significant measurement uncertainty involved in this valuation, the valuation of inventory was significant to our audit.</p> <p>See Note No. 9 to the financial statements</p>	<p>We verified the appropriateness of management's assumptions applied in calculating the value of the inventory by:</p> <ul style="list-style-type: none"> • Evaluating the design and implementation of key inventory controls. • Attending inventory counts on sample basis and reconciling the count results to the inventory listing to test the completeness of data. • Reviewing the requirement of inventory provisioning and action there upon by the management. • Comparing the net realizable value obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories.
Contingent Liability	
<p>The Company is subject to a number of claims and litigations. The amounts of claims are significant and estimates of the amounts of provisions or contingent liabilities are subject to management judgement. These claims and regulatory matters are uncertain in timing of resolutions and amount or consequences.</p> <p>These claims and litigation matters were a key audit matter due to the amounts involved, potential consequences and the inherent difficulty in assessing the outcome. The assessment of whether or not a liability should be recognized involves judgement from management</p>	<p>We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the legal provision and contingency processes.</p> <p>We enquired to those charged with governance to obtain their view on the status of the litigations.</p> <p>We enquired of the Company's internal legal counsel for the litigation and inspected internal notes and reports. We also reviewed formal confirmations in this regard from external counsel.</p> <p>We also validated the completeness and appropriateness of the related disclosures in Note No. 49 of the financial statements.</p>
Related party transactions	
<p>The Company has related party transactions with its subsidiaries and other related parties as described in Note No. 40 of the financial statements.</p> <p>We focused on identification of related parties and disclosure of related party transactions in accordance with relevant accounting standards.</p>	<p>Our audit procedures amongst others included the following:</p> <ul style="list-style-type: none"> • Evaluated the design and tested the operating effectiveness of controls over identification and disclosure of related party transactions. • Evaluated the transactions among the related parties and tested material accounts balances. • Evaluated the disclosures in the financial statements in compliance with IAS 24.

Other Information

Management is responsible for the other information. The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on such work we perform, we conclude that there is a material misstatement of this other information, we are required to communicate the matter to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the financial statements of the Company in accordance with IFRSs, The Companies Act 1994, The Securities and Exchange Rules 2020 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal controls of the Company.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, The Securities and Exchange Rules 2020 and relevant notifications issued by Bangladesh Securities and Exchange Commission, we also report that:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of those books;
- c) The Company's Statement of Financial Position (Balance sheet) and Statement of Profit or Loss and Other Comprehensive Income (Profit & Loss Account) dealt with by this report are in agreement with the books of accounts and;
- d) The expenditures incurred and payment made were for the purpose of the Company's business for the year.

Dhaka
October 21, 2021



M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A

Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110310564AS841233

Beximco Pharmaceuticals Limited
Statement of Financial Position
As at June 30, 2021


		Amount in Taka	
	Notes	June 30, 2021	June 30, 2020
ASSETS			
Non-Current Assets		37,713,988,877	36,240,980,000
Property, Plant and Equipment- Carrying Value	4	34,501,205,124	33,244,656,330
Right-of-use Assets	4 (c)	319,884,849	237,100,169
Intangible Assets	5	701,794,902	580,960,330
Investment in Subsidiaries	6	2,145,185,900	2,145,185,900
Investment In Associates	7	29,325,720	29,325,720
Other Investments	8	16,592,382	3,751,551
Current Assets		13,150,677,229	12,438,793,173
Inventories	9	6,693,894,021	5,528,438,165
Spares & Supplies	10	622,433,282	735,703,950
Accounts Receivable	11	2,831,869,241	3,213,666,345
Loans, Advances and Deposits	12	2,354,576,102	2,345,039,872
Cash and Cash Equivalents	13	647,904,583	615,944,841
TOTAL ASSETS		50,864,666,106	48,679,773,173
EQUITY AND LIABILITIES			
Shareholders' Equity		36,707,591,755	32,356,359,135
Issued Share Capital	14	4,461,120,890	4,055,564,450
Share Premium		5,269,474,690	5,269,474,690
Excess of Issue Price over Face Value of GDRs	15	1,689,636,958	1,689,636,958
Capital Reserve on Merger		294,950,950	294,950,950
Revaluation Surplus	4(b)	1,121,824,646	1,125,767,451
Unrealized Gain/(Loss)		13,767,206	926,375
Retained Earnings		23,856,816,415	19,920,038,261
Non-Current Liabilities		5,265,836,197	5,692,973,418
Long Term Borrowings-Net of Current Maturity	16	1,206,717,094	1,641,924,046
Liability for Gratuity and WPPF & Welfare Funds	17	2,187,144,706	2,015,304,583
Deferred Tax Liability	18	1,871,974,397	2,035,744,789
Current Liabilities and Provisions		8,891,238,154	10,630,440,620
Short Term Borrowings	19	4,857,106,281	6,987,530,622
Long Term Borrowings-Current Maturity	20	1,401,406,013	1,421,497,401
Creditors and Other Payables	21	1,814,013,039	1,267,069,842
Accrued Expenses	22	480,501,854	609,401,272
Dividend Payable / Unclaimed Dividend	23	117,769,532	81,792,791
Income Tax Payable	24	220,441,435	263,148,692
TOTAL EQUITY AND LIABILITIES		50,864,666,106	48,679,773,173

The Notes are an integral part of the Financial Statements.

Approved and authorised for issue by the Board of Directors on October 21, 2021 and signed for and on behalf of the Board :



Osman Kaiser Chowdhury
Director


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Per our report of even date

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A


Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110310564AS841233

Beximco Pharmaceuticals Limited

Statement of Profit or Loss and Other Comprehensive Income

For the Year ended June 30, 2021


	Notes	July 2020 - June 2021	July 2019 - June 2020
			Amount in Taka
Net Sales Revenue	25	26,949,351,606	23,557,775,896
Cost of Goods Sold	26	(14,347,382,048)	(12,753,521,901)
Gross Profit		12,601,969,558	10,804,253,995
Operating Expenses		(6,532,965,326)	(5,690,899,854)
Administrative Expenses	29	(792,228,907)	(699,940,325)
Selling, Marketing and Distribution Expenses	30	(5,740,736,419)	(4,990,959,529)
Profit from Operations		6,069,004,232	5,113,354,141
Other Income	31	1,108,048,355	445,556,500
Finance Cost	32	(841,875,806)	(957,931,515)
Profit Before Contribution to WPPF & Welfare Funds		6,335,176,781	4,600,979,126
Contribution to WPPF & Welfare Funds	33	(301,675,085)	(219,094,244)
Profit Before Tax		6,033,501,696	4,381,884,882
Income Tax Expenses	34	(1,090,012,960)	(1,018,485,009)
Current Tax		(1,250,545,631)	(983,282,880)
Deferred Tax Income/ (Expense)		160,532,671	(35,202,129)
Profit after Tax		4,943,488,736	3,363,399,873
Other Comprehensive Income/(Loss)	35	12,840,831	(1,577,828)
Total Comprehensive Income		4,956,329,567	3,361,822,045
Earnings Per Share (EPS)/ Restated EPS	36	11.08	7.54

The Notes are an integral part of the Financial Statements.

Approved and authorised for issue by the Board of Directors on October 21, 2021 and signed for and on behalf of the Board :



Osman Kaiser Chowdhury
Director


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Per our report of even date

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A


Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110310564AS841233

Beximco Pharmaceuticals Limited
Statement of Changes in Equity
For the Year ended June 30, 2021

Amount in Taka

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Total
Balance as on July 01, 2020	4,055,564,450	5,269,474,690	1,689,636,958	294,950,950	1,125,767,451	926,375	19,920,038,261	32,356,359,135
Total Comprehensive Income								
Profit for the Year	—	—	—	—	—	—	4,943,488,736	4,943,488,736
Other Comprehensive Income/(Loss)	—	—	—	—	—	12,840,831	—	12,840,831
Transactions with the Shareholders:								
Cash Dividend	—	—	—	—	—	—	(608,334,668)	(608,334,668)
Stock Dividend	405,556,440	—	—	—	—	—	(405,556,440)	—
Adjustment for Depreciation on Revalued Assets	—	—	—	—	(7,180,526)	—	7,180,526	—
Adjustment for Deferred Tax on Revalued Assets	—	—	—	—	3,237,721	—	—	3,237,721
Balance as on June 30, 2021	4,461,120,890	5,269,474,690	1,689,636,958	294,950,950	1,121,824,646	13,767,206	23,856,816,415	36,707,591,755
Net Asset Value (NAV) Per Share (Note-37)								82.28

For the Year ended June 30, 2020

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Total
Balance as on July 01, 2019	4,055,564,450	5,269,474,690	1,689,636,958	294,950,950	1,131,853,004	2,504,203	17,156,858,985	29,600,843,240
Total Comprehensive Income								
Profit for the Year	—	—	—	—	—	—	3,363,399,873	3,363,399,873
Other Comprehensive Income/(Loss)	—	—	—	—	—	(1,577,828)	—	(1,577,828)
Transactions with the Shareholders:								
Cash Dividend	—	—	—	—	—	—	(608,334,668)	(608,334,668)
Adjustment for Depreciation on Revalued Assets	—	—	—	—	(8,114,071)	—	8,114,071	—
Adjustment for Deferred Tax on Revalued Assets	—	—	—	—	2,028,518	—	—	2,028,518
Balance as on June 30, 2020	4,055,564,450	5,269,474,690	1,689,636,958	294,950,950	1,125,767,451	926,375	19,920,038,261	32,356,359,135
Net Asset Value (NAV) Per Share (Note-37)								79.78

The Notes are an integral part of the Financial Statements.

Approved and authorised for issue by the Board of Directors on October 21, 2021 and signed for and on behalf of the Board :



Osman Kaiser Chowdhury
Director


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Per our report of even date

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A


Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110310564AS841233

Beximco Pharmaceuticals Limited
Statement of Cash Flows
For the Year ended June 30, 2021

		Amount in Taka	
	Notes	July 2020 - June 2021	July 2019 - June 2020
Cash Flows from Operating Activities :			
Receipts from Customers and Others		28,403,792,004	24,096,145,079
Payments to Suppliers and Employees		(20,656,123,661)	(17,060,430,359)
Cash Generated from Operations		7,747,668,343	7,035,714,720
Interest Paid		(841,875,806)	(957,931,515)
Interest Received		2,377,286	20,409,291
Income Tax Paid		(1,293,252,888)	(887,432,426)
Net Cash Generated from Operating Activities	39	5,614,916,935	5,210,760,070
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(2,463,893,877)	(2,224,544,487)
Intangible Assets		(22,864,119)	(31,745,002)
Disposal of Property, Plant and Equipment		32,751,038	3,572,001
Dividend Received		35,987,859	21,454,903
Decrease in Short Term Investment		—	323,364,536
Net Cash Used in Investing Activities		(2,418,019,099)	(1,907,898,049)
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		(462,155,826)	(959,164,164)
Net Increase/(Decrease) in Short Term Borrowings		(2,130,424,341)	(1,713,493,877)
Dividend Paid		(572,357,927)	(598,533,844)
Net Cash (Used in) / from Financing Activities		(3,164,938,094)	(3,271,191,885)
Increase/(Decrease) in Cash and Cash Equivalents		31,959,742	31,670,136
Cash and Cash Equivalents at Beginning of Year		615,944,841	582,306,048
Effect of Exchange Rate Changes on Cash and Cash Equivalents	39	—	1,968,657
Cash and Cash Equivalents at End of Year	13	647,904,583	615,944,841
Net Operating Cash Flows Per Share	38	12.59	12.85

The Notes are an integral part of the Financial Statements.

Approved and authorised for issue by the Board of Directors on October 21, 2021 and signed for and on behalf of the Board :



Osman Kaiser Chowdhury
Director


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer

Per our report of even date

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A

Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110310564AS841233

1. Reporting entity

1.1. About the Company

Beximco Pharmaceuticals Limited (BPL/ the Company) is a public limited company incorporated in Bangladesh in 1976. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). In 2018, BPL acquired 85.22% shares of NuVista Pharma Limited – a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs. Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the Company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2. Nature of Business

The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable, Large Volume Intravenous Fluids. BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets.

2. Basis of Preparation of Financial Statements

2.1 Statement of Compliance

The financial statements have been prepared in compliance with the requirements of the Companies Act, 1994, the Securities & Exchange Rules 2020, the Listing Regulations of Dhaka and Chittagong Stock Exchanges and other relevant local laws as applicable and in accordance with the International Financial Reporting Standards (IFRSs).

2.2 Basis of Measurement

The financial statements have been prepared on Historical Cost Basis except land, building and plant & machinery revalued on 31 December 2008, investment in shares of listed company valued at year end quoted price and the cash flow statement prepared on cash basis.

2.3 Presentation of Financial Statements

The presentation of the financial statements is in accordance with the guidelines provided by IAS 1: Presentation of Financial Statements.

The financial statements comprises of:

- (a) Statement of Financial Position as at the end of the year June 30, 2021;
- (b) Statement of Profit or Loss and Other Comprehensive Income for the year ended June 30, 2021;
- (c) Statement of Changes in Equity for the year ended June 30, 2021;
- (d) Statement of Cash Flows for the year ended June 30, 2021; and
- (e) notes, comprising summary of significant accounting policies and explanatory information.

2.4. Reporting Period and Comparative Information

The Financial statements cover 12 months' period starting from July 1, 2020 to June 30, 2021. The last audited financial statements were prepared for the year ending June 30, 2020. Figures for earlier year have been re-arranged wherever considered necessary to ensure better comparability with the current year.

2.5. Authorization for issue

The financial statements have been authorized for issue by the Board of Directors October 21, 2021.

2.6. Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the Company's functional currency. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

2.7. Use of Estimates and Judgments

The preparation of financial statements in conformity with the IFRSs including IASs require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses, and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.

In particular, the key areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include depreciation, inventory valuation, accrued expenses, others payable, capitalization of assets and deferred liability for gratuity.

3. Significant Accounting Policies

The accounting principles and policies in respect of material items of financial statements set out below have been applied consistently to all periods presented in these financial statements.

3.1. Revenue from Contracts with Customers

In compliance with the requirements of IFRS 15: Revenue from Contracts with Customers, revenue is recognized when the Company fulfills the performance obligations in contract with the customers. It usually occurs when customers take possession of the products or goods are delivered at destination specified in the contracts and recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, and there is no continuing management involvement with the goods.

Revenue from sale of goods is measured at the fair value of the consideration received or receivable net of returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

3.2. Property, Plant and Equipment (PP&E)

3.2.1. Recognition and Measurement

This has been stated at cost or revalued amount less accumulated depreciation in compliance with the requirements of IAS 16: Property, Plant and Equipment. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the assets to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes.

3.2.2. Maintenance Activities

The Company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

3.2.3. Depreciation

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provisions of IAS 16: Property, Plant and Equipment. Depreciation is provided at the following rates on reducing balance basis:

Building and Other Construction	2% - 10%
Plant and Machinery	5% - 15%
Furniture & Fixtures	10%
Transport & Vehicle	20%
Office Equipment	10% - 15%

3.2.4. Retirements and Disposals

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the income statement, which is determined with reference to the net book value of the assets and net sales proceeds.

3.3. Right-of-use Assets

IFRS 16: Leases has introduced a single on-balance sheet lease accounting model for leases and replaces the previously adopted IAS 17: Leases. The standard requires that an asset acquired under a lease be recognized as Right of use Asset and the corresponding liability as lease liability. The Lessee shall measure the lease liability at the present value of the future lease payment discounted using the interest rate implicit in the lease. The asset shall be depreciated over the lease period and the interest on the lease shall be charged as finance expense.

The assets acquired under lease are reported as "Right-of-use Assets" following IFRS 16. Interest costs on lease liabilities and depreciation of Right-of-use Assets are charged to the profit or loss account.

3.4. Intangible Assets

Intangible assets are stated at cost less provisions for amortization and impairments. Licenses, patents, know-how and marketing rights acquired are amortized over their estimated useful lives, using the straight line basis, from the time they are available for use. The cost of acquiring software for internal use are capitalized as intangible fixed assets where the software supports a significant business system and the expenditure leads to the creation of a durable asset. Also, the research and development expenditures that are definite to yield benefit to the Company are capitalized.

3.5. Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial Instruments comprise Financial Assets and Financial Liabilities which are recognized, classified, measured and reported following IFRS-9: Financial Instruments.

3.5.1. Financial assets

Financial assets of the Company include cash and cash equivalents, accounts receivable, other receivables and investments in marketable securities.

The Company initially recognizes receivable on the date they are originated. All others financial assets are recognized initially on the date at which the Company becomes a party to the contractual provisions of the transaction. The Company derecognizes a financial asset when, and only when the contractual rights or probabilities of receiving the cash flows from the asset expire or it transfer the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risk and rewards of ownership of the financial asset are transferred.

3.5.1.(a) Accounts Receivable

Accounts receivable are created at original invoice amount less any provisions for doubtful debts. Provisions are made where there is evidence of a risk of non-payment, taking into account aging, previous experience and general economic conditions. When an accounts receivable is determined to be uncollectible it is written off, firstly against any provision available and then to the profit and loss account. Subsequent recoveries of amounts previously provided for are credited to the profit or loss account.

3.5.1. (b) Cash and Cash Equivalents

Cash and cash equivalents include cash in hand, in transit and with banks on current and deposit accounts which are held and available for use by the Company without any restriction. There is insignificant risk of change in value of the same.

3.5.1. (c) Investment in Shares

Investment in shares of listed company is valued at a price quoted in the stock exchange at year end. Investment in other shares is valued at cost.

3.5.2. Financial Liability

Financial liabilities are recognized initially on the transaction date at which the Company becomes a party to the contractual provisions of the liability. The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. Financial liabilities include payable for expenses, liability for capital expenditure and other current liabilities.

3.6. Impairment

3.6.1. Financial Assets

Accounts receivable and other receivables are assessed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effects on the estimated future cash flows of that asset, that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy etc.

3.6.2. Non-Financial Assets

An asset is impaired when its carrying amount exceeds its recoverable amount. The Company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount by recognizing an impairment loss if, and only if, the recoverable amount of the asset is less than its carrying amount. Impairment loss is recognized immediately in profit or loss, unless the asset is carried at revalued amount. Any impairment loss of a revalued asset shall be treated as a revaluation decrease.

3.7. Inventories

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: Inventories. Cost is determined on weighted average cost basis. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale.

3.8. Provisions

A provision is recognized in the statement of financial position when the Company has a legal or constructive obligation as a result of a past event. It is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the expenditure required to settle the present obligation at the date of statement of financial position. Where the effect of time value of money is material, the amount of provision is measured at the present value of the expenditures expected to be required to settle the obligation.

3.9. Income Tax Expense

Income tax expense comprises of current and deferred tax. Income tax expense is recognized in the Statement of Profit or Loss and Other Comprehensive Income and accounted for in accordance with the requirements of IAS 12: Income Taxes.

Current Tax

Current tax is the expected tax payable on the taxable income for the year, and any adjustment to tax payable in respect of previous years. The Company qualifies as a "Publicly Traded Company"; hence the applicable Tax Rate is 22.5%. However, profit generated from export is subject to a reduced 11.25%. Additionally, certain other income are also liable to lower tax rates which can be found in Note: 34

Deferred Tax

The Company has recognized deferred tax using balance sheet method in compliance with the provisions of IAS 12: Income Taxes. The Company's policy of recognition of deferred tax assets/ liabilities is based on temporary differences (Taxable or deductible) between the carrying amount (Book value) of assets and liabilities reported in the Financial Statements and its tax base, and accordingly, deferred tax income/expenses are recognized as profit or loss.

A deferred tax asset is recognized to the extent that it is probable that future taxable profit will be available, against which temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is no longer probable that the related tax benefit will be realized.

3.10. Other Income

Dividend

Cash dividend income on investment in shares is recognized on approval of the said dividend. Stock dividend income (Bonus Shares) is not considered as revenue.

Cash Incentive on Export

Cash Incentive on Export is recognized when all conditions as laid down in the relevant incentive scheme including receipt of export remittances are satisfied and the right to claim the incentive is established.

Royalty

Royalty income is accounted for on accrual basis on fulfillment of the terms laid down in the agreement between the contracting parties.

Interest Income

Interest income is recognized on accrual basis.

Vaccine Distribution Fee

Vaccine Distribution fee is recognized on delivery of Vaccine to the designated government warehouses across the country, fulfilling the terms and conditions of the agreement. The income is reported net of relevant expenses.

3.11. Borrowing Cost

Borrowing costs are recognized as expenses in the period in which they are incurred excepting those that qualifies for capitalization under IAS 23: Borrowing Costs.

3.12. Employee Benefits

The Company maintains both defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds complying applicable laws.

The Company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19: Employee Benefits. The cost of employee benefits is charged off as revenue expenditure in the period to which the contributions relate. The Company's employee benefits include the following:

3.12.1. Defined Contribution Plan (Provident Fund)

The Company has a recognized provident fund scheme (Defined Contribution Plan) for employees of the company eligible to be members of the fund in accordance with the rules of the provident fund constituted under an irrevocable trust. Employees contribute 10% of their basic salary to the provident fund along with the Company that makes an equal contribution.

The Company recognizes contribution to defined contribution plan as an expense when an employee has rendered services in exchange for such contribution. The legal and constructive obligation is limited to the amount it agrees to contribute to the fund.

3.12.2. Defined Benefit Plan (Gratuity)

The Company took initiatives to convert its unfunded gratuity scheme to funded gratuity, which was subsequently approved by the National Board of Revenue. Though no valuation was done to quantify actuarial liabilities as per the IAS 19: Employee Benefits, such valuation is not likely to yield a result significantly different from the current provision.

3.12.3. Contribution to Workers' Profit Participation and Welfare Funds (WPPF)

This represents 5% of net profit before tax contributed by the Company as per provisions of the Bangladesh Labor Act and is payable to workers as defined in the said law.

3.12.4. Short-term Employee Benefits

Short-term Employee Benefits include salaries, bonuses, leave encashment, etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

3.12.5. Insurance Scheme

Employees of the Company are covered under insurance schemes.

3.13. Share Premium

The Share Premium shall be utilized in accordance with the provisions of the Companies Act, 1994 and as per direction of the Securities and Exchange Commission in this respect.

3.14. Proposed Dividend

The amount of proposed dividend is not accounted for but disclosed in the notes to the accounts in accordance with the requirements of the International Accounting Standard (IAS) 1: Presentation of Financial Statements. Also the proposed dividend is not considered as liability in accordance with the requirement of International Accounting Standard (IAS) 10: Events After The Reporting Period, because no obligation exists at the time of approval of accounts and recommendation of dividend by the Board of Directors.

3.15. Earnings per Share (EPS)

This has been calculated in compliance with the requirements of IAS 33: Earnings Per Share dividing the basic earnings by the weighted average number of ordinary shares outstanding during the year.

Diluted Earnings per Share

No diluted EPS is required to be calculated for the year as there was no scope for dilution during the year under review.

3.16. Foreign Currency Transactions

Foreign currency transactions are recorded at the applicable rates of exchange ruling at the transaction date.

The monetary assets and liabilities, if any, denominated in foreign currencies at the financial position date are translated at the applicable rates of exchanges ruling at that date. Exchange differences are charged off as revenue expenditure in compliance with the provisions of IAS 21: The Effects of Changes in Foreign Exchange Rates.

3.17. Statement of Cash Flows

The Statement of Cash Flows has been prepared in accordance with the requirements of IAS 7: Statement of Cash Flows. The cash generated from operating activities has been reported using the Direct Method.

3.18. Events after The Reporting Period

Events after the reporting period that provide additional information about the Company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

4 . Property, Plant and Equipment

As on June 30, 2021

Amount in Taka

Particulars	Land	Building and Other Constructions	Plant and Machinery	Furniture and Fixtures	Transport and Vehicle	Office Equipment	Total Property Plant & Equipment	Right-of-use Assets	Total
Cost									
As on July 01, 2020	3,343,741,442	7,499,761,533	14,495,139,238	281,071,740	686,005,246	585,815,483	26,891,534,682	390,192,696	27,281,727,378
Additions	—	3,694,494	119,455,263	18,597,471	—	34,888,865	176,636,093	130,204,714	306,840,807
Transferred in & Capitalized	—	298,207,642	965,316,704	1,558,986	—	2,848,259	1,267,931,591	—	1,267,931,591
Disposal during the Year	—	—	(36,523,171)	(896,228)	(21,101,899)	(253,700)	(58,774,998)	—	(58,774,998)
Cost as on June 30, 2021	3,343,741,442	7,801,663,669	15,543,388,034	300,331,969	664,903,347	623,298,907	28,277,327,368	520,397,410	28,797,724,778
Accumulated Depreciation									
As on July 01, 2020	—	2,116,657,101	6,272,267,313	133,699,879	498,744,471	394,798,590	9,416,167,354	153,092,527	9,569,259,881
Depreciation Charged	—	182,187,976	602,682,764	14,673,982	36,081,381	28,519,516	864,145,619	47,420,034	911,565,653
Adjustment for Assets disposed off	—	—	(15,299,760)	(264,188)	(14,248,029)	(109,385)	(29,921,362)	—	(29,921,362)
Accumulated Depreciation as on June 30, 2021	—	2,298,845,077	6,859,650,317	148,109,673	520,577,823	423,208,721	10,250,391,611	200,512,561	10,450,904,172
Net Book Value June 30, 2021	3,343,741,442	5,502,818,592	8,683,737,717	152,222,296	144,325,524	200,090,186	18,026,935,757	319,884,849	18,346,820,606
Capital Work in Progress 4 (a)							16,474,269,367	—	16,474,269,367
Carrying Value as on June 30, 2021							34,501,205,124	319,884,849	34,821,089,973
As on June 30, 2020									
Particulars	Land	Building and Other Constructions	Plant and Machinery	Furniture and Fixtures	Transport and Vehicle	Office Equipment	Total Property Plant & Equipment	Right-of-use Assets	Total
Cost									
As on July 01, 2019	3,343,741,442	7,497,797,147	14,503,959,431	267,440,926	690,157,709	568,771,334	26,871,867,989	308,467,914	27,180,335,903
Additions	—	1,964,386	59,327,454	13,630,814	5,219,741	18,322,149	98,464,544	81,724,782	180,189,326
Transferred in & Capitalized	—	—	—	—	—	—	—	—	—
Disposal during the Year	—	—	(68,147,647)	—	(9,372,204)	(1,278,000)	(78,797,851)	—	(78,797,851)
Cost as on June 30, 2020	3,343,741,442	7,499,761,533	14,495,139,238	281,071,740	686,005,246	585,815,483	26,891,534,682	390,192,696	27,281,727,378
Accumulated Depreciation									
As on July 01, 2019	—	1,934,157,220	5,704,119,053	118,839,763	463,605,963	365,410,593	8,586,132,592	109,697,108	8,695,829,700
Depreciation Charged	—	182,499,881	602,789,053	14,860,116	40,958,686	30,330,293	871,438,029	43,395,419	914,833,448
Adjustment for Assets disposed off	—	—	(34,640,793)	—	(5,820,178)	(942,296)	(41,403,267)	—	(41,403,267)
Accumulated Depreciation as on June 30, 2020	—	2,116,657,101	6,272,267,313	133,699,879	498,744,471	394,798,590	9,416,167,354	153,092,527	9,569,259,881
Net Book Value June 30, 2020	3,343,741,442	5,383,104,432	8,222,871,925	147,371,861	187,260,775	191,016,893	17,475,367,328	237,100,169	17,712,467,497
Capital Work in Progress 4 (a)							15,769,289,002	—	15,769,289,002
Carrying Value as on June 30, 2020							33,244,656,330	237,100,169	33,481,756,499

	Amount in Taka	
	June 30, 2021	June 30, 2020
4 (a) Capital Work in Progress is arrived at as follows :		
Opening Balance	15,769,289,002	13,724,933,841
Addition during the year	2,138,014,252	2,044,355,161
	17,907,303,254	15,769,289,002
Transferred & Capitalized	1,433,033,887	—
Building and Other Constructions	298,207,642	—
Plant & Machinery	965,316,704	—
Furniture & Fixture	1,558,986	—
Office Equipment	2,848,259	—
Intangible Assets	165,102,296	—
Closing balance	16,474,269,367	15,769,289,002
4 (b). Revaluation Surplus		
Opening Balance	1,125,767,451	1,131,853,004
Adjustment for depreciation on revalued assets	(7,180,526)	(8,114,071)
Adjustment for Deferred Tax on revalued assets	3,237,721	2,028,518
	1,121,824,646	1,125,767,451
4 (c). Right-of-use Assets		
At Cost	520,397,410	390,192,696
Accumulated Depreciation	(200,512,561)	(153,092,527)
	319,884,849	237,100,169

5. Intangible Assets

Particulars	Product Development, Licensing and Marketing Rights	ERP System	Total
Cost			
As on July 01, 2020	648,055,417	169,745,334	817,800,751
Addition / Transferred in & Capitalized	165,102,296	22,864,119	187,966,415
As on June 30, 2021	813,157,713	192,609,453	1,005,767,166
Amortization			
As on July 01, 2020	220,130,051	16,710,370	236,840,421
Amortized During the year	50,421,481	16,710,362	67,131,843
As on June 30, 2021	270,551,532	33,420,732	303,972,264
Carrying Value as on June 30, 2021	542,606,181	159,188,721	701,794,902
Carrying Value as on June 30, 2020	427,925,366	153,034,964	580,960,330

	Amount in Taka	
	June 30, 2021	June 30, 2020
6. Investment in Subsidiaries		
Nuvista Pharma Ltd.	2,125,186,000	2,125,186,000
Beximco Pharma API Ltd.	19,999,900	19,999,900
	2,145,185,900	2,145,185,900

- a. The Company acquired 10,013,474 shares representing 85.22% of the Paid Up Capital of Nuvista Pharma Ltd (NPL) . The investment in subsidiary represents the cost of the aforesaid acquisition.
- b. Beximco Pharma API limited (API) was formed with a paid up capital of Tk. 20,000,000 divided into 2,000,000 shares of Tk. 10 each, all of which excepting 10 shares are held by Beximco Pharmaceuticals Ltd (BPL).
- c. Investment in subsidiaries has been accounted for using cost method as per IAS 27: Seperate Financial Statements, in preparing financial statements of the Company.

7. Investment in Associates

This represents value of 3,900,000 Ordinary Shares of Malaysian Ringgit (RM) 1 each issued to Beximco Pharmaceuticals Ltd. by BioCare Manufacturing Sdn Bhd (“BioCare”), Malaysia. Beximco Pharmaceuticals Ltd. was issued 30% of the equity share of the Malaysian based company for providing full technical support to set up a manufacturing facility to produce specialized pharmaceutical products in Seri Iskandar Pharmaceutical Park, Perak, Malaysia. BioCare is considered to be an associate of BPL as per IAS 28: Investment in Associates and Joint Ventures. The Company follows Cost method for the investment as per IAS 27: Separate Financial Statements.

8. Other Investments

a. Investment Details (Taka):

	July 01, 2020	Unrealised Gain/ (Loss)	June 30, 2021
Bangladesh Export Import Co. Ltd. (Note : C)	2,182,101	12,840,831	15,022,932
Central Depository Bangladesh Ltd. (CDBL)	1,569,450	—	1,569,450
	3,751,551	12,840,831	16,592,382

b. Number of Shares:

	July 01, 2020	June 30, 2021
Bangladesh Export Import Co. Ltd.	167,854	167,854
Central Depository Bangladesh Ltd. (CDBL)	571,182	571,182

- c. The shares of Bangladesh Export Import Co. Ltd. are listed in Dhaka and Chittagong Stock Exchanges. The market value of each share of Bangladesh Export Import Co. Ltd. as on June 30, 2021 was Tk. 89.50 (June 30, 2020: Tk.13.00). The fair value gain of Tk. 12,840,831 has been accounted for as Other Comprehensive Income following IFRS9: Financial Instruments.
- d. Shares of Central Depository Bangladesh Ltd.(CDBL) are not traded . The value at acquisition is considered to be the fair value as on the Balance Sheet date.

	Amount in Taka	
	June 30, 2021	June 30, 2020
9. Inventories		
This consists of as follows :		
Finished Goods	1,188,526,554	972,564,349
Work in Process	282,756,046	249,838,762
Raw Materials	3,007,666,959	2,955,008,164
Packing Materials	1,104,206,746	921,692,743
Laboratory Chemicals	62,041,717	38,688,339
Physician Samples	79,764,262	69,468,235
R & D Materials	22,520,999	15,232,992
Materials in Transit	946,410,738	305,944,581
	6,693,894,021	5,528,438,165

10. Spares & Supplies

This consists of as follows :

Spares & Accessories	545,385,920	649,953,543
Stock of Stationery	16,841,919	14,209,600
Literature & Other Materials	60,205,443	71,540,807
	622,433,282	735,703,950

11. Accounts Receivable

This consists of :

Trade Receivable	2,657,960,805	2,978,567,354
Other Receivable	173,908,436	235,098,991
	2,831,869,241	3,213,666,345

Accounts Receivable is reported net of provision for bad debts of Tk. 8,169,353. It includes an amount of Tk. 840,777,271, equivalent USD 9,985,468 (June 30, 2020: Tk. 817,658,851, USD 9,710,913) receivable against export sales. Part of the export sales receivables are against Letter of Credit while the rest are unsecured but considered good.

Accounts Receivable also includes Tk.1,401,534,613 due from I & I Services Ltd., who provides distribution service to the Company and a "Related Party". The maximum amount due from the company during the year was Tk.1,695,026,636 on 31 May 2021. Additionally an amount of Tk 24,956,668 and Tk 679,830 is receivable from its subsidiary companies Nuvista Pharma Ltd. and Beximco Pharma API Ltd. respectively.

No amount was due from the directors, managing agent, managers and other officers of the company and any of them severally or jointly with any other person.

Aging of Trade Receivables :

Amount due within 6 months	2,593,603,554	2,930,309,371
Amount due for 6 months & above	64,357,251	48,257,983
	2,657,960,805	2,978,567,354

	Amount in Taka	
	June 30, 2021	June 30, 2020
12. Loans, Advances and Deposits		
This is unsecured, considered good and consists of as follows :		
Clearing & Forwarding	249,538,566	281,675,299
VAT	463,448,047	419,480,062
Claims Receivable	25,777,861	6,636,489
Security Deposit & Earnest Money	164,445,896	76,960,836
Lease Deposit	2,650,135	10,821,850
Capital Expenditure/ Project	128,076,779	209,723,000
Expenses	294,270,664	263,194,117
Bank Guarantee Margin	20,831,185	35,585,120
Advance against Salary	173,756,608	157,725,898
Rent Advance	34,886,833	29,898,335
Motor Cycle	148,885,137	154,443,129
Raw & Packing Material	460,856,879	442,658,728
Prepaid Insurance	30,641,155	150,084,798
Overseas Liaison Office	58,207,996	40,724,614
Others	98,302,361	65,427,597
	2,354,576,102	2,345,039,872

- a. The maximum amount due from the employees during the year was Tk. 175,745,823 on 31 December, 2020.
- b. No amount was due from the directors, managing agent, managers and other officers of the company and any of them severally or jointly with any other person, except as stated above.

13. Cash and Cash Equivalents

This consists of as follows :		
a. Cash in Hand (including Imprest Cash)	164,391,788	170,283,669
b. Cash at Bank :		
Current & FC Account	443,374,564	407,279,678
FDR Account	40,138,231	38,381,494
	647,904,583	615,944,841

14. Issued Share Capital

a. Authorized :		
1,000,000,000 Ordinary Shares of Tk. 10 each	10,000,000,000	10,000,000,000
50,000,000 fully convertible 5 % Preference Shares of Tk. 100 each	5,000,000,000	5,000,000,000
	15,000,000,000	15,000,000,000
b. Issued, Subscribed and Paid-up :		
51,775,750 Shares fully paid-up in cash	517,757,500	517,757,500
357,093,942 Ordinary Shares issued as stock dividend	3,570,939,420	3,165,382,980
5,951,250 Ordinary Shares issued in exchange of Shares of Beximco Infusions Ltd.	59,512,500	59,512,500
31,291,147 Ordinary Shares issued on conversion of Preference Shares	312,911,470	312,911,470
	4,461,120,890	4,055,564,450

5,951,250 Ordinary Shares of Tk. 10 each were issued to the shareholders of Beximco Infusions Ltd. on its merger with Beximco Pharmaceuticals Ltd. In 2005.

41,000,000 fully convertible 5% preference shares of Tk. 100 each were issued in 2009. 50% of the preference shares were converted into 16,169,191 ordinary shares of Tk. 10 each on February 1, 2010. The rest 50% were converted into 15,121,956 ordinary shares of Tk. 10 each on May 2, 2010.

100,037,989 Shares have been issued as underlying shares for the GDRs listed with AIM of London Stock Exchange.

c. Composition of Shareholding :

	June 30, 2021		June 30, 2020	
	Number of Shares	% of Share Capital	Number of Shares	% of Share Capital
Sponsors / Directors				
A S F Rahman	9,058,888	2.03	8,235,353	2.03
Salman F Rahman	9,080,095	2.04	8,254,632	2.04
Other Directors and Associates	116,517,180	26.11	37,019,789	9.13
	134,656,163	30.18	53,509,774	13.20
Other Shareholdings:				
Foreign Portfolio Investors (DSE/CSE)	51,907,674	11.64	48,720,273	12.01
Holders of GDRs (excluding Board Director)	84,386,054	18.92	90,943,627	22.42
Institutions (ICB, ICB Investors' Accounts & Others)	87,784,924	19.68	148,762,402	36.68
Individual Shareholders	87,377,274	19.58	63,620,369	15.69
	311,455,926	69.82	352,046,671	86.80
Total	446,112,089	100.00	405,556,445	100.00

d. Distribution Schedule of Ordinary Shares:

Range of Shareholdings	June 30, 2021		June 30, 2020		June 30, 2021		June 30, 2020	
	Number of Shareholders	% of Holding	Number of Shareholders	% of Holding	Number of Shares	% of Holding	Number of Shares	% of Holding
1 to 499	38,764	70.16%	41,587	74.13%	5,274,349	1.18%	6,052,732	1.49%
500 to 5,000	14,059	25.45%	12,340	22.00%	19,890,718	4.46%	18,684,552	4.61%
5,001 to 10,000	1,098	1.99%	1,059	1.89%	7,895,652	1.77%	7,555,392	1.86%
10,001 to 20,000	567	1.03%	484	0.86%	8,078,197	1.81%	6,983,130	1.72%
20,001 to 30,000	185	0.33%	159	0.28%	4,575,664	1.03%	4,044,868	1.00%
30,001 to 40,000	84	0.15%	81	0.14%	2,947,573	0.66%	2,832,929	0.70%
40,001 to 50,000	76	0.14%	58	0.10%	3,595,456	0.81%	2,666,648	0.66%
50,001 to 100,000	150	0.27%	129	0.23%	11,069,746	2.48%	9,472,994	2.34%
100,001 to 1,000,000	227	0.41%	162	0.29%	66,828,442	14.98%	50,405,277	12.43%
Over 1,000,000	38	0.07%	42	0.07%	316,056,292	70.83%	296,857,923	73.20%
Total	55,248	100%	56,101	100%	446,212,089	100%	405,556,445	100%

e. Market Price of Ordinary Shares:

The shares are listed with Dhaka and Chittagong Stock Exchanges of Bangladesh while the GDRs with the AIM of London Stock Exchange. Price of each Share/ GDR on the last working day of the fiscal year were:

		June 30, 2021	June 30, 2020
Dhaka Stock Exchange	Tk.	177.30	69.20
Chittagong Stock Exchange	Tk.	176.60	69.10
AIM	GBP	0.860	0.355

f. Option on unissued Ordinary Shares :

There is no option on unissued shares as on June 30, 2021.

15. Excess of Issue Price over Face Value of GDRs

This represents excess of issue price of GDRs over the face value of underlying 28,175,750 ordinary shares issued against the same number of GDRs less GDRs issue expenses.

	Amount in Taka	
	June 30, 2021	June 30, 2020

16. Long Term Borrowings - Net of Current Maturity

This is arrived at as follows :

Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	972,696,465	1,437,978,890
Lease Liability	234,020,629	203,945,156
	1,206,717,094	1,641,924,046

a. Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany

This represents part of the foreign currency loan of US\$ 51.559 million and Euro 20.222 million taken for the expansion and diversification project being implemented by the Company. Interest of US\$ loan is 6 month's USD LIBOR plus 2.25% while the same for Euro loan is 6 month's EURIBOR plus 1.30% per annum. Both the loans are secured by exclusive first charge by way of hypothecation against the machinery and equipment to be procured under the pertinent loans.

b. Lease Liability

This consists of as follows:

Within one year	113,976,268	106,584,243
Within two to five years	234,020,629	203,945,156
	347,996,897	310,529,399

17. Liability for Gratuity and WPPF & Welfare Funds

a. Gratuity Payable

Opening Balance	1,056,920,260	933,437,744
Provisions during the year	221,588,892	184,425,140
	1,278,509,152	1,117,862,884
Paid to Employees during the year	(64,575,395)	(60,942,624)
	1,213,933,757	1,056,920,260
Investment - Gratuity Fund		
Opening Balance	—	—
Payment during the year	(40,000,000)	—
	(40,000,000)	—
Closing balance at end of the Year	1,173,933,757	1,056,920,260

b. Workers Profit Participation and Welfare Fund

	1,013,210,949	958,384,323
	2,187,144,706	2,015,304,583

	Amount in Taka	
	June 30, 2021	June 30, 2020
18. Deferred Tax Liability		
Opening Balance	2,035,744,789	2,002,571,178
Addition during the Year :		
Deferred Tax on Assets -Note : 34	(160,532,671)	35,202,129
Adjustment for Deferred Tax on revalued amount	(3,237,721)	(2,028,518)
Closing Balance	1,871,974,397	2,035,744,789

19. Short Term Borrowings

Janata Bank Limited	3,077,454,947	3,963,918,204
AB Bank Limited	1,014,765,029	1,106,352,880
First Security Islamic Bank Limited	510,141,234	510,491,234
Liability for UPAS Letter of Credit	254,745,071	1,406,768,304
	4,857,106,281	6,987,530,622

- a. Short term borrowings from Janata Bank represents revolving credit facilities renewable annually. The borrowing carries 9% interest.
- b. Loan from AB Bank represents a revolving overdraft limit to Tk 50 Crore and a Time loan of Tk. 60 crore payable in monthly installments.
- c. The loan with Janata Bank and AB Bank is secured by hypothecation of fixed and floating assets of the Company excepting the machinery and equipment financed by ODDO BHF Aktiengesellschaft, Frankfurt, Germany.
- d. The borrowing from First Security Islamic Bank Ltd represents a Bai-Murabaha (Hypo) Credit facility of Tk.50 crore for purchasing of raw and packing materials. The facility is secured by corporate guarantee and second charge by way of hypothecation on present and future fixed and floating assets of the Company excepting the machinery and equipment financed by ODDO BHF Aktiengesellschaft, Frankfurt, Germany.

20. Long Term Borrowings-Current Maturity

Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	1,287,429,745	937,110,252
Lease Liability	113,976,268	106,584,243
AB Bank Limited	—	377,802,906
	1,401,406,013	1,421,497,401

21. Creditors and Other Payables

Goods & Services	622,523,948	485,464,404
Provident Fund	797,569,927	726,878,755
Advance Against Sales	298,396,187	12,393,114
Others	95,522,977	42,333,569
	1,814,013,039	1,267,069,842

22. Accrued Expenses

This is unsecured, falling due within one year and consists of as follows :

For Expenses	178,826,769	390,307,028
Workers' Profit Participation and Welfare Funds - (current year)	301,675,085	219,094,244
	480,501,854	609,401,272

23. Dividend Payable / Unclaimed Dividend

The Dividend Payable/Unclaimed dividend as on June 30, 2021 includes prior years' dividend of Tk. 81,113,713 unclaimed to date. The unclaimed dividend reported under Creditors and Other Payables in the prior period has been reclassified in this financial statement. Subsequent to the Balance Sheet date an amount of Tk 64,297,249 has been paid to the Capital Market Stabilization Fund (CMSF) in compliance to BSEC directive no. BSEC/CMRRCD/2021-386/03 dated January 14, 2021.

	Amount in Taka	
	June 30, 2021	June 30, 2020
24. Income Tax Payable		
Opening Balance	263,148,692	167,298,238
Provision for the year	1,250,545,631	983,282,880
	1,513,694,323	1,150,581,118
Income Tax Paid	(1,293,252,888)	(887,432,426)
	220,441,435	263,148,692

	Amount in Taka	
	July 2020 - June 2021	July 2019 - June 2020
25. Net Sales Revenue		
Domestic Sales	23,825,350,346	20,805,985,652
Export Sales	3,124,001,260	2,751,790,244
	26,949,351,606	23,557,775,896

a. Revenue consists of sales of pharmaceutical formulation products of wide range of therapeutic categories in different dosage forms and strengths and Active Pharmaceutical Ingredients (APIs). The quantity sold under different broad categories are as follows:

Product Category	Unit	Quantity	
		July 2020 - June 2021	July 2019 - June 2020
Tablet, Capsule, Suppository & DPI	Million pcs.	7,316.90	6,778.75
Liquid, Cream and Ointment, Suspension, IV Fluid, Amino Acid, Ophthalmic, Nebulizer Solution, Injectable, Inhaler and Insulin	Million pcs.	119.19	114.54
Active Pharmaceutical Ingredients	Kg	181,903	190,552
Liquid Nitrogen	Liter	352,970	438,734

b. The value of Export Sales in equivalent US Dollar is 37,106,411 in 2020-21 as against US Dollar 32,745,911 in 2019-20.

Amount in Taka

	July 2020 - June 2021	July 2019 - June 2020
--	-----------------------	-----------------------

26. Cost of Goods Sold

This is made-up as follows :

Work-in-Process (Opening)	249,838,762	420,135,832
Materials Consumed (Note: 27)	11,428,162,801	9,491,277,964
Factory Overhead (Note: 28)	3,446,781,489	3,153,943,937
Total Manufacturing Cost	15,124,783,052	13,065,357,733
Work-in-Process (Closing)	(282,756,046)	(249,838,762)
Cost of Goods Manufactured	14,842,027,006	12,815,518,971
Finished Goods (Opening)	972,564,349	1,155,804,007
Finished Goods available	15,814,591,355	13,971,322,978
Cost of Physician Sample transferred to Sample Stock	(278,682,753)	(245,236,728)
Finished Goods (Closing)	(1,188,526,554)	(972,564,349)
	14,347,382,048	12,753,521,901

Item wise quantity and value of Finished Goods Stock are as follows :

Stock as June 30, 2021	Unit	Quantity	Value (Tk.)
Tablet, Capsule, Suppository & DPI	Million pcs.	504.72	640,992,836
Liquid, Cream and Ointment, Suspension, IV Fluid, Amino Acid, Ophthalmic, Nebulizer Solution, Injectable, Inhaler and Insulin	Million pcs.	9.77	529,368,303
Active Pharmaceutical Ingredients	Kg	5,890	18,165,415
			1,188,526,554

Stock as June 30, 2020	Unit	Quantity	Value (Tk.)
Tablet, Capsule, Suppository & DPI	Million pcs.	451.57	535,160,110
Liquid, Cream and Ointment, Suspension, IV Fluid, Amino Acid, Ophthalmic, Nebulizer Solution, Injectable and Inhaler	Million pcs.	7.23	421,235,247
Active Pharmaceutical Ingredients	Kg	5,674	16,168,992
			972,564,349

27. Materials Consumed

This is made-up as follows :

Opening Stock	3,915,389,246	3,690,300,531
Purchase	11,686,688,977	9,716,366,679
Closing Stock	(4,173,915,422)	(3,915,389,246)
	11,428,162,801	9,491,277,964

Amount in Taka

July 2020 - June 2021

July 2019 - June 2020

28. Factory Overhead

Salary & Allowances	1,328,827,639	1,164,060,001
Repairs and Maintenance	316,507,536	278,944,645
Insurance Premium	34,761,486	33,154,830
Municipal Tax & Land Revenue	8,898,435	7,485,850
Registration & Renewals	17,174,084	19,443,939
Travelling & Conveyance	34,900,276	24,252,401
Entertainment	2,644,001	2,058,287
Research and Development	280,881,455	242,175,885
Rent	13,524,226	4,756,535
Printing & Stationery	31,165,292	28,658,943
Telephone, Cellphone, Internet & Postage	10,791,816	9,599,588
Toll Expense	257,499,789	245,250,757
Electricity, Gas & Water	227,941,467	199,203,953
Training & Conference	9,614,915	6,129,368
Plant Certification and Regulatory Approvals	15,156,941	37,358,555
Depreciation	824,966,915	827,924,271
Security Expenses	25,624,559	19,794,331
Other Expenses	5,900,657	3,691,798
	3,446,781,489	3,153,943,937

a. Salary and Allowances include Company's Contribution to provident fund amounting to Tk. 23,447,314

b. Repairs and Maintenance includes maintenance of office, premises, vehicles, building, equipment and other infrastructures. Also included therein, imported stores and spares that has been consumed during the year.

c. Other expenses does not include any item exceeding 1% of total revenue.

29. Administrative Expenses

Salary & Allowances	439,818,179	402,132,499
Rent	16,222,800	12,494,000
Repairs and Maintenance	56,771,422	49,579,163
Registration & Renewals	6,299,916	5,019,043
Travelling & Conveyance	26,851,992	25,983,471
Entertainment	6,498,289	5,745,084
Printing & Stationery	5,725,309	4,869,332
Audit Fee	2,000,000	1,800,000
Telephone, Cellphone, Internet & Postage	4,272,321	4,102,321
Electricity, Gas & Water	14,078,915	11,669,432
Legal & Consultancy	10,456,662	15,679,054
Business Acquisition Cost	18,208,232	—
Company Secretarial, Regulatory Fee and AGM Expense	37,042,133	34,599,077
Municipal Tax & Land Revenue	353,080	237,016
Training & Conference	783,336	4,853,033
Depreciation	31,904,798	32,019,171
Meeting Fee	3,128,000	2,013,650
Security Expenses	14,112,817	11,209,371
Other Expenses	97,700,706	75,935,608
	792,228,907	699,940,325

a. Salary and Allowances include Company's Contribution to provident fund amounting to Tk.8,644,309

b. Repairs and Maintenance includes maintenance of office, premises, vehicles, building, equipment and other infrastructures.

c. Meeting Fee is paid to the Directors for attending Board and other Committee Meetings.

d. Travelling & Conveyance includes foreign travel Tk. 1,015,336 (in 2020 Tk.10,163,463)

e. Other expenses does not include any item exceeding 1% of total revenue.

	Amount in Taka	
	July 2020 - June 2021	July 2019 - June 2020
30. Selling, Marketing and Distribution Expenses		
Salary & Allowances	2,111,616,016	1,814,891,870
Rent	82,752,962	77,674,161
Repairs and Maintenance	31,561,657	11,169,984
Travelling & Conveyance	552,791,027	501,475,286
Entertainment	64,055,502	55,361,967
Printing & Stationery	39,958,791	36,243,329
Telephone, Cellphone, Internet & Postage	65,439,973	48,665,728
Software & Licences	33,596,270	26,876,458
Electricity, Gas & Water	20,107,493	14,609,690
Market Research & New Products	71,595,632	61,977,278
Training & Conference	120,555,180	106,900,944
Insurance Premium	32,094,000	27,514,266
Sample Expense	347,209,107	303,551,534
Advertisement	1,769,732	339,292
Field Operation	44,864,430	38,162,913
Events, Programs & Campaign	266,667,446	181,475,156
Brand Development	139,998,190	103,983,835
CSR Expenses	11,036,539	79,166,624
Sales Promotion Expenses	135,410,431	124,237,987
Books, Journal and Periodicals	8,047,595	7,590,396
Salesforce Logistics	23,398,324	16,732,466
Clinical Studies and Research	6,488,050	5,002,419
Pharmacovigilance	27,087,836	14,768,459
Literature and News Letter	221,415,292	189,320,900
Registration & Renewals	139,697,491	62,136,798
Export Insurance, Freight and C&F Expenses	158,409,899	225,789,212
Distribution Commission	437,367,829	376,830,927
Delivery Expense	385,580,530	335,270,945
Depreciation & Amortization	121,825,781	115,796,376
Security Expenses	20,158,622	19,941,269
Bad Debts	3,025,000	2,983,000
Other Expenses	15,153,792	4,518,060
	5,740,736,419	4,990,959,529

- a. Salary and Allowances include Company's Contribution to provident fund amounting to Tk. 42,188,361
- b. Distribution Commission is paid to I & I Services Ltd., a " Related Party" for rendering distribution services throughout the country.
- c. Repairs and Maintenance includes maintenance of office, premises, vehicles, building, equipment and other infrastructures.
- d. Sample Expense includes VAT on sample.
- e. Other expenses does not include any item exceeding 1% of total revenue.

Amount in Taka

	July 2020 - June 2021	July 2019 - June 2020
31. Other Income		
Interest Income	2,377,286	20,409,291
Dividend Income	35,987,859	21,454,903
Royalty	69,272,533	172,940,165
Distribution Commission Income	139,631,437	111,757,229
Cash Incentive on Export	309,745,032	139,620,667
Exchange Rate Fluctuation Gain / (Loss)	(3,716,895)	13,196,829
Vaccine Distribution Fee	542,265,041	—
Forfeited PF Refund	8,588,660	—
Profit/(Loss) on Sale of Fixed Assets (Note 41)	3,897,402	(33,822,584)
	1,108,048,355	445,556,500

a. Royalty income of Taka 28,742,584 comes from licensing of BPL products to Nuvista Pharma Limited while the remaining amount is from overseas business.

b. The Distribution Commission is received from the subsidiary company Nuvista Pharma Limited for providing delivery of Nuvista's products using the BPL's distribution network across the country as per the agreement entered into between the companies on an arm's length basis.

c. In December 2018, Government declared 10% incentives on net FOB value of export of finished pharmaceutical formulation products subject to fulfillment of certain conditions. The incentive claimed during the reporting period has been accrued and accounted for. Further details are available in Note 3.10.

d. Exchange rate fluctuation losses has been netted off with the exchange rate fluctuation gains. An exchange loss of Tk. 6,857,486 has arisen from the translation of outstanding foreign currency loan from ODDO BHF Aktiengesellschaft, Frankfurt, Germany translated at the exchange rate prevailing on the financial position date.

e. Beximco Pharma entered into a tripartite agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Pvt. Ltd ("SII"), for the supply of 30 million doses of Oxford University/AstraZeneca SARS-CoV-2 vaccine, AZD1222, in Bangladesh. The Company delivered 7 million vaccine during the reported year. As per agreement, the Company is to receive fees for the import, storage and delivery of the vaccine to the GOB warehouses across the country. The Company is also responsible for replenish any quantity of loss arising from the cold chain disruptions at its own cost. Any future earning from this source is dependent on the delivery of the committed quantity of vaccine under the agreement. Income from Vaccine distribution is reported net of related expenses.

f. In compliance to FRC circular no. 179/FRC/FRM/Notification/2020/2 dated July 7, 2020 the Company has recovered the forfeited PF contribution from the Provident Fund Trust which has been reported as Forfeited PF Refund.

32. Finance Cost

Interest on Bank Borrowings	562,867,528	733,669,187
Interest on Lease Finance	35,970,714	27,790,746
Interest on Loan from PF, WPPF & Welfare Fund	190,970,118	166,837,043
Other Bank Charges	52,067,446	29,634,539
	841,875,806	957,931,515

33. Contribution to WPPF & Welfare Funds

This represents statutory contribution by the Company as per Bangladesh Labour Act 2013. The amount is computed @ 5% of net profit before tax (after charging such contribution).

Amount in Taka	
July 2020 - June 2021	July 2019 - June 2020

34. Income Tax Expenses

This consists of as follows :

a. Current Tax		
Tax provision for current Year (Note 3.9)	1,250,545,631	983,282,880
b. Deferred Tax Expense	(160,532,671)	35,202,129
	1,090,012,960	1,018,485,009

Deferred Tax Expense is arrived at as follows :

Property, Plant & Equipment (Difference in book value & Tax base)	9,501,989,318	9,205,043,771
Deferred liability (Gratuity)	(1,173,933,757)	(1,056,920,260)
Bad Debts	(8,169,353)	(5,144,353)
Temporary Difference	8,319,886,208	8,142,979,158
Tax Rate	22.5%	25%
Deferred Tax Liability at end of the year	1,871,974,397	2,035,744,789
Deferred Tax Liability at beginning of the year	2,035,744,789	2,002,571,178
Change in Deferred Tax Liability	(163,770,392)	33,173,611
Deferred tax on Revaluation Surplus	3,237,721	2,028,518
Deferred Tax charged to profit or Loss and Other Comprehensive Income	(160,532,671)	35,202,129

Reconciliation of Effective tax rate	2020-21		2019-20	
	%	Tk.	%	Tk.
Profit before Tax		6,033,501,696		4,381,884,882
Applicable Tax	22.50%	1,357,537,882	25.00%	1,095,471,221
Effect of lower rate on Export Profit excluding Cash Incentive	-1.56%	(94,206,509)	-2.20%	(96,362,751)
Effect of lower rate on cash incentive	-0.64%	(38,718,129)	-0.48%	(20,943,100)
Effect of lower rate on dividend income	-0.01%	(899,696)	-0.02%	(1,072,745)
Effect of permanent disallowances	0.86%	51,624,342	0.94%	41,392,384
Deferred tax impact for changing tax rate & others	-3.07%	(185,324,930)	0.00%	—
Income Tax Expense	18.07%	1,090,012,960	23.24%	1,018,485,009

a. Export Profits are subject to 11.25% Tax rate

b. 10% Tax deductible at source on the cash incentives are treated as final tax liability on such income as per the Income Tax regulations

c. Dividend Income is taxable @ 20%

	Amount in Taka	
	July 2020 - June 2021	July 2019 - June 2020
35. Other Comprehensive Income/(Loss)		
Fair Value Gain/(Loss) on Investment in Listed Shares Note 8 (a)	12,840,831	(1,577,828)
	12,840,831	(1,577,828)

36. Earnings Per Share (EPS)/ Restated EPS

a. Earnings attributable to the ordinary shareholders	Tk.	4,943,488,736	3,363,399,873
b. Weighted average number of shares outstanding during the year (Note 3.15)		446,112,089	446,112,089
Earnings Per Share (EPS)	Tk.	11.08	7.54

	June 30, 2021	June 30, 2020
37. Net Asset Value (NAV) Per Share		
Total Assets	50,864,666,106	48,679,773,173
Less Total Liabilities	(14,157,074,351)	(16,323,414,038)
Net Assets	36,707,591,755	32,356,359,135
Number of Shares	446,112,089	405,556,445
Net Asset Value (NAV) Per Share	82.28	79.78

	July 2020 - June 2021	July 2019 - June 2020
38. Net Operating Cash Flows Per Share (NOCFPS)		
Net Cash Generated from Operating Activities	5,614,916,935	5,210,760,070
Number of Ordinary Shares	446,112,089	405,556,445
Net Operating Cash Flows Per Share (NOCFPS)	12.59	12.85

Amount in Taka

	July 2020 - June 2021	July 2019 - June 2020
--	-----------------------	-----------------------

39. Reconciliation of Net Profit with Cash Flows from Operating Activities

Profit after Tax	4,943,488,736	3,363,399,873
Adjustment to reconcile net profit to net cash provided by operating activities :		
Non-cash Expenses :	996,862,434	1,267,944,433
Depreciation	911,565,653	914,833,448
Amortization	67,131,843	60,906,370
Gratuity & WPPF	171,840,123	266,403,789
Exchange rate fluctuation (Gain)/loss	6,857,486	(9,401,302)
Deferred tax	(160,532,671)	35,202,129
Non-operating items:	(39,885,261)	10,399,024
Dividend Income	(35,987,859)	(21,454,903)
(Profit) /Loss on sale of Fixed Assets	(3,897,402)	33,822,584
Effect of exchange rate changes on Cash and Cash Equivalents*	—	(1,968,657)
Changes in working Capital	(285,548,974)	569,016,740
(Increase)/Decrease in Inventories	(1,165,455,856)	45,111,006
(Increase)/Decrease in Spares & Supplies	113,270,668	(20,362,634)
(Increase)/Decrease in Accounts Receivable	381,797,104	112,224,252
(Increase)/Decrease in Loans, Advances & Deposits	(9,536,230)	(71,999,051)
Increase/(Decrease) in Creditors and Other Payables	565,982,015	294,969,732
Increase/(Decrease) in Accrued Expenses	(128,899,418)	113,222,981
Increase/(Decrease) in Income Tax Payable	(42,707,257)	95,850,454
Net cash Generated from Operating Activities	5,614,916,935	5,210,760,070

*The Company used Janata Bank's applicable (US Dollar-Taka) exchange rate as on June 30, 2021 which remained unchanged with the exchange rate as on June 30, 2020. As such, there was no effect of exchange rate on Cash and Cash Equivalents.

40. Related Party Disclosures

Following transactions were carried out with related parties in the normal course of business on arms length basis:

Name of Related Parties	Nature of Transactions	Value of Transaction	Balance at year end	Balance Type
a. I & I Services Ltd.	Delivery of Products	27,348,232,493	1,401,534,613	Dr.
	Distribution Commission	437,367,829		
b. Nuvista Pharma Ltd	Toll Manufacturing	27,882,074	1,379,979	Cr.
	Cost of services	56,571,923	4,449,651	Dr.
	Royalty	28,742,584	5,875,790	Dr.
	Dividend	35,047,159	—	
	Distribution commission	139,631,437	14,631,227	Dr.
c. Beximco Pharma API Limited	Short Term Advance	135,470	679,830	Dr.

41. Particulars of Disposal of Property, Plant and Equipment

The following assets were disposed off during the year ended June 30, 2021:

Particulars of Assets	Cost	Accumulated Depreciation	Written Down Value	Sales Price	Profit / (Loss)	Mode of Disposal
Plant & Machinery	36,523,171	15,299,760	21,223,411	21,133,368	(90,043)	Negotiation
Office Equipment	253,700	109,385	144,315	143,772	(543)	Negotiation
Furniture & Fixtures	896,228	264,188	632,040	632,040	—	Negotiation
Transport & Vehicle	21,101,899	14,248,029	6,853,870	10,841,858	3,987,988	Negotiation
Tk.	58,774,998	29,921,362	28,853,636	32,751,038	3,897,402	

42. Payment / Perquisites to Managers and Directors

The aggregate amounts paid to/ provided for the Managers and above of the company is disclosed below :

	Amount in Taka
Remuneration	433,526,806
Gratuity	36,377,866
Contribution to Provident Fund	16,770,675
Bonus	42,705,419
Medical	16,741,931
Others	14,919,803
Total	561,042,500

- The above includes salary, allowances, and perquisites amounting Tk. 64,468,438 paid to the Managing Director
- No remuneration is paid to Directors of the board other than meeting attendance fees which has been separately reported.
- No amount of money was expended by the company for compensating any member of the board for special services rendered.

43. Production Capacity and Utilization

Item	Unit	Production Capacity		Actual Production and Capacity Utilization			
		June 2021	June 2020	July 2020 to June 2021		July 2019 to June 2020	
		Quantity	Quantity	Quantity	%	Quantity	%
Tablet, Capsule, Suppository & DPI	Million Pcs	5,885.53	5,842.87	7,093.47	120.52%	6,586.29	112.72%
Liquid, Cream and Ointment, Suspension, IV Fluid, Amino Acid, Ophthalmic, Nebulizer Solution, Injectable, Inhaler and Insulin	Million Pcs	102.70	100.98	115.36	112.33%	115.39	114.27%
Active Pharmaceuticals Ingredient (API)	Matric Ton	22.00	—	4.61	20.95%	—	—

Production does not include goods manufactured under contract manufacturing arrangement from third party manufacturing sites.

44. Capital Expenditure Commitment

There was no capital expenditure contracted but not incurred or provided for at June 30, 2021.

45. Claim not Acknowledged as Debt

There was no claim against the Company not acknowledged as debt as on June 30,2021.

46. Un-availed Credit Facilities

ODDO BHF Aktiengesellschaft, Frankfurt, Germany approved an ECA term loan of Euro 20.22 million to partially finance the machinery and equipment for the expansion project being implemented by the Company. An amount of Euro 13.25 million has been disbursed as on Balance Sheet date. The remaining Euro 6.97 million is disburseable against procurement of the machinery & equipment.

47. Foreign Currency Payments & Receipts:

	Foreign Currency (Equivalent US\$)	Taka
Payments :		
Materials, Spares and Capital Machinery	117,646,013	9,990,687,199
Foreign Currency Loans, Fees & Expenses	17,504,877	1,474,594,231
Receipts :		
Export Sales & Others	38,467,352	3,238,247,158

48. Commission / Brokerage to selling agent :

No commission was incurred or paid to any sales agent nor any brokerage or discount other than conventional trade discount was incurred or paid against sales.

49. Contingent Liability

The Company has a contingent liability aggregating Tk. 150,788,789 against disputed income tax claims for the year 1999, 2007, 2008 and 2010. The Company has filed Income Tax Reference cases with the High Court Division of the supreme court against these claims.

There is also a disputed VAT claim aggregating has Tk. 144,113,691 against the Company. The Company own the verdict of the Appellate Tribunal in its favor. The concerned authority has filed appeal to the honorable High Court against this verdict. Additionally, there are claims of custom duty aggregating Tk. 22,507,358 against the indemnity bond issued by the Company in connection with import of certain plant and machinery. The company has filed writ petitions against these claims.

If any liability arises on disposal of the cases, the Company shall provide for such liability in the year of final disposal.

50. Events after The Reporting Period

- The Board of Directors of the Company recommended 35% cash dividend (i.e. Tk. 3.50 per share) for the year 2020-21. The dividend proposal is subject to shareholders' approval at the forthcoming Annual General Meeting.
- The Board of Directors of Nuvista Pharma Limited (NPL) has declared cash dividend @ 40% (i.e. Tk. 4.00 per share) for the year 2020-21. The proposed dividend is subject to approval of the shareholders of NPL in the forthcoming Annual General Meeting.
- Subsequent to the Balance Sheet date Beximco Pharma completed the acquisition of 54.6% stakes in Sanofi Bangladesh Ltd. at a consideration of approximately Taka 469.62 crore (equivalent £39.35 million) pending final closing adjustments, if any.

51. Financial Risk Management

The management of company has overall responsibility for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risks for its use of financial instruments.

- Credit risk
- Liquidity risk
- Market risk

51.1 Credit Risk

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the company's receivables. Management has a credit policy in place and exposure to credit risk is monitored on an ongoing basis. As at June 30, 2021 substantial part of the receivables are those from its related company and subject to insignificant credit risk. Risk exposures from other financial assets. i.e. Cash at bank and other external receivables are nominal.

51.2 Liquidity Risk

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure as far as possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses including financial obligations through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. In extreme stressed conditions the company may get support from the related company in the form of short term financing.

51.3 Market Risk

Market risk is the risk that any change in market prices such as foreign exchange rates and interest will affect the company's income or the value of its holdings financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

a. Currency risk

The company is exposed to currency risk on export revenues and import of raw material, machineries and equipment. Majority of the company's foreign currency transactions are denominated in USD. Additionally the Company has foreign currency loan which shall be repaid in foreign currency. However, The Company maintains an Export Retention Quota (ERQ) account in USD where 50% of the export earnings are deposited. This partly contributes to minimize the currency risk associated with payments in foreign currency.

b. Interest rate risk

Interest rate risk is the risk that arises due to changes in interest rates on borrowing. An increase in interest rates will result in higher borrowing costs and impact the Company's profitability. The Company continuously monitors and negotiates viable deals to minimize the interest rate risk. Further, the company tries to remain at a lower level of gearing to minimize the impact of financing costs. With its strong ability to generate cash flows from operating activities, the company tries to pay off its debts on due time to minimize the impact of an increase in interest rates. The company has arrangement with banks to transfer the sales proceeds into its overdraft account on a real time basis through RTGS system to minimize borrowing cost.


The foreign currency loan is subject to floating rates of interest. The company has not entered into any type of derivative instrument in order to hedge interest rate risk as at the reporting date.



Osman Kaiser Chowdhury
Director



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer

Dhaka
October 21, 2021

Financial Statements
Nuvista Pharma Limited

Directors' Report to the Shareholders

On behalf of the Board of Directors of Nuvista Pharma Limited, I am pleased to present the Directors' Report and the Audited Financial Statements for the year ended 30 June 2021 together with the Auditors' Report thereon.

Operating Performance

We concluded year 2020-21 with remarkable success amidst the disruptions created by the ongoing pandemic. The economic and business environment remained challenging throughout the financial year, especially in the first and fourth quarter, when Bangladesh faced two surges of COVID-19 upsetting the life and livelihood of the people. However, gaining experience from the past and relying on our strength of resilience, we reimagined and redesigned our operating and business strategies to exploit the maximum business potentials. We adjusted our customer interaction model to stay closer to them than ever before. During this time, we stepped up our contact with our core specialty doctors through digital channels, face-to-face visit and with other scientific activities on virtual digital platforms. We re-aligned our manufacturing and other support functions to fit to the challenging condition consequent to which we managed uninterrupted production and supply of our products to the market. Thanks to the Company's employee-friendly policies giving highest priority on the health and safety of the people and unceasing support that encouraged them to contribute their fullest, resulting in improved business and operational performance.

Our sales revenue increased by a significant 24.04% to reach a new height of Tk. 2,572.1 million in 2020-21 as against Tk. 2,073.6 million of preceding year. Most of our key therapeutic segments registered faster growth than the industry. During the year, we added 10 new products in our portfolio and got encouraging market response. They contributed Tk. 71.5 million in sales in the first year of introduction, which shows their strong growth potential. The new products that we launched in 2019-20 continued to perform well in their respective market categories and contributed Tk. 217.3 million in 2020-21. Also in 2020-21, we generated Tk. 66.3 million from rendering toll services to other pharmaceutical companies.

The Company earned an after-tax net profit of Tk. 299.7 million in 2020-21 as against Tk. 243.8 million in 2019-20, marking a significant 22.93% growth. Impressive achievement of sales, improved gross margin predominantly because of the revenue mix and leverage effect of higher sales, and proper containment of operating expenses helped to attain the growth in net profit. The Net Operating Cash Flows (NOCFPS) and the Net Asset Value (NAV) per share increased to Tk. 34.8 and Tk. 86.8 in 2020-21 from Tk. 28.2 and Tk. 64.8 respectively, of the previous year.

Profit and its Appropriation

	Amount in Taka	
	Year ended 30 June 2021	Year ended 30 June 2020
Net Profit before tax	421,484,155	334,282,670
Provision for tax	(121,785,501)	(90,471,845)
Net Profit after tax	299,698,654	243,810,825
Unappropriated profit from previous year	442,959,982	222,649,477
Payment of dividend	(41,125,560)	(23,500,320)
Profit available for appropriation	701,533,076	442,959,982
Recommended for appropriation:		
Proposed dividend	(47,000,640)	(41,125,560)
Retained Earnings after proposed dividend	654,532,436	401,834,422

Dividend

The Board of Directors recommends 40% cash dividend i.e. Tk. 4.00 per share for the year ended 30 June 2021 to the Shareholders subject to the approval of the Shareholders in the Annual General Meeting (AGM) of the Company.

Composition of Board of Directors

The Board of Directors is composed of:

Mr. Nazmul Hassan, MP : Chairman and Director
Mr. S. M. Rabbur Reza : Managing Director
Mr. Mohammad Ali Nawaz : Director
Mr. Md. Golam Yahia : Nominee Director, Ministry of Industries
Prof. Mamtaz Uddin Ahmed : Independent Director

Retirement and Re-Election of Director

Mr. Mohammad Ali Nawaz, Director of the Company retires by rotation as per Article 125 and 126 of the Articles of Association of the Company and being eligible, offer himself for re-election as Director and is placed for approval by the shareholders in the AGM.

Auditors

The existing auditors A. Qasem & Co., Chartered Accountants, who were appointed as auditors of the Company in the 46th AGM of the Company carried out the audit for the year ended 30 June 2021.

A. Qasem & Co., Chartered Accountants, the auditors of the Company retires at this meeting and have expressed their willingness to continue in office for the year ended on 30 June 2022 subject to the approval of the shareholders in the 47th AGM of the Company. The Board recommends for reappointment of A. Qasem & Co., Chartered Accountants as auditors of the Company for the year ended on 30 June 2022.

On behalf of the Board,



Nazmul Hassan, MP
Chairman

18 October 2021

Independent Auditor's Report
To the Shareholders of Nuvista Pharma Limited
Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Nuvista Pharma Limited (the Company), which comprise the statement of financial position as at 30 June 2021, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at 30 June 2021, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirement that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, we also report the following:

- (a) we have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
- (b) in our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books; and
- (c) the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account and returns.

A. Qasem & Co.

Chartered Accountants

RJSC Firm Registration No.: 2-PC7202



Mohammad Motaleb Hossain, FCA

Enrolment Number: 0950

DVC: 2110270950AS148231

Dhaka, 18 October 2021

Nuvista Pharma Limited
Statement of financial position
As at 30 June 2021

	Notes	30 June 2021	Amount in Taka 30 June 2020
ASSETS			
Non-current assets			
Property, plant and equipment	4	1,094,483,583	1,144,501,502
Capital work-in-progress	5	13,167,670	180,908
Intangible assets	6	14,498,907	—
Total non-current assets		1,122,150,160	1,144,682,410
Current assets			
Inventories	7	488,258,898	456,155,729
Trade receivables	8	68,992,110	111,672,826
Loans, advances and deposits	9	62,372,394	45,959,627
Cash and cash equivalents	10	27,506,945	18,976,993
Total current assets		647,130,347	632,765,175
Total assets		1,769,280,507	1,777,447,585
EQUITY AND LIABILITIES			
Shareholders' equity			
Share capital	11	117,501,600	117,501,600
Reserves and surplus	12	902,470,740	643,897,646
Total equity		1,019,972,340	761,399,246
Non-current liabilities			
Lease liabilities - long term portion	13	—	4,915,288
Long term bank borrowings	14	—	4,751,056
Gratuity payable	15	148,113,060	128,748,851
Deferred tax liabilities	16	117,591,532	131,938,710
Total non-current liabilities		265,704,592	270,353,905
Current liabilities			
Lease liabilities - current portion	13	—	1,531,045
Short term bank borrowings	17	166,074,847	442,114,287
Trade payables	18	146,680,936	115,882,471
Liabilities for expenses	19	96,229,644	106,386,071
Income tax payable	20	2,064,899	22,737,718
Other liabilities	21	72,553,249	57,042,842
Total current liabilities		483,603,575	745,694,434
Total liabilities		749,308,167	1,016,048,339
Total equity and liabilities		1,769,280,507	1,777,447,585

The annexed notes 1 to 35 form an integral part of these financial statements.

Nazmul Hassan

Nazmul Hassan
Chairman

Rabbur Reza

S.M. Rabbur Reza
Managing Director

Mohammad Ali Nawaz

Mohammad Ali Nawaz
Director

As per our report of same date

Dhaka, 18 October 2021

A. Qasem & Co.
Chartered Accountants
RJSC Firm Registration No.: 2-PC7202

Motaleb
Mohammad Motaleb Hossain, FCA
Enrolment Number: 0950
DVC: 2110270950AS148231

Statement of profit or loss and other comprehensive income

For the year ended 30 June 2021

	Notes	Amount in Taka	
		30 June 2021	30 June 2020
Revenue	22	2,572,104,337	2,073,588,946
Cost of goods sold	23	(1,238,556,183)	(966,727,371)
Gross profit		1,333,548,154	1,106,861,575
General and administration expenses	24	(104,244,983)	(92,526,184)
Selling and distribution expenses	25	(773,583,577)	(608,640,157)
Profit from operations		455,719,594	405,695,234
Non-operating income	26	3,648,109	1,174,140
Interest expenses	27	(16,809,340)	(55,872,570)
Profit before tax and WPPF		442,558,363	350,996,804
Contribution to WPPF		(21,074,208)	(16,714,134)
Profit before tax		421,484,155	334,282,670
Tax expense			
Current	20	(136,132,679)	(103,385,538)
Deferred	16	14,347,178	12,913,693
		(121,785,501)	(90,471,845)
Profit after tax		299,698,654	243,810,825
Other comprehensive income		—	—
Total comprehensive income for the year		299,698,654	243,810,825
Earnings Per Share (EPS)		25.51	20.75

The annexed notes 1 to 35 form an integral part of these financial statements.

As per our report of same date

Nazmul Hassan

Nazmul Hassan
Chairman

Rabbur Reza

S.M. Rabbur Reza
Managing Director

Mohammad Ali Nawaz

Mohammad Ali Nawaz
Director

As per our report of same date

Dhaka, 18 October 2021

A. Qasem & Co.
Chartered Accountants
RJSC Firm Registration No.: 2-PC7202

Motaleb
Mohammad Motaleb Hossain, FCA
Enrolment Number: 0950
DVC: 2110270950AS148231

Nuvista Pharma Limited

Statement of changes in equity

For the year ended 30 June 2021

Amount in Taka

Particulars	Share capital	Reserves and surplus						Total
		General reserve	Share premium	Pre-incorporation profit	Revaluation reserve	Retained earnings	Total reserves and surplus	
Balance as at 1 July 2019	117,501,600	7,511,991	30,844,170	243,737	162,337,766	222,649,477	423,587,141	541,088,741
Dividend paid						(23,500,320)	(23,500,320)	(23,500,320)
Profit after tax for the year ended 30 June 2020	—	—	—	—	—	243,810,825	243,810,825	243,810,825
Balance as at 30 June 2020	117,501,600	7,511,991	30,844,170	243,737	162,337,766	442,959,982	643,897,646	761,399,246
Number of shares								11,750,160
Net assets value per share								64.80
Balance as at 1 July 2020	117,501,600	7,511,991	30,844,170	243,737	162,337,766	442,959,982	643,897,646	761,399,246
Dividend paid						(41,125,560)	(41,125,560)	(41,125,560)
Profit after tax for the year ended 30 June 2021	—	—	—	—	—	299,698,654	299,698,654	299,698,654
Balance as at 30 June 2021	117,501,600	7,511,991	30,844,170	243,737	162,337,766	701,533,076	902,470,740	1,019,972,340
	Notes	11	12	12.1	12	12.2	12	12
Number of shares								11,750,160
Net assets value per share								86.80

The annexed notes 1 to 35 form an integral part of these financial statements.

Nuvista Pharma Limited
Statement of cash flows
For the year ended 30 June 2021

	Notes	Amount in Taka	
		30 June 2021	30 June 2020
A. Cash flows from operating activities			
Cash receipts from customers and others		2,618,368,138	1,994,406,632
Cash paid to suppliers and employees		(2,033,598,933)	(1,563,184,360)
Cash generated from operation		584,769,205	431,222,272
Interest paid	19 & 27	(19,577,082)	(54,587,576)
Income tax paid	20	(156,805,498)	(44,966,705)
Net cash generated from operating activities		408,386,625	331,667,991
B. Cash flows from investing activities			
Purchase of property, plant and equipment		(56,789,046)	(19,011,295)
Purchase of intangible assets		(14,870,674)	—
Proceeds from disposal of property, plant and equipment		80,133	74,250
Net cash used in investing activities		(71,579,587)	(18,937,045)
C. Cash flows from financing activities			
Proceeds from/(payment to) long term bank borrowings	14	(36,034,605)	(38,459,361)
Proceeds from/(payment to) short term bank borrowings	17	(244,755,891)	(257,170,269)
Payment for lease liability	13	(6,446,333)	(2,826,903)
Dividend paid		(41,040,257)	(23,450,146)
Net cash (used in)/from financing activities		(328,277,086)	(321,906,679)
D. Net increase/(decrease) in cash and cash equivalents (A+B+C)		8,529,952	(9,175,733)
E. Opening cash and cash equivalents		18,976,993	28,152,726
F. Closing cash and cash equivalents (D+E)		27,506,945	18,976,993
Net operating cash flow per share		34.76	28.23
Number of shares		11,750,160	11,750,160

The annexed notes 1 to 35 form an integral part of these financial statements.

1. Reporting entity

1.1 Nuvista Pharma Limited (“the Company”) was originally a subsidiary of Netherlands-based Organon International. The Company has been operating in Bangladesh since 1964, with a local manufacturing facility at Tongi, Dhaka. In the post-independent Bangladesh, it was incorporated as Organon (Bangladesh) Limited under Bangladesh Companies Act as a private limited company. Following the divestment of Organon’s equity to the local management in 2006, the Company was renamed as Nuvista Pharma Limited. In 2011, the Company, through amendments to its Memorandum and Articles of Association, became a public Limited Company under the Companies Act 1994.

In 2018, Beximco Pharmaceuticals Limited, a public limited company listed with Bangladesh Stock Exchanges and AIM of London Stock Exchange, acquired majority shareholdings in Nuvista Pharma Limited. Beximco Pharma, through this acquisition, became the immediate and ultimate parent of Nuvista Pharma with 85.22% of Nuvista’s equity. Government of Bangladesh holds 12.92% shares of the Company while the rest is held by other local shareholders.

1.2 The registered office of the Company is located at Plot no. 107/A, Mascot Plaza (8th floor), Sonargaon Janapath, Sector-7, Uttara C/A, Dhaka-1230, Bangladesh.

1.3 The Company produces various pharmaceutical products including oral contraceptives, hormone, steroid, anti-histamine, anti-fibrinolytic, gastrointestinal, musculoskeletal, respiratory, vitamin & mineral supplement and women’s health products which are sold in the domestic market. The Company also provides toll manufacturing services to other pharmaceutical companies.

2. Basis of preparation

2.1 Statement of compliance

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994 and other applicable laws and regulations.

2.2 Basis of measurement

The financial statements have been prepared on the historical cost basis except revaluation of certain property, plant and equipment.

2.3 Functional and presentational currency

These financial statements are prepared in Bangladeshi Taka (Taka/Tk.), which is the Company’s functional currency. All financial information has been presented in Taka and rounded off to the nearest integer.

2.4 Use of estimates and judgments

The preparation of financial statements requires management to make judgment, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.

Estimates and underlying assumptions are reviewed on an on going basis.

2.5 Going concern

The Company has adequate resources to continue its operation for the foreseeable future. For this reason the directors continue to adopt going concern basis in preparing the financial statements. The current resources and credit facilities of the Company are sufficient to meet the present requirements of its existing business.

2.6 Statement of cash flows

Statement of cash flows has been prepared in accordance with as per IAS 7: “Statement of cash flows” under direct method.

2.7 Reporting Period

These financial statements cover one year from 1 July 2020 to 30 June 2021.

3. Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these financial statements.

3.1 Share capital

Share capital represents the total amount of shareholders capital that has been paid in full by the ordinary shareholders. Holders of ordinary shares are entitled to receive dividends as declared from time to time.

3.2 Leases

IFRS 16 introduced a single, on-balance sheet accounting model for lessees. As a result, the Company, as a lessee, has recognised right-of-use assets representing its rights to use the underlying assets and lease liabilities representing its obligation to make lease payments.

The Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred.

The right of use asset is depreciated using the straight line methods from the commencement date to the earlier of the end of the useful life of the right of use asset or the end of the lease term.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate.

3.2.1 Office rent

As per IFRS 16, a contract is a lease if the contract conveys the right to control the use of an identified asset. As per terms of the agreement of office rent (clause 4.13, 17(m), 4.8, 4.9, 4.15, 4.18, 4.23) lessor has the right to control the use of office building. Furthermore, the lessee and lessor each has the right to terminate the lease by giving 90 days notice period without permission from the other party with no penalty clause. As a result, the contract does not meet the criteria of lease as defined under IFRS 16.

3.3 Staff gratuity fund

The Company operates an unfunded gratuity scheme, provision in respect of which is made annually for all eligible employees. Gratuity payable to all eligible employees at the end of each year is determined on the basis of the existing rules and regulations of the Company. Subsequent to the Balance Sheet date the Company has initiated the process to convert the unfunded gratuity scheme to funded gratuity.

3.4 Employees provident fund

The Company subscribes to a contributory provident fund for its permanent employees which is administered by a Board of Trustees and is funded by contributions from employees and from the Company @ 10% of the basic pay. These contributions are invested separately from the Company's business.

3.5 Property, plant and equipment

3.5.1 Recognition and measurement

Property, plant and equipment (PPE) is recognised as an asset if it is probable that future economic benefits associated with the asset will flow to the entity and the cost of the item can be measured reliably.

Property, plant and equipment are stated at cost or valuation less accumulated depreciation and impairment losses, if any. Cost includes expenditure that is directly attributable to the acquisition of the assets, bringing the assets to the location and condition necessary for it to be capable of operating in the manner intended by management.

3.5.2 Subsequent costs

The costs of replacing part of an item of property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its costs can be measured reliably. The costs of the day to day servicing of property, plant and equipment are recognised in the Statement of profit or loss and other comprehensive income as incurred.

3.5.3 Depreciation

Depreciation is recognised in the Statement of profit or loss and other comprehensive income on a straight line basis over the estimated useful lives of each item of property, plant and equipment. Depreciation on property, plant and equipment is charged from the month of acquisition. In case of disposals, depreciation is charged up to the immediate previous month of disposal. No depreciation is charged on leasehold land and capital work-in-progress. Depreciation is calculated and charged on all other property, plant and equipment at the following rates on cost or valuation, considering the estimated useful lives of the assets:

Factory building and warehouse	2.5%
Motor cars and vans	20%-25%
Plant, machinery and equipment	5% -15%
Computer and IT equipment	30%
Electric fixtures and fittings	7%
Furniture and fittings	6%

Gain or loss on sale of property, plant and equipment is recognised in the Statement of profit or loss and other comprehensive income as per provision of IAS 16: "Property, plant and equipment".

3.6 Intangible assets

Intangible assets represent rights, titles and assigned trademark. Acquired intangible asset is initially capitalised at cost which includes the purchase price and other directly attributable costs. It is subsequently carried at cost less accumulated amortization and any accumulated impairment losses. Amortisation is calculated to write off the cost of intangible assets using the straight-line method over its estimated useful life.

3.7 Impairment

3.7.1 Recognition

The carrying value of the Company's assets, other than inventories, are reviewed at each Statement of financial position date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated. An impairment loss is recognized whenever the carrying amount of the asset or its cash-generating unit exceeds its recoverable amount. Impairment losses, if any, are recognised in the Statement of profit or loss and other comprehensive income. For the assets that have indefinite useful life, the recoverable amount is estimated at each Statement of financial position date.

No indication of impairment was observed in the year ended 30 June 2021.

3.7.2 Calculation of recoverable amount

The recoverable amount of an asset is the greater of net selling price and value in use. The estimated future cash flows are discounted to their present value using discount rate that reflects the current market assessment of the time value of money and the risk specific to the asset. For an asset that does not generate significantly independent cash inflows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

3.7.3 Reversal of impairment

An impairment loss recognised in prior periods for an asset shall be reversed if, and only if, there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised.

An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, had no impairment loss been recognised for the asset in prior years.

There was no reversal of impairment in the year ended 30 June 2021.

3.8 Capital work-in-progress

Capital work-in-progress represents the cost incurred for acquisition and/or construction of items of property, plant and equipment that were not ready for use at the year end and these are stated at cost.

3.9 Taxation

Tax on the Statement of profit or loss and other comprehensive income for the year comprises current and deferred tax. Tax is recognised in the Statement of profit or loss and other comprehensive income except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

3.9.1 Current tax

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the Statement of financial position date, and any adjustment to tax payable in respect of previous years.

3.9.2 Deferred tax

Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: the initial recognition of goodwill; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit other than in a business combination, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. Deferred tax assets and liabilities are offset if there is a legal enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity.

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that is no longer probable that the related tax benefit will be realised.

3.10 Inventories

Inventories include raw materials, raw materials in transit, work-in-process, finished goods and spare parts. These are valued at the lower of cost and net realisable value, with appropriate provisions for obsolete and slow-moving items. Cost is determined using the weighted average method and includes all expenses incurred in bringing the inventories to their present location and condition.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

3.11 Financial Instruments

IFRS 9 sets out requirements for recognising and measuring financial assets, financial liabilities and some contracts to buy or sell non-financial items. This standard replaces IAS 39 Financial Instruments: Recognition and Measurement.

IFRS 9 contains three principal classification categories for financial assets such as measured at amortised cost, Fair Value through Other Comprehensive Income (FVOCI) and Fair Value through Profit or Loss (FVTPL). The classification of financial assets under IFRS 9 is generally based on the business model in which a financial asset is managed and the contractual cash flow characteristics. IFRS 9 replaces the previous financial assets categories defined under IAS 39.

IFRS 9 largely retains the existing requirements in IAS 39 for the classification and measurement of financial liabilities.

3.12 Foreign currency

3.12.1 Foreign currency transactions

Foreign currency transactions are converted into equivalent Taka at the ruling exchange rates on the respective dates of such transactions and subsequently retranslated using the rate at the date of settlement.

3.12.2 Foreign currency translations

Monetary assets and liabilities denominated in foreign currencies have been converted into Taka at the exchange rate ruling at the year end.

3.12.3 Translation gains and losses

Foreign exchange difference arising on translation are recognised in the Statement of profit or loss and other comprehensive income.

3.13 Provisions

A provision is recognised in the Statement of financial position when the Company has a legal or constructive obligation as a result of past events, and it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

3.14 Revenue from Contracts with Customers

Revenue is measured based on the consideration specified in a contract with a customer. The Company recognises revenue when it transfers control over a good or service to a customer. The following steps provides information about the nature and timing of the satisfaction of performance obligations in contracts with customers, including significant payment terms, and the related revenue recognition policies:

- Identify the contract with a customer,
- Identify the performance obligations in the contract,
- Determine the transaction price,
- Allocate the transaction price to the performance obligations in the contract and
- Recognise revenue when the entity satisfies a performance obligation.

3.15 Interest expenses

Interest expense comprises interest expense on overdraft, import loan, demand loan, finance lease and term loan. All interest expenses are recognised in the Statement of profit or loss and other comprehensive income when it accrues.

3.16 Workers' Profit Participation Fund (WPPF)

The Company provides 5% of its net profit before tax (after charging such expense) as WPPF in accordance with Bangladesh Labour Act 2006.

3.17 Standards adopted but not yet effective-IFRS 17: Insurance Contracts

A new Standard IFRS 17: Insurance Contracts, has been made effective for the reporting period beginning on or after 1 January 2023. This standard, however, has no material issue that might affect the reported financial statements of the Company.

3.18 Events after the reporting date

Events after the reporting date that provide additional information about the Company's position at the reporting date are reflected in the financial statements. Events after the reporting date that are not adjusting events are disclosed in the notes when material.

3.19 General

Previous year's figures have been rearranged/reclassified wherever considered necessary to conform to current year's presentation.

4. Property, plant and equipment

Amount in Taka

Particulars	Land	Factory building	Factory warehouse	Plant and machinery	Motor vehicles	Computer and IT equipment	Equipment and electric fixtures and fittings	Furniture fittings	Total
Cost or valuation									
As at 1 July 2020	275,608,713	236,790,594	18,193,678	480,657,004	145,556,780	31,036,729	685,633,073	49,382,216	1,922,858,787
Addition/transfer during the year	—	2,391,184	2,157,644	17,558,672	—	1,421,458	16,210,165	3,160,729	42,899,852
Adjustment/disposal	—	—	—	(1,798,461)	(1,334,800)	(1,941,620)	—	—	(5,074,881)
As at 30 June 2021	275,608,713	239,181,778	20,351,322	496,417,215	144,221,980	30,516,567	701,843,238	52,542,945	1,960,683,758
Accumulated depreciation									
As at 1 July 2020	—	54,201,286	3,913,221	194,701,848	115,701,140	24,533,963	359,058,528	26,247,299	778,357,285
Charge during the year	—	5,932,272	485,511	23,157,451	16,000,885	3,685,911	41,248,709	2,391,922	92,902,661
Adjustment/disposal	—	—	—	(1,798,453)	(1,319,712)	(1,941,606)	—	—	(5,059,771)
As at 30 June 2021	—	60,133,558	4,398,732	216,060,846	130,382,313	26,278,268	400,307,237	28,639,221	866,200,175
Net book value									
As at 30 June 2021	275,608,713	179,048,220	15,952,590	280,356,369	13,839,667	4,238,299	301,536,001	23,903,724	1,094,483,583
As at 30 June 2020	275,608,713	182,589,308	14,280,457	285,955,156	29,855,640	6,502,766	326,574,545	23,134,917	1,144,501,502

4.1 Depreciation charge has been allocated as under

	30 June 2021	30 June 2020
Factory overhead included in cost of goods sold (Note 23.3)	73,241,118	80,197,666
General and administration expenses (Note 24)	2,938,395	2,996,619
Selling and distribution expenses (Note 25)	16,723,148	12,802,897
	92,902,661	95,997,182

4.2 Disclosure for revalued assets

The land is stated at revalued amount on the basis of the reports of external surveyor. The surplus on revaluation over the original cost of the assets was credited to revaluation reserve.

Land was revalued in 1976 for the first time. The Company once again revalued its land, plant and machinery, and equipment at the time of divestment of Organon (Bangladesh) Limited in 2006. The Company's land was further revalued in 2010.

5. Capital work-in-progress

Amount in Taka				
	As at 1 July 2020	Addition during the year	Transfer to property, plant and equipment	As at 30 June 2021
Factory Building		2,391,184	2,391,184	—
Factory Warehouse		2,157,644	2,157,644	—
Plant and machinery	180,908	29,043,335	17,558,672	11,665,571
Furniture		3,160,729	3,160,729	—
Equipment & Electric fixture and fittings		17,712,264	16,210,165	1,502,099
Computer and IT equipment		1,421,458	1,421,458	—
	180,908	55,886,614	42,899,852	13,167,670

6. Intangible assets

	Amount in Taka	
	30 June 2021	30 June 2020
Cost		
Balance as at 1 July	—	—
Addition during the year	14,870,674	—
Balance as at 30 June	14,870,674	—
Amortization		
Balance as at 1 July	—	—
Amortized during the year	371,767	—
Balance as at 30 June	371,767	—
Net carrying value as at 30 June	14,498,907	—

This represents rights, titles and assigned trademark of ovestin brand purchased from Merck Sharp & Dohme B. V., the Netherlands on 1 April 2021 and is amortized over 10 years.

7. Inventories

Stocks		
Finished goods	111,155,804	156,163,823
Semi-finished and Work-in-process	57,816,825	44,419,416
Raw materials	227,201,449	134,288,819
Chemicals	20,787,896	25,896,599
Packing materials	30,462,560	38,633,826
Materials-in-transit	1,544,922	16,928,409
	448,969,456	416,330,892
Stores		
Spares and accessories	8,458,918	9,928,538
Laboratory consumables	299,097	313,561
Literature, brochure and other materials	30,436,948	29,150,832
Spares-in-transit	94,479	431,906
	39,289,442	39,824,837
	488,258,898	456,155,729

	Amount in Taka	
	30 June 2021	30 June 2020
8. Trade receivables		
Ageing of the trade receivables is as follows:		
Receivables due over six months	2,588,327	3,427,476
Receivables due below six months	66,403,783	108,245,350
	68,992,110	111,672,826

Above receivables are unsecured and considered good.

Trade receivables is net off provision for bad debts Tk. 1,884,860.

9. Loans, advances and deposits

Car loan	10,931,774	4,346,942
General loan	1,756,172	1,920,061
Advance against operating expenses	1,588,959	892,511
Security deposits	3,483,184	6,580,740
VAT	24,696,302	21,594,507
Prepaid insurance	5,389,765	5,261,738
LC margin	14,120,004	4,265,999
Others	406,234	1,097,129
	62,372,394	45,959,627

10. Cash and cash equivalents

Cash in hand	115,867	100,468
Cash at banks		
Eastern Bank Limited	75,189	64,569
The City Bank Limited	520,407	415,483
Dhaka Bank Limited	655	655
IFIC Bank Limited	19,945,406	13,559,470
Shimanto Bank Limited	33,240	28,160
Janata Bank Limited	6,627,594	4,493,168
National Bank Limited	188,587	315,020
	27,391,078	18,876,525
	27,506,945	18,976,993

		Amount in Taka			
		30 June 2021	30 June 2020		
11. Share capital					
Authorised					
50,000,000	Ordinary shares of Tk 10 each	500,000,000	500,000,000		
Issued, subscribed and paid-up					
11,579,160	Ordinary shares of Tk 10 each issued for cash	115,791,600	115,791,600		
171,000	Ordinary shares of Tk 10 each issued for consideration other than cash	1,710,000	1,710,000		
11,750,160		117,501,600	117,501,600		
Shareholding position					
		Nominal value (Taka)		Percentage of holding (%)	
		30 June 2021	30 June 2020	30 June 2021	30 June 2020
Beximco Pharmaceuticals Limited		100,134,740	100,134,740	85.22	85.22
Government of Bangladesh		15,186,000	15,186,000	12.92	12.92
Other shareholders		2,180,860	2,180,860	1.86	1.86
		117,501,600	117,501,600	100	100

11.1 In 2012, the Company raised its paid-up capital from Tk. 9,791,800 to Tk. 58,750,800 by issuing 4,895,900 rights share to the existing shareholders on the basis of 5R:1 (i.e. five rights share against one existing share held on the record date). However, the subscription against the rights share (632,750 share of Tk. 10 each) held by the Ministry of Industries, Govt. of Bangladesh was received on 20 June 2013.

11.2 In 2017, the Company further raised its paid-up capital from Tk. 58,750,800 to Tk. 117,501,600 by issuing 5,875,080 rights share to the existing shareholders on the basis of 1R:1 (i.e. one rights share against one existing share held on the record date).

	30 June 2021	30 June 2020
12. Reserves and surplus		
General reserve	7,511,991	7,511,991
Share premium (Note 12.1)	30,844,170	30,844,170
Pre-incorporation profit	243,737	243,737
Revaluation reserve (Note 12.2)	162,337,766	162,337,766
Retained earnings	701,533,076	442,959,982
	902,470,740	643,897,646

12.1 Share premium

This represents the amount received on 48,959 ordinary shares @ Tk. 630 each issued in 1997.

12.2 Revaluation reserve

This represents revaluation surplus on revaluation of land made during 2006 and 2010.

	Amount in Taka	
	30 June 2021	30 June 2020
13. Lease liabilities		
Lease liabilities arising from leased vehicle as per IFRS 16 is as follows:		
Not later than one year	—	1,531,045
Later than one year and not later than five years	—	4,915,288
	—	6,446,333

14. Long term bank borrowings

Dhaka Bank Limited (Note 14.1)	—	36,034,605
Less: Current portion (Note 17)	—	(31,283,549)
	—	4,751,056

14.1 Dhaka Bank Limited

Term loans financed by Dhaka Bank Limited for setting up the new Oral Solids facility and equipment at the factory which was fully repaid in current year.

14.2 Collateral

All loans are secured by a registered mortgage on specific factory land and buildings of the Company.

14.3 Security

The loan is secured by hypothecation of fixed and floating assets of the Company including plant and machinery, equipment, furniture and fixture, inventories and receivables. Additionally, there is a corporate guarantee issued by Beximco Pharmaceuticals Limited.

15. Gratuity payable

Balance as at 1 July	128,748,851	106,585,224
Add : Provision made during the year	29,392,589	22,766,607
Add : Liability for transferred employees	—	12,455,838
	158,141,440	141,807,669
Less: Payments made during the year	(10,028,380)	(13,058,818)
Balance as at 30 June	148,113,060	128,748,851

16. Deferred tax liabilities

Deferred tax liabilities arrived at as follows:			Amount in Taka
	Carrying amount on statement of financial position date	Tax base	Taxable/ (deductible) temporary difference
Year: 2020-2021			
Property, plant and equipment	818,874,870	372,397,981	446,476,889
Gratuity payable	(148,113,060)	—	(148,113,060)
Allowance for expected credit loss	(1,884,860)	—	(1,884,860)
Temporary difference			296,478,969
Applicable tax rate for items recognised in statement of comprehensive income			30.0%
Applicable tax rate for items recognised in equity			15.0%
Deferred tax Liabilities(a):			(88,943,691)
Deferred tax liabilities on revaluation surplus			(28,647,841)
Net deferred tax liabilities			(117,591,532)
Year: 2019-2020			
Property, plant and equipment	868,892,789	420,915,448	447,977,341
Gratuity payable	(128,748,851)	—	(128,748,851)
Allowance for expected credit loss	(1,410,430)	—	(1,410,430)
Temporary difference			317,818,060
Applicable tax rate for items recognised in statement of comprehensive income			32.5%
Applicable tax rate for items recognised in equity			15.0%
Deferred tax Liabilities(b):			(103,290,869)
Deferred tax Liabilities on revaluation surplus			(28,647,841)
Net deferred tax liabilities			(131,938,710)
Deferred tax recognised in the statement of profit or loss and other comprehensive income in 2020-2021 (a-b)			14,347,178
Deferred tax recognised in the statement of profit or loss and other comprehensive income in 2019-2020			12,913,693

	Amount in Taka	
	30 June 2021	30 June 2020
17. Short term bank borrowings		
Bank overdrafts		
Dhaka Bank Limited (Limit Tk. 200,000,000)	22,608,979	77,213,282
Short term bank loans		
Dhaka Bank Limited	143,465,868	333,617,456
Current portion of long term loan (Note 14)	—	31,283,549
	166,074,847	442,114,287

Collateral and security given against short-term finance are a part of overall financing arrangement with Dhaka Bank Limited as indicated in note 14. The interest rate is 9.0% per annum and is payable on quarterly rests.

18. Trade payables

Trade payables	146,680,936	115,882,471
	146,680,936	115,882,471

This represents amount due against purchase of raw, chemical and packing materials.

19. Liabilities for expenses

Accrued expenses	94,915,558	102,329,243
Audit fees	400,000	375,000
Accrued interest	914,086	3,681,828
	96,229,644	106,386,071

20. Income tax payable

Balance as at 1 July	22,737,718	(35,681,115)
Add: Provision for the year	136,132,679	103,385,538
Less: AIT and treasury deposits during the year	(156,805,498)	(44,966,705)
Balance as at 30 June	2,064,899	22,737,718

21. Other liabilities

Salary and allowances	4,531,928	1,877,366
Provident fund dues	3,200,879	2,457,329
Workers' profit participation fund	21,074,208	16,714,134
Tax deducted at source	1,317,699	914,214
Net VAT payable	22,136,988	16,424,262
Tax on salaries	1,921,355	600,790
Final settlement of staff	3,371,107	4,351,474
Commission payable	14,631,227	13,420,717
Unpaid dividend	367,858	282,556
	72,553,249	57,042,842

	Amount in Taka	
	July 2020-June 2021	July 2019-June 2020
22. Revenue		
Net sales revenue	2,505,836,903	2,003,012,715
Toll income	66,267,434	70,576,231
	2,572,104,337	2,073,588,946

Quantitative details of sales

	Unit	Quantity	Quantity
Tabs		710,009,655	378,685,916
Caps		39,326,286	32,207,937
Amps & Suspensions		14,050,488	13,145,696
Bottles		3,319	—

23. Cost of goods sold

Opening stock of finished goods	156,163,823	99,377,976
Purchases (imported and processed products)	9,718,528	—
Cost of production (Note 23.1)	1,194,139,965	1,031,507,041
Cost of goods available for sale	1,360,022,316	1,130,885,017
Cost of physician sample	(10,310,329)	(7,993,823)
Closing stock of finished goods	(111,155,804)	(156,163,823)
	1,238,556,183	966,727,371

23.1 Cost of production

Opening stock of semi-finished and WIP	44,419,416	35,395,067
Materials consumed (Note 23.2)	679,919,902	563,093,775
Factory overhead (Note 23.3)	527,617,472	477,437,615
	1,251,956,790	1,075,926,457
Closing stock of semi-finished and WIP	(57,816,825)	(44,419,416)
	1,194,139,965	1,031,507,041

	Amount in Taka	
	July 2020-June 2021	July 2019-June 2020
23.2 Materials consumed		
Opening stock	198,819,244	163,711,619
Purchase	759,552,563	598,201,400
Closing stock	(278,451,905)	(198,819,244)
	679,919,902	563,093,775

Item wise quantity and value of finished goods stock are as follows :

Stock as June 30, 2020	Unit	Quantity	Value (Taka)
Tabs	pcs.	59,388,662	89,677,866
Caps	pcs.	11,548,926	42,908,358
Amps & Suspensions	pcs.	1,416,442	23,577,599
			156,163,823
Stock as June 30, 2021	Unit	Quantity	Value (Taka)
Tabs	pcs.	34,666,898	62,743,742
Caps	pcs.	5,765,220	18,016,722
Amps & Suspensions	pcs.	1,270,207	21,417,183
Bottle	pcs.	40,430	8,978,157
			111,155,804

23.3 Factory overhead

Salaries and allowances	189,823,190	170,579,565
Power and fuel	68,737,787	52,893,711
Factory supplies	32,904,388	30,274,741
Software and hardware support expenses	1,561,254	1,531,525
Canteen expenses	11,833,646	8,936,659
Insurance	4,894,538	3,778,508
Repair and maintenance	42,563,382	35,074,596
Security services	2,255,598	2,184,952
Toll manufacturing charges	5,830,110	5,596,120
Stores materials consumed	48,681,459	42,183,816
Product development cost	32,127,613	30,214,066
Overseas travelling expenses	—	2,876,414
Factory staff uniform	2,635,882	2,107,949
Printing and stationery	1,529,366	1,435,995
Entertainment	1,555,172	743,696
Vehicle repair, maintenance and running cost	4,000,941	3,214,754
Local authority taxes	860,740	1,548,488
Other expenses	2,581,288	2,064,394
Depreciation (Note 4.1)	73,241,118	80,197,666
	527,617,472	477,437,615

Salaries and allowances include Company's contribution to provident fund amounting to Tk. 2,203,286.

	Amount in Taka	
	July 2020-June 2021	July 2019-June 2020
24. General and administration expenses		
Salaries and allowances	60,785,836	52,704,065
Directors' fees (Note 29)	288,000	288,000
Office rent	11,454,000	11,454,000
Overseas travelling expenses	—	2,460,534
Local travelling expenses	1,315,151	1,143,053
Entertainment	957,635	807,635
Vehicle repair, maintenance and running cost	4,216,010	3,425,351
Postage, telephone, cell phone and internet	2,104,339	1,824,772
Printing and stationery	1,078,461	703,574
Repairs and maintenance	1,909,231	1,271,822
Office supplies	1,376,625	1,181,300
Software and hardware support expenses	3,959,299	3,251,729
Utilities	2,227,649	2,101,088
Canteen expenses	3,599,911	3,078,880
Local authority taxes	979,950	463,682
Medical expenses	296,152	120,357
Insurance premium	207,495	181,869
Statutory audit fees	400,000	375,000
Legal and professional expenses	145,000	144,000
Meeting and seminars	2,042,333	1,777,441
Other expenses	1,963,511	771,413
Depreciation (Note 4.1)	2,938,395	2,996,619
	104,244,983	92,526,184

Salaries and allowances include Company's contribution to provident fund amounting to Tk. 1,151,006.

	Amount in Taka	
	July 2020-June 2021	July 2019-June 2020
25. Selling and distribution expenses		
Salaries and allowances	323,220,113	275,653,657
Overseas travelling expenses	—	5,198,082
Local travelling expenses	90,892,048	61,225,363
Entertainment	2,458,196	1,077,546
Samples	14,743,772	11,518,571
Sales promotion expenses	17,364,964	14,086,181
Brand development	6,194,559	2,586,452
Product launch expenses	9,769,607	6,912,327
Sales force logistic	19,493,038	15,309,696
Employee welfare	2,227,756	2,177,427
Field operation	6,842,995	6,130,655
Books and periodicals	2,940,561	1,115,382
Royalty expenses	28,742,584	21,388,134
Literature, brochure and printed materials	33,548,922	20,051,135
Distribution commission	139,631,437	111,757,229
Event, program and campaign	7,881,573	5,084,516
Sales meeting and conference	4,367,730	2,824,876
Advertisement	5,450,647	2,216,705
Vehicle repair, maintenance and running cost	7,395,170	4,140,124
Postage, telephone, cell phone and internet	11,719,697	10,249,326
Printing and stationery	1,627,733	1,137,733
Medical expenses	2,017,261	1,577,122
Training expenses	3,041,832	2,638,389
Market survey and research	636,800	484,963
Registration and renewals	1,204,835	467,055
Insurance premium	2,711,887	2,452,723
Office rent	7,728,900	4,360,300
Bad debts	474,431	709,812
Utilities	1,034,923	752,070
Other expenses	1,124,691	553,709
Amortization of intangible assets	371,767	—
Depreciation (Note 4.1)	16,723,148	12,802,897
	773,583,577	608,640,157

Salaries and allowances include Company's contribution to provident fund amounting to Tk. 8,102,350.

26. Non-operating income

Gain on disposal of property, plant and equipment	65,024	24,692
Rental income	866,400	866,400
Sale of miscellaneous items	582,907	283,048
Forfeited PF refund (Note: 26.1)	2,133,778	—
	3,648,109	1,174,140

26.1 Forfeited PF refund

In compliance with the FRC circular number 179/FRC/FRM/Notification/2020/2, dated 07 July 2020, the Company has recovered the forfeited provident fund from the Provident Fund Trust.

Amount in Taka

July 2020-June 2021	July 2019-June 2020
---------------------	---------------------

27. Interest expenses

Interest on		
Long term loan	688,716	13,290,514
Short term finance	15,004,354	40,691,103
Finance lease	372,272	921,123
Bank charges	743,998	969,830
	16,809,340	55,872,570

28. Capacity utilisation

	Installed capacity	Actual production	Actual Utilisation
	Unit	Unit	%
Amps & Suspensions	19,822,400	13,257,582	67%
Tablet	1,322,390,400	646,357,034	49%
Capsule	56,044,880	37,359,176	67%

29. Remuneration and fees to directors

This relates to Board meeting attendance fee paid to Directors.

30. Payments made in foreign currency

Particulars	July 2020-June 2021		July 2019-June 2020
	Foreign currency (Equivalent USD)	Taka	Taka
Import of raw, chemicals and packing materials	6,095,178	521,323,600	359,506,535
Import of machinery and spare parts	437,516	37,381,755	13,228,851
		558,705,355	372,735,386

31. Related party disclosures

Following transactions were carried out with related parties in the normal course of business on arms length basis:

Name of related party	Relationship	Nature of transactions	Value of transaction	Balance at year end	Transaction Type
Beximco Pharmaceuticals Limited	Immediate and ultimate parent	Toll income	27,882,074	1,379,979	Dr.
		Royalty expenses	28,742,584	5,875,790	Cr.
		Cost of services	56,571,923	4,449,651	Cr.
		Dividend paid	35,047,159	—	
		Distribution commission	139,631,437	14,631,227	Cr.

32. Capital expenditure commitment

There was no capital expenditure contracted but not incurred or provided for at 30 June 2021.

33. Contingent liabilities

There is a contingent liability of Tk. 75,195,722 in respect of disputed tax claim for earlier years (from AY:1996-1997 to AY: 1999-2000). This matter has been referred to the High Court for a ruling and is still pending. If any liability arises on disposal of the cases, the Company shall provide for such liability in the year of disposal.

34. Number of employees engaged

The number of employees engaged for the whole period or part thereof who received a total remuneration of Tk. 36,000 and above were 1,281 (June 2020: 1,142).

35. Events after reporting date

The Board in its meeting dated 18 October 2021 recommended that 40% cash dividend i.e. Tk. 4.00 per share, totalling Tk. 47,000,640 be paid for the year 2020-21. The dividend proposal is subject to shareholders' approval at the forthcoming annual general meeting.

Nazmul Hassan

Nazmul Hassan
Chairman

Rabbur Reza

S.M. Rabbur Reza
Managing Director

Mohammad Ali Nawaz

Mohammad Ali Nawaz
Director

Financial Statements
Beximco Pharma API Limited

Beximco Pharma API Limited

DIRECTORS' REPORT to the Shareholders

I am pleased to place before you the Directors' Report and the Audited Accounts of the Company for the year ended 30 June, 2021 along with the report of the auditors thereon.

Beximco Pharma API Limited (BPAL) was incorporated in Bangladesh on December 12, 2017 as Private Limited Company under the Companies Act 1994. The Company is a fully owned Subsidiary of Beximco Pharmaceuticals Limited (BPL).

OPERATION

The Company intends to set up API manufacturing facility at the API Industrial Park, Gajaria, Munshigang. API Industrial Park has been set up by the Government of Bangladesh to encourage and facilitate API manufacturing in Bangladesh to reduce import dependency and ensure availability of patented APIs after graduation of Bangladesh from LDC to developing nation status. Government has also promulgated National API Policy to ensure all necessary benefits and incentives that may be required by the API manufacturers in the initial years. We have 2 (two) plots in the API Park which are now fully developed to start construction. The company has identified number of APIs it intends to manufacture. It has also short listed few Indian/ Chines Technology partners evaluating their proposals. Once done, the agreements of construction shall be signed. Because of extended effect of Covid-19 Pandemic this process got delayed and yet to be completed. Moreover, the volatility in the global API market has created some nervousness among the API manufacturers. That is why we have decided to go slow cautiously to avoid any mistake. The project decision has been intentionally put on hold at this moment due to said reason.

Once the situation normalizes, project will start rolling again. We shall keep you updated of further development in due course.

BOARD OF DIRECTORS

The Board of Director of BPAL consists of the following persons:

Nazmul Hassan MP, Chairman
S.M. Rabbur Reza, Managing Director,
Mohammad Ali Nawaz, Director
Afsar Uddin Ahmed, Director
Mamtaz Uddin Ahmed, Independent Director

AUDITOR

The existing Auditors, M. J. Abedin & Co., Chartered Accountants, National Plaza, 109, Bir Uttam C. R. Datta Road, Dhaka-1205 has carried out the audit for the year ended 30 June 2021. M. J. Abedin & Co., Chartered Accountants, National Plaza, 109, Bir Uttam C.R. Datta Road, Dhaka-1205, the Auditors of the Company has expressed their willingness to continue in office for the year 2021-22. The board after due consideration of the proposal made by the Audit Committee recommends the reappointment of M. J. Abedin & Co., Chartered Accountants as auditors for the year 2021-22.

On behalf of the Board

Nazmul Hassan

Chairman

Independent Auditor's Report

To the Shareholders of Beximco Pharma API Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Beximco Pharma API Limited, which comprise the statement of financial position as at 30 June 2021, and statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at 30 June 2021 and of its financial performance and its cash flows for the year then ended in accordance with international Financial Reporting Standards (IFRSs), the Companies Act 1994 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report.

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with, International Financial Reporting Standards (IFRSs), the Companies Act 1994, other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional Skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidences that is sufficient and appropriate to provide a basis for audit opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and based on the audit evidences obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to

continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidences obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and other applicable laws and regulations, we also report that:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of these books and;
- c) The Statement of Financial Position (Balance Sheet) and Statement of Profit or Loss and Other Comprehensive Income (Profit and Loss Account) dealt with by the report are in agreement with the books.

Dhaka
October 21, 2021

M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A





Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110280564AS311814

Beximco Pharma API Limited
Statement of Financial Position
As at June 30, 2021

		Amount in Taka	
	Notes	June 30, 2021	June 30, 2020
ASSETS			
Non-current Assets:		20,000,000	20,000,000
Advance against purchase of Land		20,000,000	20,000,000
Current Assets:		55,080	94,685
Cash and Cash Equivalents	4	55,080	94,685
TOTAL ASSETS		20,055,080	20,094,685
EQUITY AND LIABILITIES			
Shareholders' Equity		18,201,924	18,376,999
Issued Share Capital	5	20,000,000	20,000,000
Retained Earnings		(1,798,076)	(1,623,001)
Current Liabilities and Provisions		1,853,156	1,717,686
Short Term Advance		679,830	544,360
Creditors and Other Payables		1,153,326	1,153,326
Audit Fees Payable		20,000	20,000
TOTAL EQUITY AND LIABILITIES		20,055,080	20,094,685

The Notes are an integral part of the Financial Statements.


S.M. Rabbur Reza
Managing Director


Mohammad Ali Nawaz
Director

Per our report of even date.

Dhaka
October 21, 2021

M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A


Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110280564AS311814


Beximco Pharma API Limited


Statement of Profit or Loss and Other Comprehensive Income

For the Year ended June 30, 2021

		Amount in Taka	
	Notes	July 2020 - June 2021	July 2019 - June 2020
Revenue		—	—
Cost of Revenue		—	—
Gross Profit/(Loss)		—	—
Administrative Expenses	6	(175,075)	(485,200)
Profit/(Loss) from Operations		(175,075)	(485,200)
Income Tax Expense		—	—
Net Profit/(Loss) after Tax		(175,075)	(485,200)
Other Comprehensive Income		—	—
Total Comprehensive Income/(Loss) for the Year		(175,075)	(485,200)
Earnings Per Share		(0.09)	(0.24)


The Notes are an integral part of the Financial Statements.


S.M. Rabbur Reza
Managing Director


Mohammad Ali Nawaz
Director

Per our report of even date.

Dhaka
October 21, 2021


M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A

Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110280564AS311814

Beximco Pharma API Limited
Statement of Changes in Equity
 For the Year ended June 30, 2021

Amount in Taka


As at June 30, 2021


Particulars	Share Capital	Retained Earnings	Total
Balance as on July 01,2020	20,000,000	(1,623,001)	18,376,999
Net Loss for the Year	—	(175,075)	(175,075)
Balance as on June 30, 2021	20,000,000	(1,798,076)	18,201,924
Number of Shares			2,000,000
Net Assets value per shares			9.10

As at June 30, 2020

Particulars	Share Capital	Retained Earnings	Total
Balance as on July 01,2019	20,000,000	(1,137,801)	18,862,199
Net Loss for the Year		(485,200)	(485,200)
Balance as on June 30, 2020	20,000,000	(1,623,001)	18,376,999
Number of Shares			2,000,000
Net Assets value per share			9.19

The Notes are an integral part of the Financial Statements.


S.M. Rabbur Reza
 Managing Director


Mohammad Ali Nawaz
 Director

Per our report of even date.

Dhaka
 October 21, 2021

M.J. Abedin & Co.
 Chartered Accountants
 Reg No :N/A



Hasan Mahmood FCA
 Enrollment No : 0564
 DVC : 2110280564AS311814

Beximco Pharma API Limited
Statement of Cash Flows
For the Year ended June 30, 2021

	Amount in Taka	
	July 2020 - June 2021	July 2019 - June 2020
Cash Flows from Operating Activities:		
Cash receipts from customers and others	135,470	544,360
Payments for expenses & others	(175,075)	(485,200)
Net Cash Generated / (Used in) From Operating Activities	(39,605)	59,160
Cash Flows from Investing Activities	—	—
Cash Flows from Financing Activities	—	—
Increase/(Decrease) in Cash and Cash Equivalents	(39,605)	59,160
Cash and Cash Equivalents at Beginning of Year	94,685	35,525
Cash and Cash Equivalents at End of Year	55,080	94,685
Net Operating Cash Flows Per Share	(0.02)	0.03

The Notes are an integral part of the Financial Statements.


S.M. Rabbur Reza
Managing Director


Mohammad Ali Nawaz
Director

Per our report of even date.

Dhaka
October 21, 2021

M.J. Abedin & Co.
Chartered Accountants
Reg No :N/A


Hasan Mahmood FCA
Enrollment No : 0564
DVC : 2110280564AS311814

Notes to the Financial Statements

As at and for the year ended June 30, 2021

1. Reporting Entity

1.01 Statutory Background of the Company

Beximco Pharma API Limited was incorporated in Bangladesh on 12 December, 2017 as a Private Limited Company under the Companies Act, 1994. The Company is a fully-owned subsidiary of Beximco Pharmaceuticals Limited (BPL).

1.02 Nature of Business Activities

The company intends to set up a facility at API Industrial Park to manufacture Active Pharmaceutical Ingredients (APIs) for domestic and International markets. However, the Company is still in the initial phase of establishment and has carried out no operational activities.

2. Basis of Preparation

2.01 Basis of Measurement

The financial statements have been prepared under historical cost convention which does not take into consideration the effect of inflation.

2.02 Statement of Compliance

The financial statements have been prepared in compliance with the requirements of the Companies Act, 1994 and International Financial Reporting Standards (IFRSs), and other relevant and applicable local laws and regulations.

2.03 Presentation of Financial Statements

The financial statements comprise of:

- a) Statement of Financial Position as at June 30, 2021;
- b) Statement of Profit or Loss and other Comprehensive Income for the year ended June 30, 2021;
- c) Statement of Changes in Shareholders' Equity for the year ended June 30, 2021;
- d) Statement of Cash Flows for the year ended June 30, 2021 and
- e) Notes, comprising summary of significant accounting policies and explanatory information.

2.04 Reporting Period

Financial Statements of the company cover the period of 12 months from July 01, 2020 to June 30, 2021.

3. Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All financial information presented has been rounded off to the nearest Taka.

	Amount in Taka	
	June 30, 2021	June 30, 2020
4. Cash and Cash Equivalents		
This represents Cash at Bank with Current Account (IFC Bank Limited, Dhanmondi Branch)	55,080	94,685
	55,080	94,685

5. Issued Share Capital

A. Authorized:		
100,000,000 Ordinary Shares of taka 10 each	1,000,000,000	1,000,000,000
	1,000,000,000	1,000,000,000
B. Issued and Paid-up:		
2,000,000 Ordinary Shares of taka 10 each paid in cash	20,000,000	20,000,000
	20,000,000	20,000,000

C. Composition of Shareholding of Ordinary Shares

	No. of Shares	% of Shares Capital
Beximco Pharmaceuticals Limited	1,999,990	99.9995
S.M. Rabbur Reza	10	0.0005
Number of Shares	2,000,000	100

	July 2020 - June 2021	July 2019 - June 2020
6. Administrative Expenses		
Legal Expenses	30,890	—
Audit Fees	20,000	20,000
Bank Charges	1,185	840
Entertainment	—	328,460
Other Expenses	123,000	135,900
	175,075	485,200

Rabbur Reza
S.M. Rabbur Reza
 Managing Director

Mohammad Ali Nawaz
Mohammad Ali Nawaz
 Director

Dhaka
 October 21, 2021

Notice of Annual General Meeting

BEXIMCO PHARMACEUTICALS LIMITED
17, Dhanmondi R/A, Road No. 2, Dhaka-1205

NOTICE OF THE 45TH ANNUAL GENERAL MEETING

Notice is hereby given that the 45th Annual General Meeting of the Shareholders of Beximco Pharmaceuticals Limited will be held under Virtual Platform on Thursday, the 23rd December, 2021 at 10.30 a.m. to transact the following business:

AGENDA

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended on 30th June, 2021 together with reports of the Auditors and the Directors thereon.
2. To declare 35% cash dividend.
3. To elect Directors.
4. To approve the appointment of Independent Director.
5. To appoint Auditors for the year 2021-22 and to fix their remuneration.
6. To appoint Corporate Governance Compliance Auditors for the year 2021-22 and to fix their remuneration.

By order of the Board,



(MOHAMMAD ASAD ULLAH, FCS)
Executive Director & Company Secretary

Dated: November 15, 2021

NOTES:

- (1) The Shareholders whose names will appear in the Share Register of the Company or in the Depository Register on the record date i.e. 22 November, 2021, will be entitled to attend at the Annual General Meeting and to receive the dividend.
- (2) A Member entitled to attend and vote at the General Meeting may appoint a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped, must be deposited at the Registered Office of the Company, not later than 48 hours before the time fixed for the meeting.
- (3) Annual Report for the year 2020-21 will be sent through e-mail address of the Shareholders and will be available in the Website of the Company at: www.beximcopharma.com.
- (4) The Shareholders will join the Virtual AGM through the link <https://bxpharma.bdvirtualagm.com>. The Shareholders will be able to submit their questions/comments and vote electronically 1 (one) hour before commencement of the AGM and also during the AGM. For logging into the system, the Shareholders need to put their 16-digit Beneficial Owner (BO) ID/Folio Number and other credential as proof by visiting the said link.
- (5) We encourage the Shareholders to login into the system prior to the meeting. Please allow ample time to login and establish your connectivity. For any IT related guidance, Shareholders may contact vide email : monir@beximco.net or mazibur@beximco.net.



Proxy Form

BEXIMCO PHARMACEUTICALS LIMITED
17, DHANMONDI R/A, ROAD NO. 2, DHAKA-1205, BANGLADESH

I/Weof.....
.....being a member of Beximco Pharmaceuticals Limited hereby appoint
Mr./Ms./Miss.....of.....
.....as my proxy to attend and vote for me on my behalf at the 45th
Annual General Meeting of the Company to be held on Thursday, 23rd December, 2021 at 10.30 a.m. under virtual platform and at
any adjournment thereof.
As witness my hand this.....day of December, 2021.
Signed by the said in presence.....

Revenue
Stamp
Tk. 20.00

.....
(Signature of Proxy) Signature of
Shareholder(s)

Dated: Register Folio / BOID No.:

..... Dated:
(Signature of Witness)

Note: A member entitled to attend and vote at the Annual General Meeting may appoint a Proxy to attend and vote in his/her stead.
The Proxy Form, duly stamped, must be deposited at the Registered Office of the Company not later than 48 hours before the time
fixed for the meeting.

Signature Verified

.....
Authorised Signatory

www.beximcopharma.com



Follow us



Like us



Watch

BEXIMCO PHARMACEUTICALS LIMITED